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Abstract 
Tumour invasion is the key element in the high rate of mortality and 
morbidity in glioma patients. Increased expression, in neoplastic cells, of 
receptor tyrosine kinases (RTKs) of the TAM family (comprising Tyro3, Axl and 
MerTK), has been reported in several cancers including gliomas, in which they 
play a key role in tumour invasion. Axl RTK, with molecular weight of 120-140 
kDa, mediates glioma cell adhesion and invasion through a variety of ways. 
Within the scope of this thesis, Western blotting, quantitative polymerase chain 
reaction (qRT-PCR) and glioblastoma multiforme (GBM) tissue microarray 
revealed an upregulation of Axl and Tyro3 in brain tumours and two adult GBM 
cell lines, SNB-19 and UP007. Both cell lines were treated with the TAM ligand 
Gas6 and/or the specific Axl small molecule inhibitor BGB324, and analysed in 
assays for survival, 3D colony growth, motility, migration and invasion. Western 
blotting was used to detect protein expression and signal protein 
phosphorylation. In both cell lines, BGB324 inhibited specifically 
phosphorylation of Axl as well as Akt kinase further downstream. BGB324 also 
inhibited survival and proliferation of both cell lines in a concentration-
dependent manner, as well as completely suppressing migration and invasion. 
Axl inhibition by BGB324 also sensitised GBM cells to golden standard 
chemotherapeutic agent temozolomide. Furthermore, novel, unconventional 
activation mechanisms for the TAMs in human GBM cells were investigated. 
With the use of Western blotting, co-immunoprecipitation and in vitro kinase 
assays, Axl was shown to both interact with and be activated by the RTK EGFR. 
With the aid of qRT-PCR screens, EGFR was shown to promote GBM cell 
invasion through the Axl/TIMP1/MMP9 signalling axis. Additionally, 
 iii 
 
heterodimerisation of Axl with its sister RTK, Tyro3, in GBM cells was confirmed 
using co-immunoprecipitation assays; the functional significance of this complex 
was determined to be promotion of GBM cell survival. In conclusion, this thesis 
demonstrates the importance of TAM signalling in GBM, identifies novel 
molecular pathways employed by GBM cells for their survival, growth and 
spread, and thereby further strengthens the case for targeting TAM receptors 
as a novel therapeutic approach to combat both primary tumours as well as 
secondary tumours arising from drug resistance.  
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Chapter 1 
 
General introduction 
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1.1 The hallmarks of cancer 
 The word “cancer” is used to describe a condition where the body’s cells 
begin to grow and reproduce uncontrollably, are able to avoid cell death and 
proceed to invade and destroy healthy tissue, including organs (1). Cancer is 
one of the most studied diseases of our century as it poses the leading cause 
of death. Evidently, cancer is a multi-process and multi-gene disease that drives 
normal cells to become progressively malignant. Hanahan and Weinberg first 
reviewed a specific series of steps that cells must undergo to transform and 
become cancerous so-called the ‘Hallmarks of cancer’ (2). Initially, it was 
thought that there are six essential alterations in cell physiology that dictate 
malignant growth, which were later on revised to ten (3). These include: self-
sufficiency in growth signals, insensitivity to anti-growth signals, evasion of 
programmed cell death (apoptosis), limitless replicative potential, genomic 
instability, sustained angiogenesis, tissue invasion and metastasis, 
reprogramming of energy metabolism, tumour-promoting inflammation and 
evading immune destruction (2, 3)(summarised in Figure 1.1).  
Cancer cells can achieve the above hallmarks in many ways (Figure 1.1). 
Firstly, growth autonomy can be achieved either through the overexpression of 
growth receptors and secretion of growth factors leading to autocrine 
activation, or acquired mutations that lead to the constitutive activation of 
growth pathways, or downregulation of negative regulators. Furthermore, 
insensitivity to anti-growth signals is achieved through the permanent 
suppression of genes related to cell cycle inhibition and cell death, which in turn 
leads to increased genomic instability and acquisition of further mutations. 
Cancer cells are also able to escape shortening of telomeres and hence 
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senescence/death due to their ability to upregulate telomerase, an enzyme that 
maintains telomeric length at the end of each cell cycle. Another way cancer 
cells evade cell death is by acquiring mutations that disable DNA damage 
recognition and induction of programmed cell death. Due to the high energetic 
demands of cancer cells, they acquire the ability to orchestrate production of 
new vasculature around the tumour to increase supply of oxygen and nutrients. 
Furthermore, they deregulate metabolic pathways in order to maximize energy 
generation. Moreover, cancer cells develop mutations which allow them to 
excrete enzymes that breakdown the extracellular matrix and cell-cell adhesions 
thereby enabling them to invade surrounding tissue or metastasise to other 
organs. Lastly, it has become apparent that cancer cells are able to evade 
immune recognition, as well as induce tumour inflammation that recruits 
seemingly normal cells that contribute to the acquisition of hallmark traits by 
creating the tumour microenvironment (2, 3). 
 
Figure 1.1: The hallmarks of cancer. Acquired capabilities of cancer cells providing 
them with an evolutionary advantage as depicted by Hanahan and Weinberg (3).  
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1.2 The normal brain 
The human brain is the main organ of the central nervous system (CNS). It 
is located in the head, protected by the skull. The human brain consists of about 
1012 cells, of which around 1011 are considered to be neurons with the remaining 
9 × 1011 being glia. Neurons are electrically excitable cells composed of a cell 
body, dendrites and an axon. Neurons form networks that transmit information 
to the rest of the body through electrical and chemical signals (4). There are 
three main types of glial cells in the mature CNS: astrocytes, oligodendrocytes 
and microglia (5). Astrocytes are star-shaped cells found in the brain and spinal 
cord. Astrocytic processes envelop neuron-made synapses, thus regulating 
homeostatic maintenance, neurogenesis, neural cell migration and control of 
brain blood flow (5) (Figure 1.2). Oligodendrocytes are also restricted to the 
brain and produce myelin (fatty white substance) which surrounds the axon of 
neuronal cells to form an electrically insulating layer essential for the rapid 
conduction of action potentials in the CNS (6) (Figure 1.2). Microglia are the 
resident immune cells of the CNS and play important roles in combating brain 
infections and inflammation, which includes engulfing dead cells and debris (7) 
(Figure 1.2). Other important cell types present in the brain include the 
ependymal cells which are cuboidal and multi-ciliated structures (8). Ependymal 
cells line the interface between the brain parenchyma and the ventricular 
cavities and regulate the movement of cerebrospinal fluid (CSF) through the 
ventricular system (8) (Figure 1.2). 
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Figure 1.2: Glial function. Glia interact with neurons and the surrounding blood vessels. 
Oligodendrocytes wrap myelin around axons. Astrocytes extend processes that 
ensheath blood vessels and synapses. Microglia keep the brain under surveillance for 
damage or infection. Ependymal cells line the ventricles thus regulating CSF flow (4).  
 
1.3 Brain cancer 
 Brain cancer refers to the intracranial mass created by abnormal and 
uncontrolled cell division, arising either from brain cells or spread from cancers 
primarily located in other organs also referred as metastatic tumours. 
Glioblastoma multiforme (GBM) is the most common malignant primary brain 
tumour constituting 45.2% of all malignant CNS tumours and 80% of all primary 
malignant CNS tumours (9). Astrocytomas (WHO grade I to IV) are the most 
common type of glioma with the major associated tumours being pilocytic 
astrocytomas (Grade I), diffuse astrocytoma (Grade II), anaplastic astrocytoma 
(Grade III) and glioblastoma multiforme (Grade IV) (10). GBMs primarily affect 
adults, with a peak incidence ranging between 45 and 75 years and are 
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preferentially located within the cerebral hemispheres. Most GBMs arise rapidly 
de novo, with no previous lesions and are termed primary GBM (9). 
1.3.1 Glioblastoma classification 
Gliomas are classified morphologically to the glial cell type they 
resemble. In addition to the morphological classification they are usually 
distinguished by the WHO grading system. Lower grade tumours (e.g. grade I 
and II) are well differentiated and resemble normal tissue. Higher grade 
tumours (e.g. grade III and IV) are anaplastic and experience high cell atypia 
and mitotic activity (11). 
Genomic analyses of glioma samples led to the molecular 
characterisation of four different subtypes termed Neural, Proneural, Classical 
and Mesenchymal (summarised in Figure 1.3) (12). 
The classical subtype has been widely associated with amplification of 
chromosome 7 and deletion of chromosome 9p21.3 and 10. These result in 
amplification of the epidermal growth factor receptor (EGFR) and disruption of 
the retinoblastoma (RB) pathway. Glioblastoma cells belonging to the classical 
subtype also express high levels of neural precursor and stem cell marker 
Nestin. Notch and Sonic hedgehog signalling pathways are also over expressed 
(12, 13). 
The proneural subtype is characterised by mutations in isocitrate 
dehydrogenase 1 (IDH1) and amplification of the platelet–derived growth factor 
receptor (PDGFRα). Tumours belonging to the proneural type also show high 
levels of p53 mutations, loss of heterogeneity, amplification of chromosome 7, 
loss of chromosome 10 and high expression of genes involved in the 
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development of oligodendrocytes such as NKX-2, OLIG2, SOX and PDGFRα. In 
cases where no amplification of PDGFRα was observed, PIK3CA mutations were 
present (12, 13). 
The Neural subtype is characterised by high levels of neuronal markers 
such as NEFL, GABRA1, SYT1 and SLC12A5 (12, 13). 
The Mesenchymal subtype is characterised by hemizygous deletion of 
Neurofibromin (NF) 1 (a negative regulator of the Ras signalling pathway) and 
mutations in phosphatase and tensin homologue (PTEN). High expression of 
the mesenchymal markers YKL40, MET, CD44 and genes belonging to the 
Tumour necrosis factor (TNF) and Nuclear Factor-Kappa B (NF-κB) pathways is 
observed. The mesenchymal type is highly associated with necrosis and 
inflammatory infiltrates (12, 13).  
 
Figure 1.3: Schematic representation of the genetic changes observed in glioma 
subtype pathogenesis. EGFR, epidermal growth factor receptor; PTEN, phosphatase 
and tensin homolog; TNF, tumour necrosis factor; PDGFRA, platelet-derived growth 
factor receptor–α; IDH, isocitrate dehydrogenase; PI3K, phosphoinositol 3–kinase; 
HIF, hypoxia-inducible factor; TIC, tumour initiating cell; BCPC, brain cancer 
propagating cell (14).  
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Recently a new categorisation was proposed, splitting gliomas into 3 
molecular subgroups based on the tumour mutation status of the IDH gene and 
the co-deletion or loss of heterozygosity at chromosome 1p/19q combined with 
a mutation in telomerase reverse transcriptase (TERT) or Alpha 
Thalassemia/Mental Retardation Syndrome X-Linked (ATRX), conferring 
telomere maintenance by telomerase or through the lengthening of telomeres, 
respectively (15, 16) (Figure 1.4).  
 
Figure 1.4: New glioma classification. Schematic representation of the genetic changes 
observed in glioma subtype pathogenesis according to the new classification. IDH, 
isocitrate dehydrogenase; PTEN, phosphatase and tensin homolog; TERT, telomerase 
reverse transcriptase; ATRX, Alpha Thalassemia/Mental Retardation Syndrome X-
Linked (17). 
 
1.3.2 GBM treatment 
The current gold standard therapy for the treatment of GBM includes 
surgical tumour resection followed by the use of temozolomide (TMZ), an oral 
cytotoxic DNA-alkylating chemotherapeutic adjuvant, and radiotherapy. Studies 
by Stupp and colleagues demonstrated that administration of TMZ in 
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combination with radiation therapy followed by adjuvant TMZ treatment for 6 
months improved median overall survival compared to radiation alone (14.6 
months compared to 12.1 months) and increased twofold the 2-year survival 
from 10.4% to 26.1% (18). Despite recent advancements in the understanding 
of glioma pathology, efforts to develop a more effective treatment for GBM 
patients have not been successful. Gliomas are highly heterogeneous tumours, 
both phenotypically and genetically, thus making single targeted therapies 
unlikely to be viable. Moreover, treatment failure has also been attributed to 
the heterogeneity of gliomas which is thought to arise from the malignant 
transformation of neural progenitor cells (NPCs) present in the subventricular 
zone, the lining of the lateral ventricles, the dentate gyrus and the subcortical 
white matter of the adult brain. The first evidence supporting this theory derived 
from the isolation of glioblastoma stem cells (GSCs) from tumours, which were 
shown to share the same characteristics with NPCs: high motility, association 
with blood vessels and white matter tracts, possession of immature antigenic 
phenotypes, and activation of developmental signalling pathways (10). 
Subsequently, several theories were formed to explain how the transformation 
of NPCs results in tumour formation. The maturation arrest theory states that 
a glial progenitor cell after it becomes transformed generates abnormal progeny 
which accumulate additional mutations and impaired differentiation potential 
leading to tumorigenesis (10). These cells are thought to be resistant to therapy 
through a variety of ways including more effective DNA damage repair, 
autophagy (protein degradation system which protects cells from death) 
activation, as well as the use of differential signalling pathways (19). Another 
major barrier to successful GBM treatment is the blood-brain barrier (BBB). The 
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BBB is an extensive network of capillaries formed by endothelial cells enforced 
by astrocytes and pericytes. The BBB acts a filter for the brain preventing the 
entrance of various substances from the blood stream (20). Consequently, the 
identification of essential regulatory pathways and multifaceted targeted 
therapy is required to effectively improve GBM patient cell survival. As well as 
the design of BBB permissive therapies. 
1.3.3 GBM biological characteristics and targeted therapy 
  Gliomas exhibit high heterogeneity phenotypically resulting from a range 
of cellular features such as: unrestricted proliferation, extensive invasion, 
neovascularisation, necrosis, and resistance to apoptosis. Gliomas have the 
unique ability to diffusely invade and infiltrate surrounding brain tissue, 
intertwining themselves among native cells and so making complete surgical 
resection impossible (21). These hallmark biological processes and their links to 
specific genetic aberrations and associated signalling pathways will be discussed 
in the following subsections in relation to attempts for targeted therapies.  
1.3.3.1 Proliferation 
The first GBM hallmark is uncontrolled proliferation. Normal cells activate 
mitogenic signalling pathways upon growth factor binding, cell–cell adhesion, 
and/or contact with extracellular matrix (ECM) components. These signals 
activate transmembrane receptors which in turn promote gene expression 
leading to cell division. GBM cells overcome normal impositions on the control 
of growth signals through multiple mechanisms which mainly include activation 
of receptor tyrosine kinases (RTKs).  
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Constitutive activation of receptors is achieved through overexpression 
or genetic amplification of growth factor receptor genes, as well as through 
gene mutations that lead to ligand-independent signalling. Alternatively, 
intracellular signalling pathways can be constitutively activated through 
activating or suppressing mutations in propagating signalling proteins (14, 21). 
Amongst the most deregulated signalling pathways are the mitogen-activated 
protein kinase (MAPK) and the phosphatidylinositol-4,5-bisphosphate 3-kinase 
(PI3K) pathways (summarised in Figure 1.5). 
The MAPK pathway is activated by growth factor signalling, mutation, or 
overexpression and involves the sequential activation of Ras, Raf, MEK and ERK 
kinases which leads to the relocation of ERK kinase to the nucleus where it 
phosphorylates nuclear transcription factors that induce the expression of genes 
promoting cell cycle progression (22). Mutations that constitutively activate Ras 
are the most common in human cancer; however very few have been reported 
in glioma, thus Ras over-activation is believed to be achieved primarily through 
RTK overexpression/constitutive activation (23). One important MAPK 
downstream transcription target is cyclin D1, which a crucial cell cycle 
progression protein (24). Under normal conditions, the cell cycle is halted by 
the RB protein which binds and sequesters the E2F family of transcription 
factors, thus preventing transactivation of genes essential for progression of 
the cell cycle. Growth factor stimulation of the MAPK cascade leads to the 
induction of cyclin D1 which associates with the cyclin-dependent kinases 
(CDK)4 and CDK6 which in turn phosphorylate RB, thus enabling E2F mediated 
gene expression which allows entry to the S-phase and cell cycle progression 
(25, 26). In GBM the cell cycle checkpoint is deregulated in a variety of ways 
 12 
 
allowing uncontrolled division. The Rb1 gene is found mutated in ∼25% of GBM 
patients (27). RB activity is also lost through the inactivation of p16Ink4a, a 
negative regulator of CDK4 and CDK6, or amplification of CDK4 (28).  
The PI3Ks are heterodimers comprised of a catalytic and a regulatory 
subunit and are activated in response to mitogenic signals. The PI3Ks catalyse 
the phosphorylation of phosphatidylinositol-4,5-bisphosphate [PtdIns(4,5)P2] to 
produce phosphatidylinositol (3,4,5)-trisphosphate [PtdIns(3,4,5)P3], thus 
creating docking sites for a multitude of signalling proteins (29). PIK3CA gain-
of-function point mutations have been detected with 15% frequency in GBM 
(30). Furthermore, PI3K is directly antagonised by PTEN, which is found 
inactivated in 50% of high-grade gliomas either by mutations or epigenetic 
mechanisms, each resulting in uncontrolled PI3K signalling (31, 32). The 
phosphoinositide-dependent kinase (PDK1) and Akt are then recruited to the 
membrane where Akt is activated via phosphorylation of two key residues, T308 
and S473, respectively (33). Assessment of the phosphorylation status of these 
residues is often the method of choice for monitoring PI3K pathway activity in 
cell lines and primary tumours, including GBM samples, 85% of which have 
been reported to display activated Akt. Akt phosphorylates many proteins 
involved in the regulation of cell growth, proliferation, metabolism, and 
apoptosis (34). 
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Figure 1.5: Summary of PI3K and MAPK pathways. Upon PI3K activation by RTKs, PIP2 
is converted into PIP3 thus leading to PDK1 recruitment and downstream activation of 
Akt. PTEN negatively regulates PI3K signalling by dephosphorylating PIP3, converting 
it back to PIP2. Akt activation leads to both positive and negative regulation of a wide 
range of target proteins (not all shown). The Ras signalling pathway is also activated 
by growth factors binding cell membrane RTKs through GRB2 (growth factor receptor-
bound protein 2), SOS, Ras, Raf, MEK (mitogen-activated ERK kinase) and ERK, leading 
to cell proliferation. BAD, BCL-2-associated agonist of cell death; FOXO, forkhead box 
O; RHEB, Ras homologue enriched in brain; TSC2, tuberous sclerosis 2 (35). 
 
As mentioned earlier, the MAPK and PI3K pathways are mainly activated 
through binding of growth factor ligands to RTKs. Cancer cells upregulate 
autocrine loops, undergo genomic amplification, and/or mutation of the 
receptor leading to constitutive activation in the absence of ligand. The most 
prominent deregulated receptor identified to be essential for gliomagenesis is 
EGFR. EGFR gene amplification indeed characterises the classical subgroup of 
GBM, which accounts for 25%–30% of cases. Further characterisation showed 
that EGFR mutations often occur simultaneously with EGFR rearrangement 
and/or focal amplification; these occur in 57% of GBM cases, making it the most 
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prevalent deregulated receptor in GBM (36). Wild-type EGFR is classically 
activated through ligand binding such as epidermal growth factor (EGF), 
transforming growth factor-, heparin-binding EGF-like growth factor, 
amphiregulin, epiregulin, betacellulin, and epigen (37). In GBM, however, 
activation of EGFR occurs independently of ligand through cross-talk between 
RTKs at the cell surface or between EGFR mutants and the wild-type receptor 
(38, 39). EGFR mutations in GBM are common with the leading variant being 
EGFR variant (v)III (EGFRvIII) which results from  truncation of exons 2-7 at the 
extracellular domain rendering it constitutively active (40). Moreover, EGFRvIII, 
unlike the wildtype EGFR, fails to internalise upon activation and therefore has 
increased stability in the plasma membrane, contributing further to its sustained 
tumorigenic signalling (41) (Figure.1.6).  
EGFRvIII is a highly validated glioma target as evidenced by the capacity 
of activated EGFR mutants to enhance tumorigenic behaviour of human GBM 
cells by reducing apoptosis and increasing proliferation (42, 43). Consistent with 
enhanced apoptosis resistance by EGFRvIII mediated through upregulation of 
Bcl-XL (a pro-survival member of the Bcl-2 family)(43), activated EGFR has also 
been shown to confer radio- and chemo-resistance to GBM cells by sequential 
activation of Ras and both the MAPK and PI3K cascades (44). Moreover, it has 
been recently identified that EGFR and EGFRvIII are often co-expressed and are 
able to heterodimerise resulting in enhanced downstream signalling (45).  
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Figure 1.6: EGFR signalling. Binding of EGF to EGFR, activates downstream signalling 
pathways including the MAPK and PI3K/AKT. The EGFRvIII mutant is constitutively 
active and can induce signal transduction in the absence of EGF by heterodimeric 
association with WT EGFR. Activated EGFR phosphorylates EGFRvIII triggering nuclear 
transport of EGFRvIII, enhanced phosphorylation of STAT3, and increased EGFRvIII-
STAT3 interaction in the nucleus, which drives transformation (45). 
 
1.3.3.1.1 Targeted kinase inhibition with small molecule inhibitors 
Generally, protein kinases catalyse the transfer of the terminal 
phosphate of ATP to substrates that contain either serine, threonine or tyrosine 
residues (46, 47). All kinases typically share a conserved arrangement of 
secondary structure elements that are arranged into 12 subdomains that fold 
into a bi-lobed catalytic core structure with ATP binding taking place in a deep 
cleft located between the lobes (46, 47). ATP binds the cleft and forms 
hydrogen bonds with the kinase 'hinge', the fragment that connects the amino- 
and carboxy-terminal kinase domains (46, 47). The ribose and triphosphate 
groups of ATP bind in a hydrophilic channel extending to the substrate binding 
site that features conserved residues that are essential to catalysis. All kinases 
have a conserved activation loop, which regulates the kinase activity and 
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contains conserved DFG (Asp-Phe-Gly) and APE (Ala-Pro-Glu) motifs at the start 
and end of the loop, respectively (46, 47) (example for EGFR is given in Figure 
1.7). The activation loop is fluid and can adopt a number of conformations with 
the extremes being catalytically competent and usually phosphorylated form, 
and an 'inactive' form in which the activation loop blocks the substrate binding 
site (46, 47).  
 
Figure 1.7: EGFR activation. The kinase domain of the EGF receptor is kept in an 
inactive state by a leucine wedge. ATP binds the inactive EGFR kinase causing the 
displacement of the activation fragment thus causing receptor heterodimerisation and 
subsequent autophosphorylation (48).  
 
There are four main types of small molecule inhibitors that can block 
kinase activity depending on their binding site. Type 1 inhibitors recognise the 
active (DFG-in) conformation of the kinase and compete with ATP for the 
binding site. Type 1 inhibitors typically consist of a heterocyclic ring system that 
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occupies the purine binding site, where it serves as a scaffold for side chains 
that occupy the adjacent hydrophobic regions I and II (49) (Figure 1.8A).  
Type 2 inhibitors recognise the inactive kinase conformation (‘DFG-out’) 
of the kinase. Movement of the activation loop to the DFG-out conformation 
results in the exposure of an additional hydrophobic binding site directly 
adjacent to the ATP binding site, which the compound binds thus blocking 
kinase activation (49) (Figure 1.8B).  
 
Figure 1.8: Kinase inhibitor–protein interactions depicted by ribbon (left) and chemical 
structures (right). The chemical structures depict hydrophobic regions I and II of ABL1 
forming hydrogen bonds with the kinase inhibitor. The DFG motif (pink), hinge and the 
activation loop of ABL1 are indicated in the ribbon representations. The kinase 
inhibitors are shown in light blue. A. ABL1 in complex with the type I ATP-competitive 
inhibitor PD166326. B. ABL1 in complex with the type II inhibitor imatinib. The 
allosteric pocket exposed in the DFG-out conformation is indicated by the blue shaded 
area (right)(49). 
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Allosteric inhibitors bind outside the ATP-binding site and thereby 
modulate kinase activity. These inhibitors present the highest degree of kinase 
selectivity due to the exploitation of binding sites and regulatory mechanisms 
that are unique to a particular kinase (49).  
 Lastly, covalent inhibitors form an irreversible, covalent bond to the 
kinase active site by reacting with a nucleophilic cysteine residue and 
irreversibly blocking binding of ATP to the kinase, thereby rendering the kinase 
inactive (49). 
Due to the high prevalence of EGFR amplification and the EGFRvIII in 
GBM, several attempts have been made to target them clinically using both 
reversible and irreversible ATP-competitive SMIs. Some of the reversible 
inhibitors include erlotinib (Genentech/Roche/OSI), gefitinib (AstraZeneca), 
lapatanib (GlaxoSmithKline) and PKI166 (Novartis), and the irreversible 
inhibitors include canertinib (Pfizer/Warner-Lambert) and pelitinib (Wyest-
Ayerst) (50). Though a number of EGFR inhibitors have been developed, 
gefitinib, an ATP mimetic of the anilinoquinazoline family that covalently inhibits 
the EGFR kinase, represents the best explored inhibitor in the clinic for the 
treatment of GBM (51). The anti-tumour activity of gefitinib is independent of 
the expression level of EGFR, but is heavily determined by its ability to inhibit 
anti-apoptotic signals (52). Moreover, in in vitro studies gefitinib reduced the 
proliferation of glioma cells by autophagic mechanisms involving AMPK 
activation (51). Clinically as determined in phase II clinical trials gefitinib is well 
tolerated and displays anti-tumour activity, but the median overall survival time 
in GBM patients was only 38.4 weeks from treatment initiation (50). Moreover, 
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 it was shown that gefitinib is able to reach high concentrations in the tumour 
tissue and can efficiently dephosphorylate EGFR; however, it was unable to shut 
down regulatory circuits that promote sustained downstream signal 
transduction (53).  
Even though gefitinib is well tolerated and effective in GBM patients, the 
recurrent problem of resistance arising from various mechanisms such as 
concomitant PTEN loss or MET activation (54) limits its efficacy in the clinic. 
Additionally, recent studies show that plasma concentrations of gefitinib 
following therapy were only 6–11% of the starting dose indicating that the poor 
response observed in the clinic could also be due to insufficient delivery of the 
SMIs to the tumour (50).  
1.3.3.2 Apoptosis evasion 
Another hallmark of GBMs is resistance to death-inducing stimuli such as 
radiotherapy and chemotherapy. GBM cells have shown to evade cell death 
through the upregulation of molecules involved in mitogenic signalling such as 
RTKs, the PI3K–PTEN–Akt signalling axis (55), as well as regulatory and effector 
molecules residing in classical cell death networks of both extrinsic (death 
receptor-mediated) and intrinsic (mitochondria-dependent) mediated apoptosis 
(56). The intrinsic apoptotic pathway is regulated by the balance of pro-
apoptotic and anti-apoptotic members of the Bcl-2 family of proteins. 
Upregulation of anti-apoptotic Bcl-2 family members (BAK, BAD, BID, BAX, Bcl-
XL, Mcl-1) protects the mitochondrial membrane integrity and inhibits 
cytochrome c release, thus negatively affecting the caspase cascade and the 
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apoptotic program (56) (The extrinsic and intrinsic pathways are summarised 
in Figure 1.9). 
 
Figure 1.9: Schematic representation of the intrinsic and extrinsic apoptotic pathways. 
The extrinsic apoptotic pathway is activated by induction of the death receptor on the 
cell membrane. The intrinsic pathway is usually activated by the loss of the 
mitochondrial membrane integrity. Chemotherapy and radiotherapy-induced apoptosis 
is executed via the intrinsic pathway. , activation; , inhibition (57). 
 
Anti-apoptotic members Bcl-2 and Mcl-1 have been shown to be 
upregulated in glioma and their expression to correlate with tumour grade (58). 
Additionally, EGFRVIII can upregulate Bcl-XL in glioma cells conferring resistance 
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to the chemotherapeutic agent cisplatin (59). Also, EGFR and EGFRvIII can 
interact with Puma, resulting in its cytoplasmic sequestration and inactivation 
(60). In addition, Bcl-2 family members may contribute to gliomagenesis by 
enhancing migration and invasion through alteration of the expression levels of 
metalloproteinases and their inhibitors (61-63).  
Due to their central role and importance in apoptosis, several attempts 
to target them have been made. BH3 mimetics emerged as potent 
antineoplastic therapeutics, either alone or in combination with other drugs, 
however they exhibit low permeability by the BBB and are often associated with 
significant cytotoxic effects to non-cancer cells (56).  
1.3.3.3 Necrosis 
Necrosis presents another hallmark of GBM tumours, with studies 
supporting its presence in up to 88% of cases (64). Necrotic cell death is often 
referred to as unscheduled cell death, implying that within a multicellular 
organism it is an unregulated process, which is now known not to be true. 
During necrosis the plasma membrane is disrupted leading to the spillage of 
intracellular proteins which activates a damage response from the host immune 
system. Necrosis occurs when blood supply is limited or when energy supplies 
(ATP) are depleted (65). Recent research, shows that necrosis is a regulated 
process and can occur in a variety of ways. In glioma, necrosis is thought to be 
driven by BCL2L12, a member of the Bcl-2 family of proteins, which blocks 
caspace-3 and caspase-7 downstream of mitochondrial membrane breakdown, 
thus shifting the cell death balance from apoptosis to necrosis. BCL2L12 inhibits 
caspase-7 processing through direct physical interaction, whilst caspase-3 
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inhibition occurs through the transcriptional upregulation of the small heat 
shock protein alpha β-crystallin (66).  
1.3.3.4 Angiogenesis 
GBMs are highly vascular and are characterised by irregular and dilated 
vessels presenting vascular leakage (67). In addition to the poor vascular 
architecture, endothelial cells associated with the tumour vasculature fail to 
form tight junctions and have few associated pericytes or astrocytic foot 
processes leaving the integrity of the BBB compromised, resulting in increased 
interstitial oedema. Interstitial oedema may further compromise regional blood 
flow and intensify tumour hypoxia leading to areas of necrosis (68). Recent 
evidence suggests angiogenesis may occur following a vascular collapse in 
glioma. Hypoxia is a critical aspect of the glioma microenvironment and it has 
been associated with poor prognosis, increased angiogenesis, tumour growth, 
radio-and chemotherapy resistance, and tumour invasiveness (69, 70). Hypoxia 
induces hypoxia induced factor (HIF)-1, a heterodimeric transcriptional factor 
(71), which induces expression of pro-angiogenic and vascular permeability 
factors such as: (vascular endothelial growth factor) VEGF, endothelial nitric 
oxide synthase (eNOS), angiopoietin, ephrin and others such as: glycolytic 
enzymes, glucose transporter-1, inducible nitric oxide synthase (72) and Twist 
(73, 74). In addition to oxygen levels, EGFR or loss of tumour suppressors can 
also induce HIF-1 expression (74, 75). In human glioma biopsies, it has been 
shown that VEGF-A overexpression correlates directly to proliferation, 
vascularisation, and degree of malignancy, and therefore corresponds inversely 
to prognosis (76, 77).  
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Several types of angiogenesis inhibitors have been developed for 
therapeutic use. Because it is the main driver of angiogenesis, most approaches 
target VEGF signalling (78). Bevacizumab (Avastin®), is a humanised 
monoclonal antibody that inhibits VEGFR by sequestering VEGF-A (its natural 
ligand). To date, it has been the most successful drug in the clinic and received 
accelerated food and drug administration (FDA) approval for use in patients 
with recurrent GBM in 2009. Initial studies with bevacizumab in recurrent GBM 
showed patient response rates of 28–40% and 6-month progression free 
survival rate of 40–50% (79, 80). Despite the improved survival rates observed 
with bevacizumab, all patients eventually relapsed, thus combination therapies 
are currently investigated. Combination of bevacizumab with irinotecan, a 
chemotherapy drug, increased response up to 50.2% and the overall 
progression free survival rates to 8.9 months (79, 80). Currently, there are two 
ongoing randomised phase III clinical trials exploring bevacizumab in 
combination with radiation and temozolomide in newly diagnosed GBM but 
results from these studies are not yet available. 
1.3.3.5 Cell invasion 
One of the biggest challenges in treating GBM patients is the highly 
invasive nature of the tumour, which results in recurrent tumour development 
adjacent to the resection margin or within centimetres of the resection cavity. 
Invasion by glioma cells into regions of normal brain is driven by a multifactorial 
process involving cell interactions with the ECM and with adjacent cells, as well 
as accompanying biochemical processes supportive of proteolytic degradation 
of ECM and active cell movement. The most frequent route of invasion of glial 
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tumour cells is along white matter tracts and basement membranes of blood 
vessels as they lack the ability to penetrate the basement membrane of blood 
vessels thus promoting local spread (81) (Figure 1.10).  
 
Figure 1.10: Schematic of GBM cell invasion. GBM cells invade along white-matter 
tracts, around neurons and blood vessels, and in the subpial region. The 
immunohistostaining panel on the bottom right demonstrates individual elongated, 
hyperchromatic tumour nuclei oriented along myelinated axons. The panel at the top 
right illustrates molecular events relating to the invasion of single cells (82).  
 
Glioma invasiveness has been linked to the regulation of members of the 
family of metalloproteases (MMP) and their endogenous tissue inhibitors 
(TIMPs). In GBM, Akt signalling has been shown to increase MMP2 and MMP9 
activity thus promoting the tumour cell proteolytic capability to invade normal 
brain (83). The tumour suppressor PTEN has also been reported to suppress 
GBM invasion by suppressing proteolysis of the extracellular matrix by MMP9 
and MMP2 and by inactivating two Rho-family GTP-binding proteins, Rac and 
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Cdc42 (84). Moreover, overexpression of Bcl-w, a pro-survival Bcl-2 protein, 
has been reported to promote invasion of GBM by activating Akt signalling, 
which leads to the phosphorylation of GSK3β and allows subsequent nuclear 
translocation of β-catenin. Once in the nucleus, β-catenin upregulates target 
genes, such as MMP2, TWIST1 and Snail to promote invasion (85).  
Other proteins involved in GBM invasion include angiopoietin-2, which in 
addition to its involvement in angiogenesis also plays a role in inducing tumour 
cell infiltration by activating MMP2 (86). Ephrin receptors which mediate 
neurodevelopmental processes such as axon guidance and cell migration in 
glioma have been shown to regulate migration and invasion (21). Moreover, 
several integrins such as αvβ3 and αvβ5 are found overexpressed in GBM and 
have been shown to interact with osteopontin, a natural ligand in normal brain, 
to mediate tumour cell migration in brain tissue (21). 
The effects of several Akt-targeted drugs on GBM invasion have been 
investigated pre-clinically and clinically. Sulindac (Merck), a non-steroidal anti-
inflammatory drug (NSAID), has been shown to inhibit GBM invasion in vitro by 
dephosphorylating Akt at Ser473 (87). Arsenic trioxide (ATO), which has been 
approved by the FDA for the treatment of promyelocytic leukaemia, has been 
shown to accumulate more in brain tumours than in normal human brain 
tissues. In phase I studies, ATO was well-tolerated with TMZ and radiotherapy 
against malignant gliomas (88). BKM120 (Novartis) is a pan-class I PI3K 
inhibitor which is able to cross the BBB and has been shown to effectively inhibit 
the PI3K/Akt pathway in vitro and in vivo in glioma. Furthermore, treatment of 
various GBM cell lines with BKM120 showed a dose-dependent inhibition of  
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growth while treatment of mice with intracranial U87MG xenografts increased 
the median survival without any obvious adverse effects (89). Currently, 
BKM120 is being studied in a phase II trial in patients with recurrent GBMs 
(NCT01339052). There are also studies investigating the efficacy of this drug in 
combination with current first-line GBM treatments. There is an ongoing phase 
I study for newly diagnosed GBMs that combines BKM120 with radiotherapy 
and TMZ (NCT01473901). BKM120 is also combined with bevacizumab in a 
phase I/II study for relapsed/refractory GBMs (NCT01329660). In addition, 
there are studies verifying the efficacy of BKM120 in combination with other 
inhibitors, include: a phase Ib/II study of INC280, a c-Met inhibitor, and 
BKM120 in recurrent GBM (NCT01870726) and a phase Ib/II study of BKM120 
and one of the alkylating agents, carboplatin or lomustine, also in recurrent 
GBM (NCT0193461). 
1.3.4 The TAM family of RTKs 
RTKs are high-affinity cell surface receptors that are activated by growth 
factors, cytokines, and hormones to regulate a variety of biological processes 
both in normal and pathogenic conditions (90). To date, 58 different human 
RTKs have been identified and divided into twenty subfamilies (Figure 1.11). All 
RTKS share a similar molecular architecture comprised of a ligand-binding 
region at the N-terminus, a single transmembrane helix, and a cytoplasmic 
region that contains the tyrosine kinase as well as C- terminal regulatory regions 
(90). The TAMs are a relatively recently identified subfamily of RTKs. TAM 
receptors differ from other RTK subfamilies because they harbour a conserved 
homologous amino acid sequence within the kinase domain, KW(I/L)A(I/L)ES, 
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not present in other RTKs as well as adhesion molecule-like domains in the 
extracellular region (91, 92). 
 
Figure 1.11: Schematic representation of the 20 known RTK subfamilies(90).  
 
1.3.4.1 The structure of TAMs 
The TAM family of RTKs is so named according to its members: Tyro3 
(Sky), Axl (UFO) and MerTK. The TAMs possess an N-terminal extracellular 
region that is formed by two immunoglobulin (Ig)-like domains and two 
fibronectin type III repeats and an intracellular region with intrinsic tyrosine 
kinase enzyme activity (93) (Figure 1.12). The TAM receptor genes share similar 
genomic structures, encoding transcripts which range in size from 3 to 5 kb (94-
96). Tyro3 and Axl appear to have the most similar genomic structure (91, 97, 
98). In contrast, Axl and MerTK have the most similar amino acid sequences for 
the tyrosine kinase domain (99). Overall, the protein sequences of the human 
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TAM receptors share 31–36% amino acid sequence identity within the 
extracellular region. The intracellular domains share 54–59% sequence identity 
with greatest homology in the tyrosine kinase domain (99). The full length 
human Tyro3, Axl, and MerTK proteins contain 890, 894, and 999 amino acids, 
respectively. Although the predicted protein sizes are 97, 98, and 110 kDa for 
Tyro3, Axl, and MerTK, respectively, the actual molecular weights range from 
100 to 140 kDa for Axl and Tyro3 and 165–205 kDa for MerTK due to post-
translational modifications, including glycosylation, phosphorylation, and 
ubiquitination (97, 100, 101).  
 
Figure 1.12: The TAM RTK family structure. The TAMS share two extracellular FNIII 
and two (Ig)-like domains, followed by the intracellular tyrosine kinase. Also, in the 
diagram are depicted the tyrosine autophosphorylation sites by the asterisks and 
known SH2 domain-docking sites. (102).  
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1.3.4.2 The TAMs ligands 
The natural ligands for the TAMs are two homologous vitamin K-
dependent proteins, Gas6 (for all three TAMs) and Protein S (Tyro3 and MerTK 
only) (103, 104). Gas6 is a 678-amino acid protein comprised of 11 -
carboxyglutamic acid (Gla) residues at the N-terminal, a loop region and four 
EGF-like repeats, and a sex hormone-binding globulin (SHBG)-like structure 
(105) at the C-terminus, which is composed of two V-shaped globular laminin 
G-like (LG) domains with calcium-binding sites (106) (Figure 1.13).  
 
Figure 1.13: Gas6 structure , showing the Gla domain, EGFR-like repeats followed by 
the LG domains at the C terminus (107).  
 
Protein S has the same characteristics as Gas6 but additionally contains 
a thrombin-sensitive cleavage site at the loop region, which accounts for its role 
as a negative regulator of blood coagulation (93, 108). The glutamate residues 
in the Gla region are post-translationally modified by -glutamyl carboxylase in 
a vitamin K-dependent manner. The Gla residues mediate calcium-dependent 
binding to negatively charged membrane phospholipids on apoptotic cells (108), 
such as phosphatidylserine (PtdSer) (103). The C-terminal LG domains mediate 
binding of the protein to the TAM receptors. Specifically, the functional Gas6/Axl 
signalling complex is a heterotetramer formed by 2 receptor molecules and 2 
ligand molecules in a circular structure (109). The major binding site within the 
ligand is fully contained within the LG1 domain which interacts with both the 
Ig1 and Ig2 domains of the receptor, with no direct interaction in the dimer 
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between the 2 receptor molecules or the 2 ligand molecules (Figure 1.14). 
Moreover, MerTK and Tyro3 have been shown to lack the Gas6 binding major 
groove and bind Gas6/Protein S in a 1:1 stoichiometry (109).  
 
Figure 1.14: Gas6-LG /Axl-IG complex. A. Top view of Gas6-LG (Cyan)/Axl IG (IG1 in 
yellow and IG2 in brown) complex towards the cell membrane. B. Side view of Gas6/Axl 
complex with the cell membrane at the bottom. C. Front view of Gas6/Axl interaction, 
in the direction indicated by the arrow in B (109).  
 
In 2009, Tubby, Tulp-1 and Galectin-3 were identified as novel TAM 
ligands, although their physiological significance is still unknown. Tulp-1 was 
shown to interact with Axl, Tyro3 and MerTK in co-immunoprecipitation 
experiments, whilst Tubby interacted with only MerTK. Co-immunoprecipitation 
experiments also confirmed Galectin-3 association with MerTK, but the affinity 
for either Axl or Tyro3 has not been reported. Tubby, Tulp-1 and Galectin-3 
have been shown to promote MerTK mediated phagocytosis (110, 111).  
1.3.4.3 The TAM expression pattern  
In adult tissues, Tyro3, Axl, and MerTK exhibit widespread distribution 
with overlapping but unique expression profiles. Tyro3 is most abundantly 
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expressed in the CNS and is also found in ovary, testis, breast, lung, kidney, 
osteoclasts, and retina as well as a number of hematopoietic cell lines including 
monocytes/macrophages and platelets. Axl is ubiquitously expressed with 
noTable levels found in monocytes/macrophages, platelets, endothelial cells, 
heart, skeletal muscle, liver, kidney, and testis (100). MerTK is expressed in 
monocytes/macrophages, dendritic cells, NK cells, NKT cells, megakaryocytes, 
and platelets. High levels of MerTK expression are also detected in ovary, 
prostate, testis, lung, retina, and kidney, whereas lower levels are found in 
heart, brain, and skeletal muscle (112).  
1.3.4.4 The TAM function 
Tyro3 is the least studied of the TAM receptors; nonetheless, a handful 
of studies have provided clues as to its function in the CNS (discussed in more 
detail in Section 1.3.4.6) as well as mediation of platelet aggregation (113), 
osteoclastic bone resorption (114, 115) and normal reproductive system 
development (97, 116, 117). Tyro3 was also shown to negatively regulate type 
2 immunity through its expression on dendritic cells (118). Even though Axl 
expression has been characterised, the receptor function has been mostly 
studied in malignancy and its contribution in normal conditions is still not known 
for most cases. Axl signalling is involved in many processes ranging from the 
differentiation of cells in the erythroid lineage, protecting vascular vessels from 
injury, clearance of apoptotic cells, angiogenesis, haematopoiesis platelet 
aggregation, cell survival, proliferation, regulation of pro-inflammatory cytokine 
production and regulation of the actin cytoskeleton (119, 120). MerTK functions 
have been mostly limited in the regulation of the immune system as it has been 
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shown to mediate phagocytosis of apoptotic cells and cytokine production, as 
well as to be required for prevention of systemic autoimmune disease (112).  
1.3.4.5 TAM signalling 
The TAMs have been shown to mediate their effects through the 
activation of a variety of signalling pathways. Axl activation has been shown to 
activate the MAPK pathway, the PI3K pathway, as well as phospholipase C-γ 
(PLC-γ). Further Axl binding partners include SOCS-1, Nck2, RanBPM, and C1-
TEN through their Scr homology 2 (SH2) domains (93, 120) (Summarised in 
Figure 1.15). MerTK activation has also been linked to PI3K and PLC-γ 
signalling, as well as to the STAT transcription factor pathway and vav1. Tyro3 
has been shown to activate the PI3K and MAPK signalling (93, 120).  
 
Figure 1.15: Summary of Axl signalling pathways leading to platelet aggregation, cell 
survival, proliferation, regulation of pro-inflammatory cytokine production, and 
regulation of the actin cytoskeleton (120).  
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1.3.4.6 TAMs and the central nervous system  
In the nervous system, the TAM receptor and their ligands have been 
shown to be expressed by both neurons and glial cells. Tyro3 particularly is 
highly expressed in human brain tissue whilst the expression of both Axl and 
MerTK within the CNS is more restricted with overall expression being lower 
(121). Tyro3 expression was confirmed in the olfactory bulbs, cerebral cortex, 
piriform cortex, all cortical layers of the cerebellum, the amygdala, hippocampus 
and the cerebellum (122). Axl and MerTK are expressed at low levels in the 
Purkinje cell layer of the cerebellum, endothelial cells , oligodendrocytes, 
Schwann cells, and astrocytes (123), with the most important site of Axl 
expression in the brain being the vasculature (124). Gas6 has been shown to 
be expressed in the hippocampus, midbrain, the cerebellum, as well as the 
ventral spinal cord (125) . In contrast, protein S is expressed only at low levels 
in the CNS, in the locus coeruleus, choroid plexus, as well as in astrocytes  and 
in retinal pigment epithelial cells (126).  
Even though TAM expression is well characterised in the brain little is 
known about their function (summary of known function presented in Figure 
1.16). Axl has been shown to promote survival and growth of GnRH neuronal 
through the induction of the MAPK/ERK1/2 pathway as well as PI3K/Akt and 
PI3K/Rac/Rho pathway to regulate migration (127, 128). Tyro3 was detected 
over the surface of dendrites and axons and has been shown to modulate 
synaptic plasticity through the MAPK and PI3K signalling pathways in the 
dendritic compartment of hippocampal and cortical neurons (129). Moreover, 
Tyro3 when activated by Protein S protects against excitotoxic injury by 
activating Akt which in turn increases Bcl-2 and Bcl-XL levels (130). Protein S-
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Tyro3 signalling has also been shown to be involved in maintaining the integrity 
of the BBB although the exact mechanisms are still unknown (124). Gas6 
activation of Tyro3 also protects oligodendrocytes from TNF-mediated toxicity 
and promotes myelination by oligodendrocytes (131, 132).  
The TAM receptors have also been shown to regulate the brain immune 
system. All three TAMs are expressed by microglia and negatively regulate 
dendritic cells and macrophages in the brain. Studies in triple knockout mice 
revealed that without the TAM receptors, activated microglia produce increased 
amounts of pro-inflammatory cytokines, leading to increased brain 
inflammation (133, 134).  
Amongst their other various functions in the brain, the TAMs have also 
been shown to be important for normal brain development and most particularly 
in the maintenance of the stem cell pool. Wang and colleagues showed that, 
following genetic tagging and isolation of NSCs, the TAMs are expressed in 
accordance with stem cell markers and introduction of a dominant negative 
form of Axl and a double Axl/MerTK knockout promoted neural stem cell 
differentiation (135). The importance of the TAMs and their ligands in the stem 
cell pool maintenance is also supported by studies showing that loss of Gas6 
reduces the stem-like cell populations, while Protein S inhibits subventricular 
cell proliferation. In the same study, they also report that NPCs maintain a high 
level of reactive oxygen species (ROS), which has been shown to promote 
neural stem cell renewal; moreover, ROS is also produced during the γ-
carboxylation of Gas6 and Protein S (136).  
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Figure 1.16: TAM signalling in cells of the CNS. The schematic represents a 
generalization of the important TAM signalling pathways. A. Protein S mediates survival 
of cortical and hippocampal neurons through Tyro3. B. Gas6 stimulates both migration 
and survival through Axl in GnRH neuronal cells. C. Gas6-Tyro3 signalling regulates 
neuronal repair and synaptic plasticity. D. Axl mediates survival signalling via Gas6. E. 
Microglia express Axl and MerTK. Gas6 has been shown to bind both Axl and MerTK, 
limiting inflammatory responses and promoting phagocytosis in microglia, while Tubby 
reportedly binds MerTK and promotes phagocytosis in macrophages and retinal 
epithelial pigment cells (128).  
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1.3.4.7 TAMs and GBM 
Additional to their role in normal CNS function, Hutterer and colleagues 
have demonstrated by mRNA expression studies that Axl and Gas6 are 
overexpressed in high grade gliomas. High Axl/Gas6 expression in patients with 
GBM correlated with poor overall survival, indicating that Axl may significantly 
contribute to glioma progression. Immunohistochemical studies also revealed 
that Axl/Gas6 are not only expressed in tumour cells but also in the tumour 
vasculature (137). Given the significance of Axl expression observed in many 
other tumours, the role of the TAMs in brain cancer has become a topic of great 
interest.  
Transfection of glioma cells with a truncated Axl protein, which served 
as a dominant negative (DN) inhibitor of the kinase, resulted in decreased 
growth. This growth disadvantage was independent of Gas6 stimulation. 
Introduction of Axl-DN cells into nude mice correlated with in vitro experiments, 
showing reduced tumour growth compared to control cells without affecting the 
tumour vasculature but instead by decreasing invasive potential. Detailed 
assessment of the effect of Axl on cell migration revealed that Axl-DN cells have 
a reduced locomotor activity and disrupted cell-cell adhesion. Magnetic 
resonance imaging (MRI) scans of injected mice also revealed that Axl-DN mice 
had smaller tumours compared to Axl-WT mice (138).  
Further studies by Wang and colleagues show that MerTK is also 
overexpressed in high grade glioblastomas. Additionally, knockdown of MerTK 
resulted in morphological changes with GBM cells appearing elongated and 
forming more compact spheres compared to the rounded and amoeboid shaped 
control cells. Treatment of shMerTK and control cells with etoposide , 
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topoisomerase inhibitor chemotherapeutic drug, also revealed that MerTK 
knockdown sensitised cells to apoptosis, while control cells showed elevated 
MerTK activation upon DNA damage and increase resistance to etoposide (139). 
In agreement with the previous study, knockdown of MerTK or Axl was also 
demonstrated to increase apoptosis and chemosensitivity in astrocytoma upon 
serum starvation (140).  
B cell-specific Moloney murine leukaemia virus integration site 1 (BMI1) 
is a master regulator of NPCs stemness and self-renewal through the negative 
regulation of the INK4A locus, which encodes p16, p15 and p14, and p21 genes. 
BMI1 is often found overexpressed in brain cancers. BMI1 was shown to 
regulate self-renewal in CD133+ populations and proliferation and cell fate 
determination in CD133– populations (141). Recently, Gas6 was shown to be a 
novel target gene for BMI1 although the exact mechanism remains elusive 
(142). BMI1 belongs to the multiprotein complex PRC1. The PRC1 complex in 
cooperation with the initiation complex PRC2-enhancer of zeste homologue 2 
(EZH2) mediate  methylation of histone proteins, primarily at lysine 27 of 
histone H3 (H3K27) to induce gene silencing (143). Interestingly, Axl has been 
shown to be directly regulated by EZH2 in glioma. EZH2 was shown to be up-
regulated and co-expressed with Axl in glioblastoma cells. Further studies 
revealed EZH2 positively regulates Axl expression independently of methylation 
(144). Furthermore, knockdown of EZH2 in glioblastoma significantly reduced 
the invasive character of the cells and this was shown to be mediated by Axl. 
The authors also point out that EZH2 is required during EMT for E-cadherin 
repression by Snail. Axl has been extensively associated with Snail mediated 
EMT in breast cancer and this could represent another potential link between 
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EZH2 and Axl (145). Given the importance of the polycomb proteins in NSC and 
GSC maintenance and regulation, it could hint at Axl/Gas6 as a novel regulatory 
signalling pathway in this process.  
 Furthermore, Axl inhibition by the small molecule BMS-777607 was 
shown to result in increased apoptosis, decreased proliferation and migration 
in vitro and ex vivo in SF126 and U118 GBM cells. In vivo, in xenografts tumour 
volume was reduced by 56%. Moreover Axl blockade had anti-angiogenic 
effects and expression of Axl was localised in hyper cellular tumour regions, the 
migratory front of tumour cells in pseudo-palisades, and in vascular proliferates 
within the tumour (146), indicating that Axl may be involved in the regulation 
of many GBM hallmark features.  
 TAM signalling has only been started to be investigated in glioma and 
the full repercussions of expression and downstream signalling need to be 
investigated in more detail. Therefore, lessons from how the TAMs are involved 
in glioma progression can undoubtedly inform on their involvement in other 
cancers. 
1.3.4.8 TAMs in other cancers 
The TAMs were linked to cancer at the outset of their discovery. Axl was 
originally isolated from chronic myelogenous leukaemia (CML) cells where it 
was also found to possess transforming abilities (94) and since then has been 
linked to several other leukaemia subtypes such as B-cell chronic lymphocytic 
leukaemia, where its overexpression promotes survival through its association 
with other kinases (147). Interestingly, Axl overexpression has been also shown 
to increase Imatinib (tyrosine kinase inhibitor) and doxorubicin 
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(chemotherapeutic drug) chemoresistance in CML (148) and acute myeloid 
leukaemia (149) respectively. Increased resistance to Imatinib due to Axl and 
MerTK overexpression has also been reported in gastrointestinal stromal 
tumours (150) and non-small lung carcinoma (151). Additionally, studies using 
knockdown of Axl by short hairpin (sh)RNA revealed that Axl promotes the 
survival of cutaneous squamous carcinoma cells through Akt activation and 
inhibition of the pro-apoptotic factors of the Bcl-2 family of proteins. In the 
same study, it was also demonstrated that Axl knockdown results in increased 
cytochrome c release upon UV treatment (152). Recently, Tyro3 has been 
identified to regulate expression of Microphthalmia-associated transcription 
factor (MITF), a master regulator of melanocyte development, in melanoma 
and to promote tumorigenesis in spite of B-Raf-induced senescence (153). 
Tyro3 was also shown to promote cell proliferation and chemoresistance in 
breast cancer (154). 
 Along with increasing chemo resistance and promoting cell survival the 
TAMs have been also shown to promote tumour growth and invasion/migration. 
Global gene expression profiling revealed Axl and Tyro3 to be up regulated in 
thyroid cancer and their expression to be essential for cell proliferation and 
invasion. Inhibition of either of these kinases induced apoptosis and inhibition 
of Axl signalling decreased tumour cell invasion and migration. Silencing of the 
Axl receptor additionally impaired tumour vasculature, indicating a possible 
involvement in tumour angiogenesis (155). Studies by Gjerdrum and colleagues 
showed that Axl overexpression in metastatic breast cancer is induced by 
epithelial-to-mesenchymal (EMT) mediators Twist, Snail and Zeb2, in a process 
in which cells lose their adhesive properties and increase their migration 
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potential. In the same study, they show that Axl can positively impact on the 
expression of these mediators and is possibly involved in a positive feedback 
loop (156). In a similar study, Vuoriluoto and colleagues show that Slug and H-
Ras induced-EMT in basal-like breast cancer cells is dependent on the up-
regulation of vimentin, a type III intermediate filament protein, which in turn 
mediates invasion and migration by up-regulating Axl. Axl signalling was shown 
to be able to drive migration and extravasation of breast cancer cells from the 
blood stream even in the absence of vimentin, indicating that Axl is a highly 
significant regulator of metastasis (157). 
 Axl has also been demonstrated to regulate migration/invasion through 
induction of MMP9 by the activation of the ERK/NF-κB pathway and by 
mediating chromatin remodelling by Brg-1. Additionally, Axl activation by Gas6 
stimulated the expression of the pro-survival Bcl-2 family of proteins Bcl-2 and 
Bcl-XL and activated NF-κB thus suppressing apoptosis. MMP9 expression by Axl 
signalling was found to be independent from Gas6 stimulation, implicating that 
possibly Axl activation is mediated by distinct pathways as well (158). The high 
importance of Axl signalling in metastasis was elegantly demonstrated also in 
prostate cancer. Axl was found to be overexpressed in castrate resistant 
prostate cancer and to significantly increase migration, invasion and 
proliferation by activation of the PI3K/ NF-κB pathway. Moreover, Axl was 
shown to promote the secretion of IL-6 and paracrine STAT3 activation 
increasing prostate cancer proliferation (159).  
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1.3.4.9 TAMs as key targets in cancer 
 Axl has been at the forefront of scientific research due to its involvement 
in tumour chemoresistance. As with many RTKs several small molecule drugs 
were developed in order to block activity.  
The most noteworthy Axl inhibitor to date is BGB324 (R428; Rigel 
Pharmaceuticals, BergenBio). BGB324 has the highest specificity and activity 
towards Axl compared to other inhibitors available (IC50=14 nmol/L). BGB324 
is clinical phase I for aggressive and metastatic cancers (160). 
Other drugs inhibiting Axl though non exclusively are available in the 
market and include Bosutinib (SKI606, PF5208763, Bosulif; Pfizer) which mainly 
targets Bcr-Abl1 and Src (IC50=1 and 3.5 nmol/L, respectively) but can also 
block Axl with an IC50 of 174 nmol/L. Bosutinib was authorized by the FDA and 
the European Medicines Agency (EMA) in 2012 for the treatment of patients 
with Philadelphia chromosome-positive CML. Bosutinib is currently in a phase II 
clinical trial for glioblastomas and breast cancer (161). Cabozantinib (XL184, 
Cometriq; Exelixis) targets a variety of kinases including VEGFR-2 (IC50=0.035 
nmol/L), Met (IC50=1.3 nmol/L), Ret (IC50=5.2 nmol/L) as primary targets, as 
well as Kit (IC50=14.3 nmol/L), Flt-3 (IC50=11.3 nmol/L), and Axl (IC50=7 
nmol/L) and was authorized by the FDA and the EMA in 2012 for the treatment 
of medullary thyroid cancer and is currently in a phase III clinical trial for 
hepatocellular, renal, and prostate cancers (162). Sunitinib (SU11248, Sutent; 
Pfizer) was authorized by the FDA in 2006 for treatment of renal cell carcinomas 
and imatinib-resistant gastrointestinal stromal tumours, and in 2011 for 
pancreatic neuroendocrine tumours. It is an inhibitor targeting Flt-3 (IC50=0.5 
nmol/L), VEGFR-2 (IC50=20 nmol/L), Kit (IC50=22nmol/L), as well as Axl 
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(IC50=5 nmol/L) and currently also in clinical trials for NSCLC (163). Further Axl 
inhibitors in Phase II clinical trials include Foretinib (XL880, GSK1363089; 
Exelixis, GlaxoSmithKline) which primarily targets Met, VEGFR-2, Ron, Tie- 2, 
and Kit (IC50=0.4, 0.86, 3, 1.1, and 3.7 nmol/L, respectively) as well as Axl 
(IC50=11 nmol/L) and is a type II inhibitor presently in a phase II clinical trial 
for NSCLC and in phase I/II for breast cancer (164). MGCD265 (Mirati 
Therapeutics) is a potent inhibitor of Met (IC50=1 nmol/L), Ron (IC50=2 nmol/L), 
VEGFR 1/ 2/3 (IC50=3, 3, and 4 nmol/L, respectively), Tie-2 (IC50=7 nmol/L), 
and Axl (IC50=10 nmol/L). It is currently in phase I/II clinical trials for NSCLC 
and in phase I for advanced malignancies (163). Early stages of phase I clinical 
trials inhibitors include BMS777607 (ASLAN002; Aslan Pharmaceuticals and 
Bristol-Myers Squibb), a type II Met inhibitor (IC50=3.9 nmol/L) that also acts 
on Ron (IC50=1.8 nmol/L), Flt-3 (IC50=16 nmol/L), Tyro3 (IC50=4.3 nmol/L), 
MerTK (IC50=14 nmol/L), and Axl (IC50=1.1 nmol/L). BMS777607 is currently in 
a phase I clinical trial for advanced or metastatic solid tumours (146). 
LY2801653 (Eli Lilly Company) strongly inhibits Ron (IC50=0.8 nmol/L), Met 
(IC50=4.7 nmol/L), Axl (IC50=11 nmol/L), and Flt-3 (IC50=31 nmol/L) (59) and 
is currently in a phase I clinical trial for advanced cancers (165). Lastly, S49076 
(Servier) targets Met (IC50=2 nmol/L), FGFR-1 (IC50=68 nmol/L), FGFR-2 
(IC50=95 nmol/L), FGFR-3 (IC50=200 nmol/L), and Axl (IC50=56 nmol/L) is 
currently in a phase I clinical trial for advanced solid tumours (166).  
 The issue with all these inhibitors though is that they are not highly 
specific and can inhibit a variety of other RTKs with higher affinity. Given the 
emerging role of Axl in malignancy novel specific inhibitors or neutralising 
antibodies should be developed and tested in the clinic.  
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1.3.5 Project significance 
Gliomas are highly heterogeneous, invasive tumours that do not respond 
to traditional therapies. One of the biggest challenges in treating glioma is 
targeting all tumour hallmarks effectively so that cancer cells undergo a shock 
and eventual cell death. Axl was recently shown to be overexpressed in glioma 
and studies up to now have together demonstrated its importance in regulating 
major GBM hallmarks, although the mechanisms and the full extent of its 
overexpression still remain unknown. The purpose of this PhD was to 
investigate the expression of TAMs in GBM, to map out key TAM signalling 
pathways that contribute to GBM tumorigenesis, and to assess the anti-cancer 
effects of novel TAM inhibitors in GBM cells. The results of this study would 
provide a better understanding of how we can utilise Axl blockade as a novel 
improved approach in GBM patient treatment.  
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Chapter 2 
 
Materials and Methods 
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2.1 Cell culture 
2.1.1 Human cell lines 
The human GBM cell lines used in this study were UP007 (established in-
house from GBM biopsy resected at King’s College Hospital, London under ethics 
permission LREC00-173/11/SC/0048) and SNB-19 (DSMZ German Brain 
Tumour Bank). Both cell lines were authenticated in-house as described 
previously (167) and were mycoplasma tested. Cell lines used in screens or 
confirmation of principles are summarized in Table 1.  
Table 1: Cell lines used throughout the duration of project 
Cell line Type Source 
HA-c Human astrocytes ATCC 
hcMEK/D3 Human cerebral microvascular endothelial cells ATCC 
Neurons Human neuroblastoma cells ATCC 
SNB-19 Human GBM cells DSMZ 
UP007 Human GBM cells In house 
MDA-MB-231 Human breast cancer cells ATCC 
SCC-25 Human head and neck cancer cells ATCC 
Detroit Human head and neck cancer cells ATCC 
ATCC, American type culture collection; DSMZ, Deutsche Sammlung von 
Mikroorganismen und Zellkulturen.  
2.1.2 Maintenance of cell lines 
All cell culture was carried out in a Class II biological safety cabinet 
(Herasafe, Heraeus, Thermo Scientific). All consumables used for cell culture, 
such as glass Pasteur pipettes, cell culture flasks and pipette tips, were either 
sterile as purchased (plasticware) or through autoclaving (glassware). Prior to 
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use, they were sterile and sprayed with 70% ethanol and Mycozap (Lonza, 
Slough, UK) before being placed in the hood. All solid waste was autoclaved, 
while liquid waste was aspirated into a flask containing a working concentration 
of Virkon (Lonza) disinfectant solution.  
Cells were normally cultured in “complete” medium, comprising 
Dulbecco’s Modified Eagle Medium (Fisher Scientific, Loughborough, UK) 
supplemented with 10% foetal bovine serum (FBS; Lonza), 2 mM L-glutamine 
(Life technologies, Paisley, UK) and 1% penicillin/streptomycin (Fisher 
Scientific). Cells were grown in a humidified incubator with 5% CO2 at 37◦C, and 
were typically passaged into a desired vessel once they reached 80% 
confluency. Cells were washed with 10 ml warm phosphate buffered saline 
(PBS) and incubated with trypsin/EDTA solution (Lonza) for 5 minutes at 37oC. 
The detached cells were re-suspended in 10 ml complete medium to inactivate 
the trypsin, then centrifuged at 1150 rpm for 5 minutes and the pellet re-
suspended in complete medium and plated at 1:10 dilution.  
2.1.3 Recovery of cryopreserved cells 
Vials of frozen cells were rapidly defrosted in 370C water bath to reduce 
dimethyl sulfoxide (DMSO) contact. 10 ml media was applied in a drop wise 
manner to the cells to avoid shock and to dilute the DMSO. Cells were 
centrifuged 1150 rpm for 5 minutes, the supernatant discarded and pellets re-
suspended in 10 ml media. The cells were then placed in a 75 cm2 flask (“T75”). 
The medium was replaced after 24 hours to remove any remaining DMSO 
before experimental use. 
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2.1.4 Cell counting  
Cells were suspended in 10 ml media and counted using a 
haemocytometer, Glasstic® slide (Hycor Biomedical Ltd, Edinburgh). Ten µl of 
cell suspension was loaded onto the counting chamber, which was mounted 
onto a light microscope to visualise the cells. Two squares were counted as 
shown in the diagram bellow (Figure 2.1). The cell concentration was 
determined by dividing the counted cells by the number of squares and 
multiplying by 104 to derive the number of cells per ml.  
 
Figure 2.1: Schematic representation of haemocytometer square indicating counting 
margins 
 
2.1.5 Cell treatments 
Cells were treated either with ligands or SMI at concentrations and time 
points as indicated throughout the text. All drugs were diluted in DMSO at stock 
concentrations of 100 µM, aliquoted and stored at -80oC until usage. Ligands 
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were diluted in dH2O or PBS (Life technologies) according to the manufacturers 
protocol, aliquoted and stored at -80oC until usage.  
2.2 Western Blotting 
2.2.1 Cell lysis and protein extraction   
For cell lysis, the media was aspirated and the cells were washed twice 
in ice-cold PBS. For Western (immuno-) blotting, cells were lysed in ice-cold 
RIPA lysis buffer (150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 
0.1% SDS, 50 mM Tris, pH 8.0) supplemented with the respective 
serine/threonine and tyrosine phosphatase inhibitors calyculin A (Sigma, 
Dorset, UK) and sodium orthovanadate (Fisher scientific) as well as a protease 
inhibitor cocktail (Fisher scientific). Cells were further shaken in lysis buffer at 
4oC on a shaker for 30 minutes before collection. Lysates were clarified by 
centrifugation at 14 000 x g for 10 minutes at 4oC. The soluble supernatant was 
transferred into new Eppendorf tubes and stored at -200C until required. For 
immunoprecipitations, cells were lysed in Pierce™ IP Lysis Buffer (Thermo 
Scientific) supplemented with the same phosphatase and protease inhibitors 
(Fisher scientific). Lysates were used immediately for immunoprecipitation 
experiments. 
2.2.2 Protein quantification   
Usually, cells that had been plated in equal numbers in multi-well plates 
were expected to produce similar amounts of total protein extract for 
downstream assays. However, where protein concentration in samples was 
quantified, the BCA (bicinchoninic acid) protein assay was employed. Bovine 
serum albumin (BSA; 1 mg/ml stock; Sigma) was diluted to protein standard 
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concentrations of 10, 20, 30, 40 and 50 µg/ml, and 25 µl pipetted into a 96-
well plate in duplicate wells. For each sample, the whole cell lysate was diluted 
1:10 in distilled water and 10 µl of diluted sample was pipetted into the same 
96 well plate. 200 µl of 1x BCA working reagent (1:50 reagent B: reagent A) 
was added to standards and samples. The plate was incubated at 37oC for 30 
minutes before absorbance at 592 nM was measured on a spectrophotometric 
microplate reader (Synergy; BioTek, Potton, UK). The absorbance readings of 
the BSA standards were utilised to generate a standard curve to determine the 
protein concentrations of each sample.  
2.2.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS–PAGE)  
The apparatus glass plates were cleaned with distilled water and 70% 
ethanol prior to mixing the gel. The gel was mixed and poured into the gel 
apparatus, a comb was inserted and the gel was left to polymerise. Once set, 
the comb was removed and the wells washed with distilled water and running 
buffer (25 mM Tris base, 190 mM glycine and 0.1% SDS, pH 8.3). The cell 
lysate was mixed with 4x loading (“Laemmli”) buffer (0.313 M Tris-HCl (pH 6.8), 
10% SDS, 0.05% bromophenol blue, 50% glycerol; all purchased from Fisher 
scientific) supplemented with 5 mM DTT (Fisher scientific). Samples were boiled 
for 5 minutes at 95oC. Samples were loaded onto a 10% gel (10% Protogel 
(National Diagnostics), 0.1 M Tris pH 8.8, 3% Sucrose, 0.05% sodium dodecyl 
sulphate (SDS), 0.05% N,N,N,N – tetramethylethyl-enediamine (TEMED; Fisher 
scientific), 0.05% ammonium persulphate (APS)], and stacking gel (3% 
acrylamide for electrophoresis (Protogel; National diagnostics, Hessle, UK), 0.05 
M Tris, 3% Sucrose. 0.05% SDS, 0.025% TEMED, 0.05% APS). PageRuler Plus 
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Prestained Protein Ladder, a mixture of nine blue-, orange- and green-stained 
proteins (10 to 250 kDa), was used as size standards.  
2.2.4 Protein transfer  
The separated proteins were transferred onto an activated 
polyvinylidene fluoride membrane (PVDF; Millipore, Nottingham, UK) using a 
wet transfer method (transfer buffer: 25 mM Tris base, 200 mM Glycine, 0.04% 
SDS and 0.005% Tween-20). Transfer occurred by applying 350 mA for 2 hours 
at 4oC. Non–specific protein binding was blocked by incubating PVDF blots for 
1 hour in 5% non–fat milk/TBST when blotting for total protein and in 5% 
BSA/TBST when blotting for phospho–proteins. Membranes were incubated 
with primary antibodies (Table 2) overnight at 40C in 5% milk or 5% BSA/TBST. 
The membranes were washed 3 times for 10 minutes in TBST, then incubated 
with the corresponding secondary antibody (Table 3) for 1 hour at room 
temperature, and again rinsed three times in TBST. The presence of protein–
bound antibody was detected with enhanced chemiluminescence development 
reagent (Luminata Forte; Millipore) for 3 minutes and visualised with a high 
sensitivity CCD camera imaging platform (Chemidoc MP; Bio-Rad, Hemel 
Hempstead, UK). The software ImageJ  (168) was used for densitometric 
quantification of Western blot band intensities.  
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Table 2: List of primary antibodies used for immunoblotting  
Antibody Species Dilution Source 
Axl (C-20) Goat polyclonal 1:1000 Santa Cruz 
Tyro3 (C-20) Goat polyclonal 1:1000 Santa Cruz 
MerTK (B-10) Mouse monoclonal 1:1000 Santa Cruz 
EGFR (D38B1) Rabbit polyclonal 1:1000 Cell Signalling 
β-Actin Rabbit polyclonal 1:10000 Sigma 
Akt 1/2/3 (S473) Rabbit polyclonal 1:1000 Santa Cruz 
ERK1/2 Mouse monoclonal 1:1000 Santa Cruz 
pAxl Rabbit polyclonal 1:500 R&D systems 
pSky/Mer Rabbit polyclonal 1:1000 Cell Signalling 
pEGFR Goat polyclonal 1:1000 Santa Cruz 
Akt1/2/3 Rabbit polyclonal 1:1000 Santa Cruz 
pERK Mouse monoclonal 1:1000 Santa Cruz 
 
Table 3: List of secondary antibodies used for immunoblotting 
Antibody Dilution Source 
Anti-rabbit HRP 1:2000 Dako 
Anti-rabbit AP 1:5000 Cell Signalling 
Anti-Goat HRP 1:5000 Promega 
Anti-Goat AP 1:2000 Santa Cruz 
Anti-mouse HRP 1:2000 Dako 
 
2.3 Immunohistochemistry 
Brain tumour tissue microarray with normal tissue as control, containing 
35 cases of glioblastoma, 2 adjacent brain tissue and 3 normal brain tissue with 
core diameter 1.5 mm and 5 µm thickness (GL805a; US Biomax, Rockville, MD, 
Figure 2.2) and brain tumour tissue array with brain tissue as control, containing 
12 cases with core diameter 1.5 mm and 5 µm thickness (T175a; US Biomax, 
Rockville, MD, Figure 2.3) were deparaffinised using histology grade xylene 
(Sigma-Aldrich, Dorset, UK) for 5 minutes and rehydrated using decreasing 
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concentrations (100%, 70%, 50%, 30%) of molecular grade ethanol (Fisher 
Scientific) for 1 minute and 30 seconds respectively. Slides were then rinsed for 
2 minutes in water. Antigen unmasking was performed in 0.01 M sodium citrate 
(Fisher Scientific), pH 6 at 95ºC with two changes for 5 minutes each. The slides 
were washed twice for 2 minutes in deionised water. Endogenous peroxidase 
activity was blocked by incubating with 0.1% hydrogen peroxide (Sigma-
Aldrich) at room temperature. Following three 5 minute washes with PBS, the 
slides were blocked with 1.5% rabbit serum in PBS for 1 hour. The slides were 
then incubated with anti-Axl antibody at 1:100 dilution (goat polyclonal; R&D 
Systems) in 1.5% rabbit serum/PBS for 2 hours. The slides were then washed 
with PBS 3 times for 5 minutes and incubated with biotinylated anti-goat IgG 
secondary antibody (Sigma) in 1.5% rabbit serum/PBS for 1 hour at room 
temperature. The slides were then incubated for 30 minutes with avidin-biotin 
enzyme reagent VECTASTAIN ABC Kit (Vector laboratories, Peterborough, UK) 
and washed with PBS three times for 5 minutes. The slides were then developed 
using ImmPACT DAB Peroxidase (HRP) Substrate (Vector laboratories) for 10 
seconds and washed with deionising water 3 times for 5 minutes. The tissues 
were counter-stained with haematoxylin and dehydrated through increasing 
concentrations of alcohols (50%, 70%, 95%, 100%) for 30 seconds and 1 
minute respectively, followed by xylene for 1 minute, after which they were 
mounted with DPX mountant (Sigma-Aldrich). Images were captured by a Zeiss 
Axiophot brightfield microscope at 20x magnification.  
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Figure 2.2: GL805a microarray panel display. Cer - Cerebrum  - Malignant tumor, 
 - NAT,  - Normal tissue.  
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Figure 2.3: T175a microarray panel display. Bra - Brain  - Benign tumor,  - 
Malignant tumor,  - Normal tissue 
 
2.4 Molecular biology techniques 
2.4.1 Transient knockdown with short interfering RNA (siRNA) 
Cells were transfected with a pool of four siRNA nucleotides targeting 
Axl, Tyro3 or TIMP1 (Santa Cruz, CA, USA), depending on the particular 
investigation, at concentrations indicated. Control cells were transfected with a 
pool of non-targeting siRNA at the same concentration. Transfection was 
achieved using INTERFERin reagent (Polyplus, Reading, UK). INTERFERin and 
siRNA complexes were prepared in serum free DMEM (Life Technologies), 
vortexed and incubated at room temperature for 15 minutes before the total 
 54 
 
mixture was added to cells in culture medium. Cells were then incubated with 
the mixture for 48 or 72 hours before cell lysis or mRNA extraction for either 
confirmation of knockdown or cell signalling investigation by either Western blot 
or qRT-PCR. 
2.4.2 Stable knockdown with short hairpin RNA (shRNA) 
SNB-19 and UP007 cells were transfected with 1 µg Axl shRNA plasmids 
(HuSH-29mer, OriGene) summarised in Table 4 over a period of 3 days, after 
which cells were put under 1.5 µg/ml for SNB-19 and 1 µg/ml for UP007 
puromycin selection for two weeks before clone selection. Clonal expansion was 
performed under continuous puromycin selection throughout the project.  
Table 4: Axl targeting sequences 
Construct Construct sequence Origene 
catalogue 
number 
Empty N/A TR20003 
Scramble N/A TR30012 
shAxl #1 GAACAGGATGACTGGATAGTGGTCAGCCA TR320269A / 
TI378296 
shAxl #2 GCCGCTGCCTGTGTCCTCATCTTGGCTCT TR320269B / 
TI378297 
shAxl #3 TGTGATGTTCTAAGGCTCTGAGAGTCTAG TR320269C / 
TI378298 
shAxl #4 GGCACTGTAGTTCTAAGACTCAAATGTTC TR320269D / 
TI378299 
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 2.4.3 Purification of RNA  
Cellular total RNA was isolated using GeneJET RNA purification kit (Life 
Technologies) according to the manufacturer’s protocol; RNA was finally eluted 
with 100 µl RNA–free sterile water. The purity and concentration of isolated 
total RNA was assessed using a spectrophotometer (ND-1000; NanoDrop 
Technologies, Wilmington, DE, USA) to measure the UV absorption of samples. 
The absorbance at 260 nm (A260) was used to determine the concentration of 
RNA in undiluted samples. The ratio of absorbance at 260 nm and 280 nm 
(A260/A280 ratio) was used to determine the samples’ purity, where a ratio of 
>1.8 indicated high RNA purity. As RNA optimally absorbs light at a wavelength 
of 260 nm due to its high content of nucleotides, while proteins and other 
impurities that might be contaminating the isolated RNA absorb best at 280 nm, 
the A260/A280 ratio is the preferred way to assess if an RNA sample is pure.  
2.4.4 Synthesis of complementary DNA (cDNA)  
cDNA was synthesised using a reverse transcription kit (nanoScript2RT; 
PrimerDesign, Southampton, UK). Initially a mastermix consisting of 2 µg RNA, 
sterile water and Oligo dT was heated at 65oC for 5 minutes. Following 
immediate transfer on ice, the mixture was supplemented with nanoScript2 4X 
Buffer, 10 mM dNTP mix, water and nanoScript2 enzyme. The total 20 µl 
reaction was then briefly vortexed followed by a pulse spin and incubated at 
room temperature for 5 minutes and then at 42oC for 20 minutes. The reaction 
was heat-inactivated by incubation at 75oC for 10 minutes. cDNA was used for 
amplification or stored at -20OC.  
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2.4.5 Real time quantitative real-time polymerase chain reaction-
(qRT-PCR) 
qRT-PCR amplification was performed in 96-well plates in a mastermix 
for probes (Roche, Burgess Hill, UK) and run on a LightCycler® 96 System 
(Roche). The genes investigated using pre-designed primers/probes were 
purchased from Integrated DNA Technologies (Leuven, Belgium). The 
primer/probe genes were labelled with FAM and VIC fluorophores which 
enabled a duplex reaction for simultaneous determination of expression of both 
gene of interest and housekeeping gene respectively. The amplification 
procedure entailed 45 cycles of 95oC for 10 seconds (melting) followed by 60oC 
for 30 seconds (annealing and extension). For the human EMT gene expression 
screen, the qRT-PCR amplifications were performed using the Human CSC and 
EMT Biomarker RT ArrayTM Kit (NanoCinna Technologists, Tehran, Iran) and a 
SYBR Green system. For each reaction β-actin and GAPDH were utilised as 
endogenous control genes. The amplification procedure entailed 95°C for 15 
seconds (1 cycle), followed by 60°C for 1 minute (45 cycles). Relative 
expression analysis was performed using the equation N=N0 x 2Cp 
(LightCycler®96 software; Roche), normalising against the gene for ATP 
synthase subunit beta (ATP5B), which was determined in-house as the best 
internal reference gene out of 12 genes tested (geNorm kit, Primerdesign, 
Southampton, UK). The primers used are summarised in the Table below:  
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Table 5: Primers used in qRT-PCR 
Primer Sequence Source 
Axl NM_021913(2) IDT 
Tyro3 NM_006293(1) IDT 
MerTK NM_006343(1) IDT 
Gas6 NM_000820(3) IDT 
CD44 NM_000610(8) IDT 
CCND1 NM_053056(1) IDT 
MMP9 NM_004994(1) IDT 
MMP2 NM_001127891(2) IDT 
TIMP1 NM_003254(1) IDT 
ATP5B NM_001686.3 Life technologies 
GAPDH NM_001686.3/ NM_001256799.1 Life technologies 
IDT, Integrated DNA technologies 
 
2.4.6 Determination of most stable reference genes for signalling 
studies 
The double-dye (hydrolysis) probe geNorm 12 gene kit qRT-PCR Array 
contained multiple reference genes. The geNorm module in qbase+ version 2.5 
(Biogazelle, http://www.qbaseplus.com) was used to compute expression 
stability values for all reference targets. geNorm analysis was performed in Cq 
values directly exported from the Roche LightCycler 96 software. geNorm 
calculates the gene expression stability measure M (M-value) for a reference 
gene as the average pairwise variation V for that gene with all other tested 
reference genes. Stepwise exclusion of the gene with the highest M value allows 
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ranking of the tested genes according to their expression stability (24). The 
geNorm algorithm determines the pairwise variation Vn/n+1, between two 
sequential normalisation factors containing an increasing number of genes. A 
large variation means that the added gene has a significant effect and should 
preferably be included for calculation of a reliable normalisation factor. 
Additional reference genes are not required if the cut-off value is below 0.15 as 
set by Vandesompele et al. (2002) (24) Rank aggregation analysis was 
performed in the R statistical programming environment (version 3.0.2) using 
the Rankaggreg package (version 0.4–3) (25). To determine the best 
housekeeping gene for our study, we treated SNB-19 and UP007 cells with 
BGB324 IC50 concentrations, as well as Axl shRNA clones and vehicle controls 
and screen for gene stability. The 7 most stable genes for each cell line under 
the two conditions as shown in Table 6 were compared and ATP5B was 
determined to be the best housekeeping gene under all conditions.  
 
Table 6: Housekeeping gene stability ranking 
SNB-19 
RNAi 
SNB-19 
BGB324 
UP007 
RNAi 
UP007 
BGB324 
UBC RPL13A B2M UBC 
ACTB GAPDH SDHA ATP5B 
CYC1 EIF4A2 18S CYC1 
GAPDH SDHA EIF4A2 EIF4A2 
YWHAZ B2M RPL13A TOP1 
SDHA UBC UBC RPL13A 
TOP1 ATP5B ATP5B ACTB 
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2.4.7 Immunoprecipitation 
Cells were grown to confluence and treated as indicated. To extract 
proteins, cells were washed with ice-cold PBS and lysed in Pierce IP lysis buffer 
(Thermo Fisher) (See section 2.2.4). Following a 10-minute centrifugation at 
10,000 x g, the lysates were pre-cleared by incubation with 10 µl protein A/G-
agarose beads (Santa Cruz) for 1 hour at 4°C with constant rotation. Lysates 
were then incubated with 2 µg immunoprecipitation (IP) antibodies for 2 hours 
at room temperature, with constant rotation. Antibodies against GAPDH or 
Tensin2 (Santa Cruz) were used as species-aligned negative control IP 
antibodies. Following incubation, 20 µl of protein A/G-agarose beads was added 
to each sample and incubated further for 2 hours. The beads were then 
separated by centrifugation at 8,000 x g for 1 minute and washed once with 
ice-cold IP lysis buffer and thrice with PBS (Life Technologies). Finally, 4x SDS-
PAGE loading buffer was added to the beads and solubilised samples underwent 
SDS-PAGE and Western blotting.  
2.4.8 Luciferase reporter assay  
50 000 cells were seeded in complete medium and allowed to adhere 
overnight. The next day, 500 ng of the reporter plasmids containing promoter 
fragments and a 1:100 dilution of the positive transfection control 
(pGL4.74[hRluc/TK] vector expressing Renilla luciferase, Promega) were mixed 
with JetPrime transfection reagent (Polyplus) according to the manufacturers 
protocol, and added to the cells. After 4 hours of incubation at 37ºC, the 
transfection medium was replaced with fresh medium and expression was 
allowed to occur for further 48 hours. Cells were passively lysed in luciferase 
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assay lysis buffer and analysed for luciferase levels and activity as follows: 20 
µl of crude cell lysate was added to 100 µl LARSII solution (luciferase assay 
substrate in assay, for firefly luminescence) and the luminescence level was 
measured for 10 seconds using a luminometer (1450 microbeta, Perkin Elmer, 
Waltham, MA). Following measurement, 100 µl Stop and Glo reagent (for 
Renilla luminescence) was added and the luminescence was read again. The 
luminescence values measured were subtracted from background readings 
(untransfected control lysates) and then normalised against the Renilla 
luciferase positive transfection control.  
2.5 Functional assays  
2.5.1 Cell survival/growth assay 
The MTS assay measures the reduction of 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) 
compound in the presence of phenazine methosulphate (PMS), which relies on 
NAD(P)H-dependent oxidoreductase enzymes and therefore reflects the 
metabolic activity of the cell; this correlates with cell proliferation and viability 
(169). This assay therefore served as an indicator of cell growth following 
treatment with Gas6 and cytotoxicity following treatment with small molecule 
inhibitors and TMZ (170). 1,500 cells per well were seeded in 96-well plates and 
incubated overnight, prior to various treatments (see above). Three or seven 
days’ post drug or Gas6 treatment respectively, MTS reagent (Fisher Scientific) 
was added to cells at 0.4 µM in the presence of 0.3 nM PMS (Sigma) and 
incubated for a further 2 hours, after which absorbance was measured at 492 
nm using a spectrophotometric microplate reader (Synergy; BioTek, Potton, 
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UK). The calculation used to calculate the IC50 concentrations is summarised in 
the following formula:  
 
 
 
where AbsIC50 is the absorbance at 492nm that is expected to be generated with 
the 50% inhibitory concentration of the inhibitor, AbsIC100 is the absorbance at 
492 nm generated with complete cell death following addition of inhibitor 
representing the 100% inhibitory concentration, AbsIC0 is the absorbance at 492 
nm generated with cell culture as control representing the 0% inhibitory 
concentration and AbsBG is the background absorbance at 492 nm generated 
with the detection reagents at non-toxic concentrations and without interaction 
with the test compounds (170).  
2.5.1 Apoptosis assay 
Cell membrane changes occur early in apoptosis with externalisation of 
the phospholipid phosphatidylserine (PS) from the inner membrane to the outer 
leaflet. The calcium–dependent phospholipid–binding protein Annexin V binds 
strongly to PS on the external membrane. Detection of fluorochrome–labelled 
Annexin V by flow cytometry has been exploited as a marker of early apoptosis. 
This assay was used assess the cytotoxicity of the Axl SMI BGB324. 30,000 cells 
per sample were treated with 2.5 µM and 5 µM (SNB-19) or 1 µM and 2 µM 
BGB324 (UP007) or vehicle (DMSO) for 24 hours. Following drug treatments, 
the cells were centrifuged at 400 x g for 5 minutes and re-suspended in Annexin 
V binding buffer and incubated with Annexin V-CF488A conjugate and Hoechst 
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33342 (Insight Biotechnology, Wembley, UK) for 15 minutes at 37oC using a 
heating block. The cells were then spun down at 400 x g for 5 minutes and 
washed with Annexin V binding buffer twice by repeating the centrifugation and 
resuspension. Finally, the cells were resuspended in 100 µl supplemented with 
10µg/ml propidium iodide (Insight Biotechnology) and 30 µl was loaded onto a 
special chamber slide (NC-Slide A2™) and cell populations were analysed for 
Annexin V/PI fluorescence (NucleoCounter® NC-3000™; Chemometec A/S, 
Allerød, Denmark) according to the manufacturer’s protocol.  
2.5.2 Scratch wound assay 
Linear cell migration along a surface was measured by scratch wound 
assay, where a linear scratch was made in a confluent cell monolayer with a 
200 µl yellow pipette tip. Following injury, wound closure was monitored using 
an inverted Zeiss Axiovert 200M microscope housed in a live cell imaging 
chamber under normal cell culture conditions (37°C, 5% CO2, humidified 
atmosphere). Images of 4 points per well were captured every 3 hours over a 
total period of 21 hours. Image analysis following the experiment was 
performed using ImageJ, and cell migration rates (area change/hour) calculated 
thereafter.  
2.5.3 Cell motility assay 
GBM cells were seeded in 24-well plates at low density (1,500 cells/well). 
Following treatment with BGB324 or vehicle (DMSO), live cell microscopic 
images of 4 points per well were taken every 20 minutes for 24 hours under 
normal culture conditions (37°C, 5% CO2, humidified atmosphere) using a Zeiss 
Axiovert 200M inverted live cell microscope with time-lapse imaging at 10x 
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magnification. Quantification of cell tracking, measuring distance and trajectory 
were performed using ImageJ with its ‘Cell Tracking’ plug-in. In total, 60 cells 
per condition were tracked randomly for a period of 3 hours, with total distance 
(µm) and average velocity (µm/min) being calculated.  
2.5.4 3D colony growth assay 
Wells of 24-well plates were first coated with 0.5 mL of complete 
medium/0.5% agar, and then overlaid with GBM cells suspended in complete 
medium/0.35% agar at low density (1,500 cells/well). Cells were incubated for 
2 weeks in total, with media and treatments being replenished weekly. Colonies 
present at the end of the incubation period were stained by incubation with 
0.05% crystal violet solution (Fisher Scientific) for 1 hour. Images were taken 
of each well using a Zeiss Stemi SVG dissecting microscope (1.5x 
magnification), and colonies were counted in 5 different fields of view.  
2.5.5 Cell invasion assay 
Modified Boyden transwell chambers were used to assess cell invasion 
through extracellular matrix. Briefly, polycarbonate hanging inserts (Corning, 
Amsterdam, The Netherlands) were coated with 60 µg/ml Geltrex™ LDEV-free 
reduced growth factor basement membrane matrix (Life Technologies). 
Invasion in the cell culture incubator was allowed to occur over 6 hours for 
UP007 cells (20,000 cells/well) and 16 hours for SNB-19 cells (10,000 
cells/well). Non-invading cells on the upper surface of the membrane were 
removed with a cotton swab and cells that had invaded and adhered to the 
lower side of the membrane were fixed for 15 minutes with 37% formaldehyde 
solution containing 10-15% methanol (Sigma). Following fixation and brief 
 64 
 
wash with PBS, the adherent cells were stained with 0.5% crystal violet. Images 
were captured by a Zeiss Axiophot brightfield microscope and cells were 
counted in 5 random fields at a 10x magnification. Invasion was expressed as 
mean fold±standard error of the mean (SEM) of the number of total cells 
counted per well.  
2.5.6 Cell cycle analysis 
SNB-19 cells were serum starved for 24 hours prior to being treated with 
50 ng/ml EGF alone or in combination with 2.5 μM BGB324, or vehicle (DMSO) 
for 24 hours. Following drug treatments, the cells were centrifuged at 400 x g 
for 5 minute, washed with PBS and resuspended in 70% ethanol/PBS (Thermo 
Fisher Scientific) for 2 hours on ice. Following a PBS wash, the cells were 
incubated with 1 µg/ml DAPI, 0.1% Triton X-100 in PBS (Chemometec A/S, 
Allerød, Denmark) for 5 minutes at 37oC. Thirty μl of stained cells was loaded 
onto a special chamber slide (NC-Slide A2™) and cell populations were analysed 
for DAPI fluorescence (NucleoCounter® NC-3000™; Chemometec) according 
to the manufacturer’s protocol.  
2.5.7 In vitro kinase activity assay 
The Axl Kinase Enzyme System (Promega) was employed according to 
the manufacturer’s protocol with minor modifications. Briefly, each of 
recombinant Axl or EGFR kinases (Stratech Scientific, Suffolk, UK) was 
incubated for 30 minutes with the appropriate substrate peptide 
(DCLDGLYALMSRC, 0.2 µg/µl; Pepceuticals Ltd, Leicester, UK), which contained 
Tyrosine 779 (Y779) of human Axl within it, in the presence or absence of the 
EGFR inhibitor gefitinib (10 µM) or Axl inhibitor BGB324 (10 µM), in Kinase assay 
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reaction buffer containing ATP (25 μM). DMSO was used as vehicle control 
instead of inhibitor. ADP-GloTM reagent (Promega) was then added to the wells 
and incubated at room temperature for 60 minutes. Finally, the Kinase detection 
reagent was added for 30 minutes at room temperature. Luminescence was 
read using a microplate luminometer (BMG Labtech Fluorstar Optima, 
Offenburg, Germany). To determine the kinase activity of native Axl pulled 
down SNB-19 cells by IP, the beads pellet obtained from Axl IP (described 
above) was washed a final time with Axl reaction buffer (8,000 x g for 1 minute). 
The Kinase assay reaction buffer, containing ATP (25 μM) and the Axl substrate 
peptide (0.2 µg/µl) (Promega) were added directly to the pellet, and the kinase 
reaction incubated for 30 minutes at room temperature. The reaction was 
stopped, developed and detected in the same way as for recombinant kinases 
above.  
2.5.8 Assessment of –tyrosine kinase phosphorylation status using 
an antibody array system 
The simultaneous assessment of phosphorylated tyrosine kinases was 
assessed using the R&D Proteome Profiler TM Array Human Phospho-kinase 
Array kit (R&D). Each array system has antibodies directed against 43 
phosphorylated tyrosine kinases and 2 related total proteins spotted in duplicate 
on a nitrocellulose membrane. Positive and negative internal controls were also 
spotted onto the membranes. Protein determination was performed and 50 µg 
of whole cell lysate incubated with each array overnight at 4OC, hybridising to 
the arrays via the membrane–bound antibody. The membranes were washed 6 
times in TBST for 5 minutes each wash to remove excess lysate. A secondary 
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pan–phosphor-tyrosine antibody was applied for 4 hours which bound to the 
phosphorylated tyrosine residues. The membranes were washed 6 times in 
TBST for 5 minutes each wash to remove antibody. Signals were detected by 
chemiluminescence provided by each kit. The pixel density of each array spot 
was measured and expressed as optical density (OD)/mm2. To account for 
variation in exposure, 6 blank readings and readings over the negative control 
markers were performed. All signal readings were exported to Microsoft Excel. 
The mean signal for the pair of duplicate spots representing each TK was 
determined and the median blank and negative reading was subtracted to give 
the final reading.  
2.6 Statistical analyses 
All data are expressed as mean±SEM, obtained from a minimum of 3 
independent experiments, each constituting multiple replicates per condition. 
Quantitative data were analysed by Analysis of Variance (ANOVA) with post hoc 
Tukey test for multiple comparisons with one control group or multiple time 
points/treatments or paired t-test for comparisons of control with treatment 
Statistical analyses and graphical representations were performed using Prism 
(GraphPad Software Inc). The level of statistical significance is indicated in the 
figures and accompanying legends. Western blot film processing was performed 
using Adobe Photoshop CC 2014 software (Adobe Systems Incorporated, CA, 
USA).  
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Chapter 3 
 
Investigating TAM receptors 
and their ligands in GBM 
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3.0 Introduction  
Brain cancer is often associated with high mortality rates and is one of 
the most frequent tumours of the economically active population. Glioblastoma 
multiforme (GBM), the most common type of brain cancer in adults, is highly 
heterogeneous and aggressive, with patients facing a year of survival after 
diagnosis (171). Despite intensive research, no real progress has been made in 
treating this malignant type of tumour. 
Vajkoczy et al, first reported Axl overexpression in gliomas and noted 
that high Axl/Gas6 expression in GBM patients correlated with poor overall 
survival, indicating that Axl may significantly contribute to glioma progression. 
Experimental blockade of Axl signalling with either siRNA or introduction of 
dominant negative Axl protein resulted in decreased growth and invasive 
potential of GBM cells in culture (137, 138, 140). Axl and Gas6 mRNAs were 
then demonstrated to be overexpressed in high grade gliomas and more 
specifically, glioma cells of pseudopalisades and reactive astrocytes (137). 
Moreover, Axl/Gas6 co-expression occurred in tumour vessels with no 
expression detected in non-neoplastic surrounding tissue (137). Interestingly, 
Axl inhibition by siRNA resulted in a better response to the current mainstay 
glioma chemotherapeutic agent temozolomide, as well as more recent 
combination chemotherapeutic drugs carboplatin, and vincristine (140, 172, 
173). Together, these observations suggest the TAMs to be an attractive new 
target for GBM therapy.  
The primary aim of this section is to provide an in depth characterisation 
of the TAMs in two human GBM cell lines in terms of TAM expression and 
activation by established as well as novel ligands, with the aim of forming a 
 69 
 
better understanding of the role of TAM signalling in promoting GBM 
progression.  
3.1 Results  
3.1.1 The TAMs are overexpressed in GBM cells 
To begin with, an expression screen of all TAMs in different human brain 
cell types, as well as the GBM cell lines involved in this study, was conducted. 
The commercially available SNB-19 and in-house UP007 GBM cell lines were 
selected for this study. First, in advance of the first TAM experiments, a 
population doubling time analysis was performed for both cell lines by plating 
an equal number of cells (10 000) and then counting them using a 
haemocytometer every 24 hours for 3 days. The values were plotted as shown 
in Figure 3.1A and the population doubling time was calculated using the 
equation derived from the slope. SNB-19 cells were calculated to double every 
27 hours and UP007 cells every 30 hours. In addition, clonogenic assays 
confirmed that the SNB-19 cell line has a greater proliferative capacity as 
indicated by the number of colonies produced after two weeks in soft agar 
(Figure 3.1B). However, the UP007 cell line was the more invasive of the two, 
as more cells were able to invade through a matrix compared to SNB-19 cells 
over 6 hours (Figure 3.1C). 
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Figure 3.1: Cell line characteristics. A. Cell number plotted versus time graph. 
Population doubling time was calculated by the line equation (N=3). B. Bar graph 
showing the number of colonies counted for each cell line after two weeks in soft agar 
(N=3). C. Representative pictures of cell invasion. Cells were allowed to invade through 
matrix for 6 hours before staining using PDGF-AA as a chemoattractant (N=1 
experiment); scale bar=55 µm. Unpaired two-tailed student t-test. Data are 
mean±SEM *p<0.05. PDT, population doubling time. 
 
After establishing these fundamental phenotypic characteristics of the 
cells, a comparative expression analysis of the TAM receptors across the various 
cell types was performed. As shown by Western blotting in Figure 3.2A, all three 
TAMs were expressed in human brain microvascular endothelial cells 
(hcMEK/D3), whilst only Axl and Tyro3 were expressed in normal human 
astrocytes (HA-c). Both Axl and Tyro3 were found to be highly expressed in 
both of the GBM cell lines SNB-19 and UP007, whilst MerTK was expressed at 
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low levels in SNB-19 cells. qRT-PCR confirmed the Western blot results, showing 
similar expression patterns at the mRNA level (Figure 3.2B-E). Additionally, 
Gas6 mRNA was found at high levels in cultured normal human cerebellar 
astrocytes and the UP007 cell line (Figure 3.2E). As MerTK levels were minimal 
in the SNB-19 cell line and not detectible in the UP007 cell line, the rest of the 
studies focused only on Axl and Tyro3 receptors.  
 
Figure 3.2: TAM and ligand screen. A. Western blot screen of TAM receptors in protein 
extracts from a panel of human brain cell cultures: microvascular endothelial cells 
(hCMEC/D3), astrocytes (HA-c) and two GBM cell lines, SNB-19 and UP007. B. 
Quantitative PCR analysis of mRNA expression of the genes for Axl, MerTK, Tyro3 and 
Gas6 in extracts from human whole brain (WB), endothelial cells, astrocytes, SNB-19 
and UP007 cells (N=3 separate experiments).  
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In conjunction with previous studies on Axl expression in GBM available 
on Gene Expression Omnibus (GEO) profiles, a public functional genomics data 
repository, slides with a brain tumour tissue microarray (TMA), including normal 
brain sections, were immunostained for Axl and Tyro3. Staining confirmed 
expression of Axl in reactive astrocytes in 14 out of 73 GBM samples (Figure 
3.3), whilst Tyro3 expression varied in samples with high and low expression in 
the normal brain and GBM tissues (Figure 3.4).  
 
Figure 3.3: Axl screening and tumour formation abilities. Left panel shows 
representative images for Axl staining in normal brain, middle panel presents Axl 
negative GBM and Axl positive GBM is presented in right panel. Arrows represent Axl 
positive endothelial cells in normal brain vasculature and positive astrocytes in Axl 
positive GBM tissue. Scale bar=68 µm. 
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Figure 3.4: Tyro3 screening. Left panel shows representative images for Tyro3 staining 
in normal brain, middle panel presents low Tyro3 expression in GBM tissue and high 
Tyro3 expression in GBM is presented in right panel. Arrows represent Axl positive 
endothelial cells in normal brain vasculature and positive astrocytes in Axl positive GBM 
tissue. Scale bar=53 µm. 
 
Moreover, in collaboration with researchers at the University of Bergen, 
orthotopic implantation of 500 000 SNB-19 and UP007 cells into nude rats was 
performed. The SNB-19 cells were able to produce tumours whilst the UP007 
cell line failed (Figure 3.5).  
 
Figure 3.5: Axl tumour formation abilities. Left: representative image of cell 
implantation into rat brain in a stereotactic frame. Middle: Coronal section showing 
MRI detection of tumour mass (red arrow) of SNB-19 cells 9 months after implantation. 
Right: Coronal section MRI scan of rat brain injected with UP007 cells, with no sign of 
tumour. 
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3.1.2 Gas6 activates Axl signalling in GBM cells 
Gas6 and Protein S are the natural ligands for the TAMs in both normal 
and tumorigenic environments. However, studies have indicated that 
overexpression of Axl in cancer can lead to ligand-independent activation. 
Having established the overexpression of Axl in glioblastoma cell lines, the next 
phase focused on receptor activation. Gas6 is the highest affinity ligand for all 
three TAM receptors and has also been found to be overexpressed in glioma 
(137, 138). The cultured GBM cells were stimulated with exogenous 
recombinant human Gas6 over a time course period and cell lysates were 
analysed by Western blot in order to detect receptor activation through its 
phosphorylation state. Addition of Gas6 resulted in a significant increase in 
phosphorylation of Axl in SNB-19 cells after 15 minutes of stimulation (Figure 
3.6A, p<0.0061, ANOVA with Tukey’s multiple comparison post-hoc analysis) 
but failed to do the same in UP007 cells even after 1 hour (Figure 3.6B, 
p<0.9627, ANOVA with Tukey’s multiple comparison post-hoc analysis). 
Additionally, Gas6 was unable to stimulate Tyro3 phosphorylation in both cell 
lines (Figure 3.6E-F, p<0.8504 and p<0.7441 for SNB-19 and UP007 
respectively, ANOVA with Tukey’s multiple comparison post-hoc analysis). 
However, Gas6 rapidly induced downstream intracellular Akt phosphorylation, 
a well-known downstream Axl target, in both cell lines by approximately two-
fold, therefore supporting the activation of Axl signalling in these cells (Figure 
3.6C-D, p<0.0294 and p<0.0156 for SNB-19 and UP007 cells respectively, 
ANOVA with Tukey’s multiple comparison post-hoc analysis) (Total Axl Western 
blots are shown in Appendix 1).  
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Figure 3.6: Effect of Gas6 stimulation on TAM phosphorylation and signalling in GBM 
cells. Western blot showing time-course of Axl phosphorylation by Gas6 (400 ng/ml) 
in SNB-19 and UP007 cells (A; N=5 blots for both cell lines), of Tyro3 phosphorylation 
in SNB-19 and UP007 cells (B; N=3 blots for both cell lines), and of pAkt levels (C) in 
SNB-19 (N=3 blots) and UP007 (N=4 blots) cells. Data are mean±SEM protein 
expression normalised against loading control protein; ANOVA with Tukey’s multiple 
comparison post-hoc analysis. ***p<0.001, *p<0.05 and ns, not significant, versus 
time 0.  
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3.1.3 Effect of novel proposed TAM ligands on Axl activation 
While both Gas6 and Protein S are well established ligands for the TAM 
receptors, less is known about Tulp-1, Tubby and Galectin-3; these three 
molecules were recently suggested to activate MerTK to enhance its role in 
efferocytosis (111, 174). Therefore, having investigated the effect of Gas6 on 
Axl activation, the focus turned on Tulp-1 and Galectin-3 as they have been 
shown to be overexpressed in many cancers but had hitherto not been studied 
in brain tumour cells. Comparing with the effects of Gas6 and Protein S as 
controls, the response of TAMs to Galectin-3 and Tulp-1 was tested by Western 
blotting for the phosphorylated receptors. Axl and Tyro3 were activated by both 
novel ligands in a dose-dependent manner in both cell lines. Choosing the 
higher concentrations of 500 ng/ml for Galectin-3 and 1000 ng/ml Tulp-1 
respectively (Figure 3.7A-B), time course stimulation experiments confirmed 
activation of the receptors. The SNB-19 cell line was found to be more 
responsive to both novel ligands, with Axl activation occurring within two 
minutes of ligand addition. The UP007 cell line however, did not respond to 
Tulp-1, and an increase in Axl phosphorylation was observed only after 60 
minutes of Galectin-3 ligand addition (Figure 3.7C-D).  
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Figure 3.7: Effect of ligand stimulation on TAM phosphorylation and signalling in GBM 
cells. Western blot showing dose response of Axl (A) and Tyro3 (B) phosphorylation 
by Gas6 (400 ng/ml), Protein S (1000-10 ng/ml), Galectin-3 (500-5 ng/ml) and Tulp-1 
(1000-1 ng/ml) (N=1 blot). C. Western blot showing time-course of Axl 
phosphorylation by Galectin-3 (500 ng/ml) in SNB-19 and UP007 cells (N=2 blots). D. 
Western blot showing time-course of Axl phosphorylation by Tulp-1 (1000 ng/ml) in 
SNB-19 and UP007 cells (N=2 blots). 
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3.1.4 TAM activation promotes cell growth/survival 
The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) assay has been long used in cell culture to 
measure cell growth (175). The assay enables the quantification of cell viability 
through the reduction of MTS tetrazolium compound by viable cells to generate 
a coloured formazan product that is soluble in cell culture medium (176). In 
order to assess the effect of TAM activation by traditional and novel ligands, 
cells were plated in equal numbers into 96-well plates and serum starved for 
24 hours prior to addition of ligands at increasing concentrations for 3 days. As 
shown in Figure 3.8A, Gas6 at 600 ng/ml significantly increased cell 
growth/viability after 3 days in SNB-19 cells (Figure 3.8A, p<0.0281, ANOVA 
with Tukey’s multiple comparison post-hoc analysis), whereas 1000 ng/ml of 
Gas6 was required for UP007 cells to show increased cell growth/viability 
(Figure 3.8A, p<0.0313, ANOVA with Tukey’s multiple comparison post-hoc 
analysis). In addition, Galectin-3 significantly increased growth/viability of SNB-
19 cells even at the lowest concentration of 0.5 ng/ml (Figure 3.8B, p<0.0028, 
ANOVA with Tukey’s multiple comparison post-hoc analysis). An increase in cell 
growth/viability was also observed in the UP007 cells, which required the higher 
dose of 500 ng/ml (Figure 3.8B, p<0.0374, ANOVA with Tukey’s multiple 
comparison post-hoc analysis). Tulp-1 stimulation had no effect on cell 
growth/viability as shown in figure 3.8C (p<0.9799 and p<0.7533 for SNB-19 
and UP007 cells respectively, ANOVA with Tukey’s multiple comparison post-
hoc analysis).  
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Figure 3.8: Effect of TAM activation on cell proliferation. MTS assay for serum starved 
SNB-19 and UP007 cells treated with recombinant Gas6 (0-1000 ng/ml; A), Galectin-3 
(0-500 ng/ml; B) and Tulp-1 (0-1000 ng/ml; C) for 3 days. Data are mean±SEM; N=3 
separate experiments, with each treatment in quadruplicate wells. ANOVA with Tukey’s 
multiple comparison post-hoc analysis *p<0.05; ***p<0.001 vs untreated; ns, not 
significant.  
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3.2 Discussion 
The related RTKs Axl and MerTK have recently been associated with 
glioma pathophysiology (137, 140), and therefore have emerged as attractive 
novel therapeutic targets for brain tumours as part of individualised treatment 
approaches. In this section, the TAM and TAM ligand profile for two 
glioblastoma cell lines was provided.  
3.2.1 TAM expression in the brain 
The TAMs are expressed ubiquitously in the body and have a wide variety 
of functions. Expression levels vary between tissues depending on function. 
Tyro3 is most highly expressed the nervous system, ovaries, testis, breast, lung, 
kidney, osteoclasts, retina, monocytes/macrophages, and platelets (120). Axl 
has the broadest expression profile of all the TAMs, being expressed in a wide 
variety of tissues including the hippocampus, cerebellum, heart, skeletal 
muscle, liver, kidney, testis, brain, monocytes, macrophages, platelets, 
endothelial cells and dendritic cells (120). MerTK expression is found in the 
ovary, prostate, testis, lung, retina, and kidney, and macrophages, dendritic 
cells, NK cells, NKT cells, megakaryocytes and platelets; low levels are also 
found in the heart and skeletal muscle cells (120). Of particular relevance to 
this study is the finding that the normal brain expresses very low to 
undetectable levels of MerTK and Axl (121).  
In agreement with previous studies, Axl was shown to be highly 
expressed in human normal brain microvascular endothelial cells whilst at low 
levels in cultured normal human astrocytes (123). Both qRT-PCR and Western 
blot analyses revealed that Axl is overexpressed in glioblastoma tumours (Figure 
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3.1). In accordance with previous findings by Hutterer and colleagues, Axl 
expression was also confirmed by human glioblastoma tissue staining and found 
to be mostly present in reactive astrocytes (137) (Figure 3.3). In contrast to 
previous reports showing MerTK to be overexpressed in glioma and promote 
survival and invasion (177, 178), it was found to only be expressed in human 
microvascular endothelial cells, but was absent from astrocytes and was 
detected only at low levels in the SNB-19 cell line. Tyro3 was as expected 
present in both the human microvascular endothelial cells and astrocytes (121); 
however, interestingly, it was also found to be overexpressed in both GBM cell 
lines. This indicates a novel avenue for study, as Tyro3 overexpression has not 
been previously reported in brain cancer. However, given that only two GBM 
cell lines were tested, it is not yet clear whether Tyro3 overexpression is more 
widespread in GBM or if it has any wider significance in tumorigenesis. An 
immunohistochemical analysis for Tyro3 expression in a 96 human brain cancer 
tissue microarray screen turned out futile due to lack of an effective antibody 
for immunostaining. Two different anti-human Tyro3 antibodies were tested, 
both of which appeared to stain the entire tissue non-specifically, thus making 
it impossible to make any conclusions (Figure 3.4). Ideally, both Western blot 
and qRT-PCR analysis should be performed on fresh biopsy tissues in order to 
overcome this issue. Similarly, Gas6 was only detectable by qRT-PCR analysis, 
also due to the lack of a specific antibody. Nevertheless, Gas6 was present in 
all the samples tested at the mRNA level, with highest expression in human 
astrocytes and the UP007 cell line, as also confirmed by the transcriptome 
database of acutely isolated purified astrocytes, neurons, and oligodendrocytes, 
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which was assembled by the Barres group to provide cell-type-specific markers 
(123).  
3.2.2 RTK activation by classic TAM ligands 
The TAMs are known to be activated by binding of their natural ligands 
Gas6 and Protein S, both homologous vitamin K-dependent proteins. Both 
ligands contain an N-terminal region comprised of the vitamin K-dependent set 
of post-translationally modified Gla residues, a loop region, four EGF-like 
repeats, and a SHBG-like structure that is composed of two LG domains. The 
loop region of Protein S contains thrombin-sensitive cleavage sites which are 
not present in Gas6, setting the two ligands apart (108). 
Even though Gas6 shows 43% amino-acid sequence identity with protein 
S (108), studies have shown that Axl is activated exclusively by Gas6 but not 
by Protein S (103). In contrast, Tyro3 preferentially binds Protein S compared 
to Gas6, whereas MertK binds both ligands weakly (103). Additionally, it has 
been shown that structurally, the two LG domains of Gas6 possess specific 
epitopes that crosslink the two Axl Ig domains with a 2:2 stoichiometry (Figure 
3.9), whereas Gas6 binds Tyro3 and MerTK with a 1:1 stoichiometry due to the 
lack of a major Gas6 binding site on the latter receptors (103).  
 
Figure 3.9: Binding of Gas6 on Axl receptor vs Tyro3/MerTK. Figure shows Gas6-
induced Axl homodimerisation on the left and weak Gas6 binding to either Tyro3 or 
MerTK. Figure adapted from (103).  
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Studies have shown that Axl overexpression can involve self-activation 
even in the absence of ligand (179). Indeed, in both the SNB-19 and UP007 cell 
lines, a basal Axl activation was observed, which only in the case of the SNB-
19 cell line was augmented by exogenous Gas6 (Figure 3.6). A basal level of 
Tyro3 phosphorylation was also detected by Western blot; however, exogenous 
Gas6 had no additional effect on receptor activation (Figure 3.6). Consequently, 
TAM receptor activation may occur in two ways: (i) Gas6 can activate the TAMs 
in an autocrine and/or paracrine manner. Both of our cell lines express Gas6 at 
the mRNA level, thus being able to activate the receptors fully to reach a 
saturated state. Indeed, Gas6 was present in the SNB-19 cells at lower levels 
than UP007, and therefore this could explain why this cell line was responsive 
to Gas6 stimulation, as the exogenous ligand was abler to activate the cell line 
that possessed less of the ligand and therefore was more sensitive to it. (ii) 
Alternatively, Axl and Tyro3 overexpression leads to ligand-independent 
activation, therefore addition of the ligand has no dramatic effect. Additionally, 
the independence of Gas6 observed in the case of Tyro3 could be a by-product 
of receptor heterodimerisation which is discussed in detail in Chapter 6. The 
TAMs have been speculated to heterodimerise and form a signalling complex. 
Indeed, Axl and Tyro3 have been shown to co-immunoprecipitate in rat cells 
and able to cross-phosphorylate each other (180).  
Gas6 had no effect on Tyro3 phosphorylation in both SNB-19 and UP007 
cells. Given the preferential binding of Gas6 to Axl, the particular ligand-receptor 
binding stoichiometry, as well as a greater overexpression of Axl vs Tyro3 in 
the GBM cells, Axl could act as a quencher and thereby prevent any Tyro3 
activation by the ligand.  
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3.2.3 RTK activation by novel TAM ligands 
Galectin-3 and Tulp-1 have recently been identified as novel ligands for 
the TAMs (111, 174). Galectin-3 is a member of the lectin family and is 
comprised of two protein domains, a C-terminal carbohydrate-binding domain 
and an N-terminal oligomerisation domain (181) (Figure 3.10). 
 
Figure 3.10: Galectin-3 structure. Figure was adapted by (182). 
Galectin-3 has been linked to many different cellular processes, with the 
most relevant being cell adhesion, cell growth and differentiation, cell cycle 
regulation and regulation of apoptosis (183). Moreover, Galectin-3 expression 
has been shown to be highest in GBM compared to other types of brain cancer 
and more specifically in neoplastic astrocytes, macrophages/microglial cells, 
endothelial cells and some B- and T-lymphocytes (184). Galectin-3 expression 
has been linked to glioma cell motility, angiogenesis, survival and invasion 
(Figure 3.11) but the full repercussions and mechanisms of expression are still 
unclear (185, 186). Galectin-3 expression in GBM coincides with the one for Axl, 
indicating that receptor activation by Galectin-3 could potentiate a novel 
activation mechanism for Axl. Interestingly, Galectin-3 biological functions are 
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modulated by MMP2 and MMP9 (184), both of which are downstream Axl 
targets (187). Hence, Axl may modulate Galectin-3 to promote GBM cell 
invasion and survival. Moreover, Galectin-3 overexpression could serve as to 
inhibit microglia activation through TAM activation and thus limit tumour 
induced inflammation. The functions of Galectin-3 in GBM could be numerous 
and diverse thus making it a promising target along with the TAMs. 
 
Figure 3.11: Presumed role of galectins in angiogenesis and chemoresistance. Necrotic 
foci in glioblastoma are typically surrounded by hypercellular zones referred to as 
pseudopalisades. It has been shown that pseudopalisades are hypoxic and express 
high amounts of the HIF-1. Galectin-3 (Gal-3) expression is stimulated by hypoxia via 
HIF-1 and stimulates angiogenesis in vitro and in vivo. Gal-3 has also been shown to 
interact with NG2 proteoglycan, a component of microvasculature pericytes, which 
stimulates endothelial cell motility and morphogenesis. In addition, Gal-3 is involved in 
chemoresistance, a process that is increased in hypoxic conditions (184).  
 
Tulp-1 belongs to novel family of tubby proteins which share the highly 
conserved C-terminal (Figure 3.12). Tulp-1 is selectively expressed in the retina 
and is considered to be a phagocytosis-stimulating molecule in retinal pigment 
epithelium cells (188).  
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Figure 3.12: Tub proteins structure. Figure shows the conserved c-terminal tubby 
domain which contains the DBD and the phosphatidylinositol-binding region and the 
less conserved N-terminus is (189).  
 
Information on Tulp-1 function and signalling is still scarce. Nevertheless, 
from a handful of studies, Tulp-1 was shown to interact with all three TAM 
receptors in co-immunoprecipitation experiments (111), whilst an interaction 
with Galectin-3 was only confirmed for MerTK, with its affinity for Axl and Tyro3 
being unknown in that study (174). Tulp-1 was shown to act as a bridging 
molecule through its N-terminal minimal phagocytic determinants domain for 
MerTK binding and C-terminal phagocytosis prey-binding domain for prey 
binding (111). Functionally, both ligands were found to be associated with 
MerTK associated phagocytosis (Figure 3.13) (111, 174); however, their 
physiological significance in other settings is yet to be determined.  
 
Figure 3.13: Tulp-1 facilitates phagocytosis as MerTK-dependent bridging molecule. 
Tulp1 bridges phagocytosis preys, through the C-terminal PPBD and MerTK through 
the N-terminal MPD(s) leading to phagocytosis (111).  
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 In this study, both Galectin-3 and Tulp-1 activated Axl and Tyro3 
phosphorylation in both GBM cell lines (Figure 3.7), with a more pronounced 
effect in SNB-19 cells. Tulp-1 seems to activate Tyro3 more strongly than Axl 
in both cell lines, whilst Galectin-3 showed no preference in receptor activation. 
Interestingly, Tulp-1 increased Tyro3 phosphorylation as much as Protein S, 
which is the preferred Tyro3 ligand (108); however, Galectin-3 failed to do so. 
Moreover, Galectin-3 led to Axl phosphorylation in Gas6-independent UP007 
cells whilst it had a less pronounced effect on Tyro3, indicating a stronger 
affinity for Axl, as well as a higher receptor affinity than Gas6. Even though 
phosphorylation of Axl was observed by both ligands in GBM cells, further 
devoted studies are required to determine the level of activation and affinity for 
the receptors. Since these two ligands are structurally different from Gas6 and 
Protein S, crystallographic and modelling studies can shed light on the exact 
binding sites and how these differ from canonical ligands. Moreover, it still 
unclear whether binding of Galectin-3 and Tulp-1 to the TAMs diversifies 
downstream signalling. Microarray studies following stimulation with all four 
ligands and bioinformatics analysis could indicate common pathways as well as 
point out proposed functions. Furthermore, kinase activity assays following 
ligand stimulation can indicate the degree of receptor activation, as well as 
receptor kinase functionality. In the case of glioma, it would be interesting to 
perform functional assays such as scratch wound, invasion and proliferation 
assays to identify their role. Moreover, knockdown of the ligands should be 
investigated in glioma in order to determine ligand compensation, as well as 
antagonism. It would also be interesting to investigate the effect of 
overexpression of all ligands and how their expression affects TAM receptor 
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activation and downstream signalling. Given their diverse roles, it is possible 
that ligand binding determines TAM receptor downstream response and 
predetermines the biological function regulated. For example, Galectin-3 
binding can affect the TAMs on microglia more than endothelial cells, whereas 
Gas6 may act more potent as an angiogenesis promoting factor. In this study, 
the activation of both Axl and Tyro3 receptors has been investigated however 
these results are only preliminary and were not pursued further due to time 
constraints and other priorities of the project. Thus, a more detailed 
investigation should ensue. 
3.2.4 TAM activation promotes cell growth 
In this study Galectin-3 was shown to drastically increase cell 
growth/survival after serum starvation of the cells whilst Tulp-1 had no effect. 
Even though Gas6 has previously been shown to protect cells of the CNS from 
serum deprivation-induced cell death (190), such an investigation had not 
hitherto been carried out for Galectin-3. Treatment of cells with Galectin-3 
drastically increased cell viability/growth as shown by MTS assay (Figure 3.8), 
indicating for the first time that it may act as a mitogenic or pro-survival factor. 
Moreover, Galectin-3 was able to increase cell viability/growth at lower 
concentrations than Gas6. Together with the observation that Galectin-3 
activated Axl more readily than Gas6 in time-course experiments, these results 
may suggest that Galectin-3 maybe a stronger ligand for Axl binding. However, 
this cannot be proven until biochemical and biophysical investigations are 
carried out to determine the absolute affinity, kinetics and stoichiometry of the 
protein-protein interaction between Galectin-3 and Axl. Also, as the MTS assay 
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cannot distinguish between increased proliferation or reduced cell death, to 
further investigate the comparative effects of Gas6 and Galectin-3 on GBM cells, 
a detailed cell cycle analysis should be performed after treatment in order to 
identify how each cell cycle phase is affected. This technique is based on the 
ability of a fluorescent dye to stain DNA. The fluorescence intensity correlates 
with the amount of DNA in the cell which changes as the cell exits G1 to enter 
the S and progress to G2 and M phases (191). Moreover, the effect observed 
could be the result of an alternative mechanism, as Galectin-3 has been shown 
to bind and activate other receptors as well. In order to distinguish between Axl 
and other receptors a blocking antibody for Axl can be used to prevent ligand 
binding and then stimulate cells with exogenous Galectin-3. If Galectin-3 acts 
via Axl then no change in cell viability would be observed. 
3.2.5 Summary 
This chapter focuses on the functional and molecular characterisation of 
two GBM cell lines, SNB-19 and UP007, and their responses, and 
responsiveness, to the TAM ligand Gas6 in both ligand-dependent and –
independent manners. This will enable us to further investigate any signalling 
pathways involved downstream of Axl in these cell lines as well as to elucidate 
the functional importance of Axl in GBM.  
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Chapter 4 
 
Axl blockade inhibits GBM cell 
invasion 
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4.0 Introduction  
Novel SMIs of RTKs are increasingly being developed as promising new 
targeted molecular therapies for a variety of cancers. Axl RTK has become an 
increasingly attractive target in the past years, especially since the discovery of 
its overexpression and related increased invasiveness and chemoresistance in 
a large number of cancers (102, 192, 193). BGB324 (also known as R428) [(1-
(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-((7-pyrrolidin-
1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1H-1,2,4-triazole-3,5-di-
amine)] is a highly selective SMI of Axl (out of 133 tyrosine and serine/threonine 
kinases tested) (160). In MTS assays, BGB324 was shown to affect cell viability 
with IC50 values ranging from 0.79–2.13 μmol/L in Ewing sarcoma (194) and to 
exhibit minimal off target effects with concentrations varying from 0.95 to 3.39 
µM in a variety of cell lines (160). Treatment of mesenchymal carcinoma cells 
with BGB324 abolished cell invasion and increased chemosensitivity (195), 
whilst it nullified the tumorigenic effect of triple negative breast cancer as well 
as blocking their acquired resistance to erlotinib (anti-EGFR SMI). BGB324 is 
currently in Phase 1b clinical trials for acute myeloid leukaemia and non-small 
cell lung cancer, and has so far been shown to be safely tolerated in clinical 
safety studies in healthy volunteers at doses up to 1.5 g daily 
(http://www.bergenbio.com/BGB324). Additionally, in breast cancer mouse 
models, twice daily dosing of 25, 50, and 100 mg/kg BGB324 resulted in mouse 
plasma concentrations of 2.4, 6.8, and 9.0 µM BGB324 respectively (160). 
BGB324 represents the most promising Axl SMI due to its high selectivity for 
Axl compared to other SMIs currently in trials (163)  
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In this chapter, a comprehensive study of the cell biological and 
signalling effects of BGB324 on two distinct patient-derived GBM cell lines is 
presented. Additionally, confirmation of the effects of BGB324 as being Axl-
selective was enabled through parallel experiments on the same GBM cell lines 
with Axl stably knocked down.  
4.1 Results  
4.1.1 Establishment of stable Axl knockdown cell lines 
In the previous chapter, it was established that Axl is overexpressed in 
two human GBM cell lines. To determine whether removal of Axl expression 
influences survival, proliferation and invasion in glioma cells, stable Axl 
knockdown GBM cell lines were created using 4 different short hairpin (sh) RNA 
vectors, along with additional cell clones incorporating one scramble shRNA 
vector and one empty vector. The chosen shRNA containing vectors contained 
a puromycin resistance cassette for selection. Initially, a killing curve was 
performed for one week with puromycin concentrations ranging from 0 to 1.5 
µg/ml as suggested by the manufacturer’s protocol, to determine the specific 
sensitivity of the two GBM cell lines. Cell death was observed in both cell lines 
at the higher concentrations of puromycin, and the effective, highest 
concentration of puromycin at which cells could survive was determined to be 
1 µg/ml for the SNB-19 cell line and 0.75 µg/ml for UP007 cells (Figure 4.1).  
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Figure 4.1: Puromycin killing curve for SNB-19 (left) and UP007 (right). 250 000 cells 
were plated in 6-well plates and treated with puromycin concentrations 0-1.5 µg/ml 
for two weeks. Images obtained using the x5 objective under the phase contrast 
microscope.  
 
Following puromycin titration, cells were plated in 10 cm dishes and 
transfected with 1 µg of 4 unique 29 mer shRNA OriGene constructs in retroviral 
untagged vector and control vectors (Cambridge Bioscience; Cambridge, UK). 
After three days, puromycin was added at predetermined concentrations and 
selection was allowed to occur over two weeks. Cells that had taken up the 
vector would be resistant to puromycin and thus stayed alive. After this period, 
transfected cells remaining alive in the dish were trypsinised and seeded into 
new 10 cm dishes at 1:10 dilution, which allowed single cells to adhere apart 
from each other and expand clonally thereafter.  
After 4 weeks, each of 12 clear colonies for each vector were picked with 
a yellow tip and transferred into a well of a 24-well plate, whilst remaining under 
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puromycin selection. For each cell line, 24 individual colonies were picked and 
expanded. The clones were screened for Axl expression by Western blot. For 
the SNB-19 cells, we successfully obtained a clone for each construct with 
varying Axl knockdown levels, whilst, notably, the UP007 cells only produced 
one viable clone that was able to be expanded (Figure 4.2).  
 
 
 
Figure 4.2: Western blot for selected cell clones confirming Axl knockdown for SNB-19 
(left) and UP007 (right) cells, followed by densitometric semi-quantitation of Axl 
expression normalised to β-actin. (N=1) 
 
4.1.2 Axl knockdown reduces cell growth/viability 
Following the successful establishment of stable Axl knockdown clones 
for both cell lines, the MTS assay was employed to determine the effect on cell 
growth/viability. The SNB-19 cell line was not particularly affected by Axl 
knockdown as shown in Figure 4.3 (p<0.3371, ANOVA followed by Tukey’s 
multiple comparisons test). In stark contrast, establishing viable clones with Axl 
knockdown for the UP007 cell line was challenging. The clones were not viable 
and the MTS assay also confirmed significantly decreased cell viability and 
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growth rate for the single UP007 clone lacking Axl (Figure 4.3, p<0.0001, 
ANOVA followed by Tukey’s multiple comparisons test. This suggested that 
knockdown of Axl deleteriously affected the survival of these cells.  
 
Figure 4.3: MTS assay for Axl knockdown clones. Data are mean ±SEM; N=3 separate 
experiments with each treatment in quadruplicate wells. ANOVA with Tukey multiple 
comparison post-hoc analysis *p<0.05; ****p<0.0001; ns, not significant, for 
comparisons indicated.  
 
4.1.3 Axl knockdown inhibits cell migration 
The scratch wound, or wound healing, assay is used to study cell 
migration in vitro. An artificial gap is made on a confluent cell monolayer, which 
is filled by migrating cells on the gap edge. Capture of images at regular 
intervals can then enable quantitative determination of the rate of cell migration 
(196). Near-complete Axl knockdown in SNB-19 cells severely impaired cell 
migration (Figure 4.4A, p<0.0022, ANOVA followed by Tukey’s multiple 
comparisons test). However, even a low, residual level of Axl expression in 
shRNA clones was sufficient to counteract this anti-migratory effect of Axl 
knockdown in SNB-19 cells (Figure 4.4A). A decreased migration rate was also 
observed in the single UP007 Axl knockdown clone (Figure 4.4B, p<0.0001, 
ANOVA followed by Tukey’s multiple comparisons test). 
 96 
 
 
Figure 4.4: Effect of Axl knockdown on cell migration. Representative images from 
scratch wound assay at 0 and 21 hours followed by graphical representation of area 
change per hour for (A) SNB-19 shAxl clones and control and (B) UP007 shAxl clone 
and control. Data are mean ±SEM; N=3 separate experiments with 2 scratches per cell 
clone.; ANOVA with Tukey multiple comparison post-hoc analysis ****p<0.0001, 
**p<0.01, * p<0.05 for comparisons indicated.  
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4.1.4 Selective Axl inhibition by two SMIs reduces cell viability 
For this study, the effect on cell viability of two SMIs currently in phase 
I clinical trials, BGB324 (BergenBio, Bergen, Norway) and BMS777607 (Santa 
Cruz, CA, USA) was evaluated. Cells were treated with BGB324 (5 µM-0.1 µM) 
or BMS777607 (2-100 µM) and cell viability was assessed after three days by 
MTS assay (Figure 4.5). BGB324 significantly reduced cell viability from 2 µM in 
SNB-19 cells (Figure 4.5A, p<0.0001, ANOVA with Tukey multiple comparison 
post-hoc analysis) whilst this was apparent from 1 µΜ in UP007 cells (Figure 
4.5B, p<0.0001, ANOVA with Tukey multiple comparison post-hoc analysis). 
BMS777607 on the other hand reduced cell viability from 20 µM for both SNB-
19 and UP007 cells (Figure 4.5C-D, both p<0.0001, ANOVA with Tukey multiple 
comparison post-hoc analysis). The half maximal inhibitory concentration (IC50) 
measures the concentration of an inhibitor which is required for it to reduce the 
measured response by half. In this way, the IC50 is usually used to describe the 
potency of a drug. In order to directly compare the two SMIs used in this study, 
the IC50 values were calculated from the concentration–response curves 
generated from the MTS assay. 
In the MTS assay, the IC50 for BGB324 was calculated to be 2.5 μM for 
SNB-19 cells and 1 μM for UP007 cells, whereas for BMS 777607, it was 
calculated to be 118.5 µM for SNB-19 and 35 µM for UP007 cells (Figure 4.5). 
These results indicate that the UP007 cell line is roughly 2.5-fold more 
susceptible to Axl inhibition than SNB-19, indicating that it may be more 
dependent on Axl signalling. Since BGB324 was more potent than BMS777607, 
we decided to utilise exclusively BGB324 thereafter as a research tool to inhibit 
Axl for the rest of the study. 
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Figure 4.5: MTS assays for SNB-19 (A and C) and UP007 (B and D) cells treated with 
varying concentrations of BGB324 and BMS777607 respectively followed by % 
inhibition vs Log BGB324/BMS777607 concentration graphs with IC50 values. Data are 
mean ±SEM; N=3; ANOVA with Tukey multiple comparison post-hoc analysis 
****p<0.0001, ***p<0.001, **p<0.01, * p<0.05 vs untreated (0) cells.  
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4.1.5 BGB324 selectively inhibits Axl activity in GBM 
The effect of BGB324 on Gas6-stimulated activity of Axl and Tyro3 in the 
GBM cell lines was investigated by Western blotting of the phosphorylated 
(activated) states of both RTKs. Pre-incubation with BGB324 for 1 hour, at up 
to 10 µM, did not inhibit Gas6-induced Axl phosphorylation in SNB-19 cells 
(Figure 4.6A, p<0.4875, ANOVA with Tukey multiple comparison post-hoc 
analysis). However, in UP007 cells, BGB324 markedly inhibited Axl 
phosphorylation (which was Gas6-independent) at 10 µM to below baseline 
levels (Figure 4.6A, p<0.0202, ANOVA with Tukey multiple comparison post-
hoc analysis). BGB324 had no effect on Tyro3 phosphorylation levels in SNB-19 
cells (Figure 4.6B, p<0.8387, ANOVA with Tukey multiple comparison post-hoc 
analysis), whereas it showed a trend towards significance in inhibition in UP007 
cells (Figure 4.6B, p<0.7173, ANOVA with Tukey multiple comparison post-hoc 
analysis). At 100 µM, BGB324 was toxic to all cells, as reflected by the absence 
of a band for β-actin in the Western blots (Figure 4.6A-C).  
Next, the effect of BGB324 on activation of downstream signalling was 
investigated in the GBM cells. BGB324 pre-treatment significantly inhibited 
downstream Akt phosphorylation in a concentration-dependent manner in both 
cell lines, independently of Gas6 stimulation (Figure 4.6C, p<0.0187 and 
p<0.0202 for SNB-19 and UP007 respectively, ANOVA with Tukey multiple 
comparison post-hoc analysis). Therefore, the Akt signalling pathway appears 
to emanate from Axl activation in both GBM cell lines. (Total Axl Western blots 
are shown in appendix 2). 
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Figure 4.6: Comparative efficacies of BGB324 for inhibition of Axl, Tyro3 and Akt 
phosphorylation in GBM cells. Western blots showing inhibition by BGB324 (0.1–100 
µM) of phosphorylation of Axl (A), Tyro3 (B) and Akt kinase downstream (C) stimulated 
by Gas6 (400ng/ml) in SNB-19 and UP007 cells. Data are mean ±SEM (N=3 separate 
experiments); ANOVA with Tukey multiple comparison post-hoc analysis **p<0.01, 
*p<0.05, ns, not significant, for comparisons indicated.  
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4.1.6 BGB324 inhibits GBM cell growth and colony formation 
Having observed that Gas6 stimulation of Axl promoted GBM cell 
growth/survival, and that BGB324 robustly inhibited Axl signalling in the GBM 
cells, the effect of BGB324 on cell colony formation in 3D was investigated. The 
soft agar assay was thus employed, which allows for a valid assessment of drug 
effect on cell growth and its ability to undergo unlimited division (197, 198). A 
solution of single cells was plated in soft agar and allowed to grow over the 
period of two weeks, either in the presence or absence of BGB324 at a range 
of concentrations. Colonies formed were stained with crystal violet and counted 
at 5 different fields of view; each qualifying colony was defined to consist of at 
least 50 cells (198). BGB324 significantly reduced colony formation at 0.75 µM 
in UP007 cells (p<0.0001, two-tailed student t-test) and inhibition of SNB-19 
colony formation was apparent at 2 µM of BGB324 (p <0.0001, ANOVA with 
Tukey multiple comparison post-hoc analysis) with complete inhibition being 
achieved, without cell death, at 10 µM BGB324 (Figure 4.7).  
 
 
Figure 4.7: Effect of BGB324 on long-term growth of GBM cell colonies in 3D. 
Representative micrographs of SNB-19 colonies in soft agar at 1.5x magnification 
(above; i and ii) and 15x magnification (below; iii and iv) untreated (left) or treated 
with 10 µM BGB324 (right). Histograms show average colony counts of 5 different 
fields per treatment for SNB-19 and UP007. ANOVA with Tukey multiple comparison 
post-hoc analysis for SNB-19 cells and two tailed student t-test for UP007 cells. Data 
are mean ±SEM (N=3 separate experiments); ****p<0.0001 versus untreated.  
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Due to the significant decrease in the number of colonies formed in the 
presence of BGB324 and the observation of single viable cells being present 
after two weeks, the pro-apoptotic vs cytotoxic effect of BGB324 was evaluated 
by Annexin V/PI staining with flow cytometry. Annexin V binds to 
phosphatidylserine (PS) which is exposed on the outer membrane of apoptotic 
cells, whilst propidium iodide (PI) stains dead cells. This combination of staining 
is widely used to determine the proportion of cells within a population that are 
viable, apoptotic, or necrotic (199). No significant increase in the number of 
apoptotic or necrotic cells was observed in both cell lines following 24-hour 
treatment with IC50 and double-IC50 concentrations of BGB324 (Figure 4.9, 
p<0.5413 and p<0.6359 for UP007 and SNB-19 cells respectively, Two-way 
ANOVA with Tukey multiple comparison post-hoc analysis). Therefore, the 
functional cell assays revealed that SMI inhibition of Axl at non-toxic 
concentrations specifically affected the functional parameters measured, and 
that these functions are therefore at least in part mediated by Axl. Indeed, a 
closer look at the cells through tracking under live cell imaging revealed an 
impairment in cell division upon treatment with BGB324 rather than apoptosis 
(Figure 4.8).  
 
Figure 4.8: BGB324 effect on cell division.  Effect of BGB324 on GBM cell division shown 
by representative pictures for SNB-19 cells taken every 30 minutes when untreated 
and treated with 2 µM BGB324. Arrows mark cell of interest, which is undergoing 
division over a period of 3 hours (N=3 independent experiments) at 10X magnification.  
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Figure 4.9: Representative propidium iodide (PI) vs Annexin V fluorescence intensity 
in SNB-19 cells treated with vehicle, 2.5 µM and 5 µM BGB324. Quadrants and markers 
in the displayed plots were used to demarcate the various cell populations (top panel). 
Quantified, comparative cell counts (%) are shown for healthy, apoptotic and necrotic 
cells following 24-hour BGB324 treatment of SNB-19 and UP007 cells (bottom panel). 
Data are mean±SEM (N=3 separate experiments); ANOVA with Tukey multiple 
comparison post-hoc analysis ns, not significant versus untreated. 
 
Temozolomide (TMZ) is a chemotherapeutic adjuvant to radiotherapy 
and is currently the only mildly successful chemotherapeutic agent for GBM, 
extending median survival by 3-4 months (200). Therefore, a possible 
combinatorial effect of Axl inhibition (by BGB324) and TMZ in GBM cells was 
explored. A concentration killing curve was initially conducted to identify sub-
maximal TMZ concentrations to be used with BGB324 (Figure 4.10, p<0.0001 
for both cell lines, ANOVA with Tukey multiple comparison post-hoc analysis). 
Treatment with TMZ resulted in concentration-dependent decreases in viability 
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of both UP007 and SNB-19 cells. From the killing curves, the IC50 for TMZ was 
calculated to be 24 µM for SNB-19 and 32 µM for UP007 (Figure 4.10).  
 
Figure 4.10: Effect of temozolomide (TMZ) on viability of SNB-19 and UP007 cell lines, 
Data are mean±SEM (N=3 separate experiments); ANOVA with Tukey multiple 
comparison post-hoc analysis ****p<0.0001, ***p<0.001 versus untreated (UT).  
 
 
The concentrations of 10, 25 and 50 µM of TMZ were then used in 
conjunction with 1 µM BGB324. The inhibitory effect of BGB324 at 1 µM was 
significantly enhanced by co-incubation with 10 µM of TMZ, versus either agent 
alone. Combinations of BGB324 with 50 µM TMZ did not significantly add to this 
effect, possibly due to the increased toxicity of TMZ at such high a concentration 
(Figure 4.11, p<0.0001, ANOVA with Tukey multiple comparison post-hoc 
analysis). However, all concentrations of BGB324 exhibited enhanced inhibitory 
effects when combined with sub-toxic doses 10 µM and 25 µM of TMZ (Figure 
4.11, p<0.0001, ANOVA with Tukey multiple comparison post-hoc analysis).  
 
 105 
 
 
Figure 4.11: Effect of BGB324 on GBM cell growth in combination with temozolomide 
(TMZ). MTS assay showing cell growth/survival of SNB-19 and UP007 cells treated with 
varying concentrations of TMZ alone or in combination with BGB324. Data are 
mean±SEM (N=3 separate experiments); ANOVA with Tukey multiple comparison 
post-hoc analysis, ****p<0.0001, ***p<0.001 versus untreated (UT). # indicates 
significance when compared to 10 µM of TMZ.  
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4.1.7 Inhibition of GBM cell migration and invasion by Axl small 
molecule inhibition 
One of the biggest challenges in GBM treatment is the highly invasive 
nature of the tumours, which leads to multiple relapses. Therefore, the 
effectiveness of BGB324 against the migration, motility and invasive capacity of 
the GBM cells was tested. BGB324 inhibited cell migration in both SNB-19 and 
UP007 cells in a concentration-dependent manner (Figure 4.12A, p<0.0086 and 
p<0.0001 respectively, ANOVA with Tukey multiple comparison post-hoc 
analysis). Moreover, cell tracking experiments with live cell imaging, where 
single cells were monitored for 3 hours and movement was tracked, revealed 
that sub-IC50 doses of BGB324 profoundly inhibited the motility of cells from 
both lines, affecting both average velocity of movement and total distance 
travelled (Figure 4.12B, p<0.0001 for both cell lines, unpaired two tailed 
student t-test). This indicates that BGB324 can effectively block cell motility and 
migration at doses below those that can inhibit cell growth and viability. In 
addition, Axl inhibition with BGB324 also abolished invasion of both GBM cell 
lines through extracellular matrix, when stimulated with PDGF-AA as glioma cell 
chemoattractant (Figure 4.12C, p<0.0020 and p<0.0006 for SNB-19 and UP007 
cells respectively, ANOVA with Tukey multiple comparison post-hoc analysis). 
In addition, Gas6, when itself used as a chemoattractant, also significantly 
increased cell invasion in both cell lines, an effect that was inhibited by BGB324 
(Figure 4.13A, p<0.0510 and p<0.0858 for SNB-19 and UP007 respectively, 
ANOVA with Tukey multiple comparison post-hoc analysis). Also, Gas6 
stimulation was able to increase cell migration in SNB-19 cells whereas it has 
no effect on UP007 cells (Figure 4.13B).  
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Figure 4.12: Effect of BGB324 on GBM cell migration, motility and matrix invasion. A. 
Representative images from scratch wound assay for SNB-19 cells at 0 and 21 hours 
(scale bar=390 µm) followed by graphical representation of migration rate (area 
change per hour) for SNB-19 and UP007 cells treated with varying concentrations of 
BGB324. B. Cell tracking experiments yielded data for average total distance travelled 
and average velocity for SNB-19 and UP007 cells following treatment with BGB324. C. 
Invasion assay for SNB-19 (N=3) and UP007 (N=4) cells following treatment with 
BGB324 using PDGF-AA as chemoattractant. Data are mean ±SEM (N=3 independent 
experiments); ANOVA with Tukey multiple comparison post-hoc analysis, ***p<0.001, 
**p<0.01, * p<0.05 compared to untreated (UT) or as indicated.  
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Figure 4.13: A. Invasion assay for SNB-19 and UP007 cells following treatment with 
BGB324 using Gas6 as chemoattractant. B. Effect of Gas6 on GBM cell migration shown 
by graphical representation of migration rate (area change per h) for SNB-19 and 
UP007 cells. Data are mean ±SEM (N=3 independent experiments); ANOVA with Tukey 
multiple comparison post-hoc analysis (A) and unpaired two tailed student t-test (B), 
***p<0.001, **p<0.01, * p<0.05  
  
 109 
 
4.2 Discussion 
4.2.1 Establishment of stable Axl knockdown cell lines 
Establishment of stable Axl knockdown was performed via plasmid 
insertion into the cell nucleus by transfection. This process comprises the 
formation of a complex between the nucleic acids of interest and a positively 
charged lipidic transfection reagent, which then interacts with heparan sulphate 
proteoglycans on the cell membrane. This leads to endocytosis of the 
transfection complex and its sequestration into intracellular vesicles, which 
facilitates entry of the DNA plasmid into the nucleus, leading to permanent 
genome integration (201) (Figure 4.14).  
 
 
Figure 4.14: Diagrammatic summary of lipid mediated transfection mechanism (202) 
Briefly, the DNA plasmid complexes with the lipofection reagent which in turn enters 
the cell membrane via endocytosis. 
 
Even though cationic lipid transfection remains the most popular 
transfection vehicle option for many scientists, this process results in low 
transfection efficiency due to being dependent on nucleic acid/chemical ratios, 
plasmid size, solution pH, and cell membrane conditions (203). Moreover, it is 
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time consuming and lengthy when aiming for permanent DNA plasmid 
integration. Ideally, stable knockdown is achieved rapidly with a higher 
efficiency using a lentiviral delivery system. A virus is produced with virulence 
genes env, vif, vpr, vpu, and nef deleted, containing the plasmid of interest, 
which is then used to infect the cells and integrate the plasmid into the genome 
(204) (Figure 4.15).  
 
Figure 4.15: Simplified schematic representation of viral shRNA delivery. Diagram 
adapted from (http://www.biocat.com/genomics/lentivirus-product-line). 
 
 Due to the nature of this technique, a Class II, Type A2 Biological Safety 
Cabinet is required, as well as extra precautions which are not available at the 
University of Portsmouth. Therefore, the cationic lipid transfection method was 
the best option given the facilities behind this study. A major potential caution 
to this approach came from the fact that Axl expression appeared to be restored 
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in knockdown cell clones after a period of roughly two months, thus limiting the 
number of experiments that could be performed. Given that the whole process 
of transfection, selection, clone picking and expansion as well as Axl screening 
takes about 4-5 months, no more new stable clones were established following 
detection of Axl re-expression due to time constraints. Instead, short term 
experiments requiring Axl knockdown were performed using transient 
transfection with siRNA pools. Nonetheless, shAxl knockdown clones were still 
successfully established for SNB-19 cells with knockdown levels of 40, 70, 90 
and 80% respectively whilst 80% Axl knockdown was achieved for UP007 cells 
(Figure 4.2); this enabled us to study key biological functions regulated by Axl.  
4.2.2 Genetic Axl knockdown inhibits proliferation and cell migration 
in GBM cells 
 In the first report of Axl overexpression in GBM, one of the first 
experimental observations was that Axl knockdown by either RNAi or by 
dominant negative inhibition resulted in decreased proliferation, cell migration 
and invasion (138, 140), thus making Axl an attractive target for therapy.  
In this study, the MTS assay was used to evaluate the effect of stable 
Axl knockdown on cell growth/viability. Notably, UP007 shAxl clone viability was 
drastically reduced compared to control and empty vector clones; this effect 
was apparent already during the clone selection process, as all but one of the 
UP007 shAxl cells clones were not viable. In contrast, although the SNB-19 
shAxl clones exhibited a trend towards reduced viability, quantitative analysis 
however revealed no statistically significant changes (Figure 4.3). This 
phenomenon could either be due to sufficient levels of Axl remaining in those 
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clones that could adequately support viability as normal, or the presence of 
MerTK in SNB-19, which could compensate for the loss of Axl. A double Axl-
MerTK knockdown would thus reveal the role of MerTK in growth/viability of 
the SNB-19 cell line. Cell cycle analysis would also provide more information on 
whether Axl is involved in viability or proliferation of these cells and how 
removal of Axl affects the cell cycle stages. Additionally, soft agar assays would 
provide information on the ability of these cells to expand clonally after Axl 
removal and potentiate the significance of Axl in GBM tumourigenesity.  
In accordance with previous studies, Axl knockdown significantly 
reduced cell migration as observed by wound healing assays in both cell lines 
(Figure 4.4). In SNB-19 cells, reduced migration was observed only where 90% 
knockdown was achieved, indicating that levels of Axl expression below 90% 
are sufficient to counteract this anti-migratory effect of Axl knockdown. The 
effect of Axl knockdown on cell invasion was not studied with the shAxl clones 
due to restoration of Axl expression in the stable knockdown clones at the time 
the experiments were due to be performed. Ideally, the invasion abilities of Axl 
knockdown clones should be investigated with the use of a modified Boyden 
chamber assay, where cells move through pores and enter into a 
fibronectin/matrigel matrix. Following confirmation of invasion impairment, an 
Axl plasmid transfection should rescue the phenotype, thus establishing Axl as 
a major regulator of glioma invasion. 
4.2.3 Axl inhibition by a small molecule inhibitor 
The focus of this study was to evaluate the effect of two small molecule 
inhibitors, BGB324 and BMS777607, as novel treatments for glioma, with a 
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focus on the more Axl-specific BGB324. BGB324 (Figure 4.16A) is a novel Type 
I, ATP-competitive Axl SMI, with more than 40-fold Axl selectivity compared to 
MerTK and Tyro3 and 100 fold to other kinases (205). Type I inhibitors bind the 
DFG-in conformation with a U-shaped geometry as shown in Figure 4.16B. 
 
 
Figure 4.16: Schematic representation of inhibitor binding. a) normal substrate binding, 
b) substrate binding inhibition by ATP competitive inhibitor, c) substrate binding 
inhibition by attachment of ATP non-competitive inhibitor to alternative pocket (206).  
 
BGB324 has been shown to effectively block Axl-dependent events, 
including downstream Akt phosphorylation and invasiveness of breast cancer 
cells (160). BMS777607 (Figure 4.17B), an originally designed Type II MET 
inhibitor with 3-fold higher affinity for Axl compared to MET binds the ATP 
inactivated DFG-out conformation of kinases (205, 207). Even though Type II 
inhibitors are suggested to be more selective due to their ability to adopt an 
extended conformation via interactions with DFG residues of the activation loop 
to enter an allosteric region (adjacent to the ATP binding site) that is only 
accessible in the inactive DFG-out conformation of the kinase (205) (Figure 
4.16C), both in our hands and others, BGB324 has been shown to be more 
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selective for Axl than BMS777607 (146, 160). Of course the RTK activity assays 
performed with the inhibitors in vitro do not correspond to inhibitor specificity 
or affinity. Whilst BMS777607 (1.1 nM) performed better than BGB324 (14 nM) 
in cell free in vitro assays (205) it appears to be more specific and has higher 
affinity. 
 
Figure 4.17: A. Chemical structure of Type I Axl inhibitor BGB324. B. Chemical structure 
of Type II Axl inhibitor BMS777607 (205) 
 
First, the effect of BGB324 and BMS777607 on viability of two GBM cell 
lines was investigated by MTS assay. The IC50 for BMS777607 in the MTS assay 
was calculated to be 118 µM for SNB-19 and 35 µM for UP007 cells (Figure 
4.5C-D). These values are at least tenfold higher than the IC50 values for 
BGB324, which are 2.5 µM and 1 µM for SNB-19 and UP007 cells respectively 
(Figure 4.5A-B). Other studies validate this difference in inhibitory potency 
between the two molecules measured by us. Holland et al. determined the IC50 
for BGB324 to be 14 nM in in vitro biochemical kinase assays using recombinant 
Axl protein (160), around a 100-fold more potent in this system than 
BMS777607 with its IC50 of 12.5 µM (146). Also, in vivo studies showed that 
BGB324 successfully reduced tumour growth in breast cancer at dosages 
ranging from 7–25 mg/kg twice daily (160) whilst BMS777607 reduced 
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glioblastoma tumour growth in mice at doses ranging from 30–100 mg/kg twice 
daily (146). Even though both inhibitors can effectively inhibit Axl, BGB324 
remains the most selective SMI as studies have shown 100-fold greater 
selectivity for Axl against other kinases, whilst BMS777607 has also been shown 
to inhibit Met with an IC50 of 3.9 nM (120). Taking these data collectively, 
BGB324 was the preferred SMI for the rest of the study, as it has shown 
promising results in breast and lung cancer clinical trials (160, 208) and it had 
not been studied in glioma previously.  
 The results from the experiments on BGB324 and cell viability mirrored 
those with stable knockdown of Axl, showing the UP007 cell line to be about 
two-fold more sensitive to Axl inhibition than SNB-19 cells. Following this, the 
inhibitory effect of the SMI on the activity of the Axl molecule was investigated 
by Western blot (Figure 4.6). Pre-incubation with BGB324 reduced Axl activation 
by Gas6 in both cell lines as well as downstream target Akt. Moreover, Tyro3 
showed a trend towards a significant decrease in phosphorylation in the UP007 
cell line indicating a possible interaction between Axl and Tyro3. This interaction 
is a focus of study in greater depth in Chapter 6.  
4.2.4 The Axl SMI BGB324 inhibits GBM cell growth and colony 
formation 
The significance of Axl in glioma was first shown by the introduction of 
a  DN form of Axl in glioma cells, which reduced cell proliferation by 30% 
compared to wildtype (138). Furthermore, Axl shRNA knockdown significantly 
decreased astrocytoma cell proliferation in soft agar (140). In agreement with 
previous studies, treatment with BGB324 significantly impaired the ability of 
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SNB-19 and UP007 cells to form colonies in soft agar assays in a dose-
dependent manner. Further analysis by Annexin V/PI staining and quantification 
by flow cytometry revealed that this effect was not due to cell death caused by 
cytotoxicity, as doses of up to double the IC50 concentrations over a period of 
24 hours did not increase the number of apoptotic or necrotic cells but impaired 
the ability of cells to divide (Figure 4.8 and 4.9).  
Even though several studies report Axl knockdown or blockade to reduce 
cell growth in a variety of cancers including ovarian (209) and pancreatic (119) 
cancers, the mechanisms behind this phenomenon remain to be determined. 
Prior to this study, only one report had shown that pharmacologic Axl inhibition 
or siRNA targeting inhibits cell growth and induces cell-cycle arrest and 
apoptosis. This study was in acute myeloid leukaemia (AML), where Axl 
blockade inhibited  FLT3 RTK hyperactivity brought about as a result of internal 
tandem duplication (210). This finding indicated an important role for Axl in 
regulation of the cell cycle in AML. To explore this role further, a comprehensive 
study can be carried out on the cytoskeletal changes occurring during cell 
division, e.g. by fluorescent microscopy, as well as investigation of genes 
altered during the cell cycle by qRT-PCR following Axl inhibition to pinpoint the 
exact mechanism. Moreover, each cell cycle phase should be analysed 
separately in order to identify during which specific phase Axl is most involved.  
 Temozolomide (TMZ) is currently the only mildly successful 
chemotherapeutic agent for GBM, extending median survival by 3-4 months 
(200). In our study, we also observed an increase in sensitivity to TMZ when 
Axl was concomitantly blocked with BGB324. From the killing curves, the IC50 
for TMZ was calculated to be 24 µM for SNB-19 and 32 µM for UP007 (Figure 
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4.10). When used in conjunction with 1 µM BGB324, a significant decrease was 
observed with as low as 10 µM of TMZ; this indicates a possible synergy 
between the two treatments (Figure 4.11). In agreement with our results, a 
study by Keating and colleagues showed Axl knockdown in astrocytoma cells to 
significantly reduce the IC50 of TMZ from 68.6 μmol/L to a range of 1 to 18.2 
μmol/L (140). However, ideally, TMZ-resistant cell lines should be used to 
evaluate accurately the effect of Axl knockdown to TMZ chemosensitivity.  
4.2.5 BGB324 inhibits cell migration and invasion in GBM  
Axl has been established as a major regulator of invasion in glioma. In 
three different studies, Axl knockdown (137, 140), introduction of a dominant 
negative Axl form (138) and pharmacological inhibition with the less potent Axl 
SMI BMS777607 (146) resulted in reduced GBM cell invasion. More specifically, 
in a study by Vajkoczy et al., introduction of Axl-DN cells into nude mice 
correlated with in vitro experiments, showing reduced tumour growth compared 
to control cells without affecting the tumour vasculature but instead by 
decreasing invasive potential (138). Detailed assessment of the effect of Axl on 
cell migration revealed that Axl-DN cells have a reduced locomotor activity and 
disrupted cell-cell adhesion (138). At the molecular level, Axl has been 
associated with BMI1, a master regulator of NPCs stemness and self-renewal. 
BMI1 is often found overexpressed in brain cancers (141). Recently, Gas6 was 
shown to be a novel target gene for BMI1 although the exact mechanism 
remains elusive (142). BMI1 belongs to the multiprotein complex PRC1. The 
PRC1 complex in cooperation with the initiation complex EZH2 mediate 
methylation of histone proteins to induce gene silencing (143). Axl has been 
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shown to be directly regulated by EZH2 in glioma, where EZH2 was shown to 
be up-regulated and co-expressed with Axl in glioblastoma cells, furthermore, 
EZH2 appeared to positively regulate Axl expression independently of changes 
in methylation (144). In addition, knockdown of EZH2 in glioblastoma 
significantly reduced the invasive character of the cells and this was shown to 
be mediated by Axl. The authors also point out that EZH2 is required during 
EMT for E-Cadherin repression by Snail. Axl has been extensively associated 
with Snail-mediated EMT in breast cancer; this therefore could represent 
another potential link between EZH2 and Axl (145).  
In agreement with previous studies we have shown that inhibition of Axl 
either by knockdown or inhibition with BGB324 significantly reduces cell 
migration as observed in scratch wound assays in a dose-dependent manner. 
Moreover, by cell tracking under live cell imaging microscopy, the calculated 
total distance travelled and the velocity of cell migration were shown to be 
reduced significantly at sub-IC50 concentrations (MTS assay) for SNB-19 and at 
the IC50 concentration (MTS assay) for UP007 cells. Also, cell invasion 
stimulated by PDGF-AA as chemoattractant was also reduced to basal levels by 
BGB324 in both cell lines (Figure 4.12), indicating that Axl mediates the invasive 
character of GBM cells in response to diverse humoral cues. Indeed, studies 
have shown that Axl mediates tumour invasion and chemoresistance through 
the activation of the PI3K/Akt pathway in breast cancer (211, 212) as well as 
ovarian cancer (187). The BGB324 inhibition of GBM cell migration and invasion 
we observed could be the result of suppressed Akt signalling. Indeed, Akt has 
been shown to enhance MMP2 in mammary epithelial cells, MMP9 production 
via NF-κB in fibrosarcoma cells and fibroblast motility by phosphorylating Girdin, 
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an actin-binding protein that promotes stress fibre formation and lamellipodia 
(213). The exact mechanism present in glioma requires further investigation. 
In addition, Gas6 was also an effective direct chemoattractant for SNB-19 cells, 
which likely was mediated via Axl as these cells are more responsive to Axl 
stimulation by Gas6 than UP007. However, in slight contrast, when itself used 
as chemoattractant, Gas6 significantly increased cell invasion of both SNB-19 
and UP007 cell lines (Figure 4.13). Furthermore, Axl inhibition by BGB324 
inhibited invasion only marginally, perhaps indicating that Gas6 may promote 
invasion only partly via Axl kinase.  
 In conclusion, the data in this chapter indicate that targeting Axl for 
inhibition by a specific SMI such as BGB324 has robust anti-tumour effects on 
GBM cells and could potentially be effective in restraining tumour invasion in 
vivo and, in combination with other agents, could effectively prolong glioma 
patient survival. Further studies will be needed to explore the anti-GBM tumour 
efficacy of Axl SMI BGB324 in vivo and ultimately in glioma patients. However, 
despite the promising initial signs of success with BGB324 in other cancers, it 
as yet unknown whether the drug can cross the blood-brain barrier, which 
represents one of the greatest challenges in drug delivery to the brain (214). 
This question can be answered with the aid of animal models. Specifically, 
glioma patient biopsies can be orthotopically injected in the brain of 
immunocompromised nude rats and allowed to grow before injecting BGB324 
intraperitoneally. Depending on tumour volume of treatment compared to 
vehicle control and positive controls, it can be demonstrated if BGB324 is 
suitable for treating glioma patients. Moreover, by using a fluorescent tagged 
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version of the drug, following rat sacrifice, immunostaining can reveal blood 
brain carrier permeability to BGB324.  
4.2.6 Summary 
Two cultured adult GBM cell lines, SNB-19 and UP007, were treated with 
the novel Axl small molecule inhibitor BGB324, and analysed in assays for 
survival, 3D colony growth, motility, migration and invasion. Western blot was 
used to detect protein expression and signal protein phosphorylation. In both 
cell lines, BGB324 inhibited specifically phosphorylation of Axl as well as Akt 
kinase further downstream. BGB324 also inhibited survival and proliferation of 
both cell lines in a concentration-dependent manner, as well as completely 
suppressing migration and invasion. In conclusion, small molecule inhibitor-led 
targeting of Axl may be a promising therapy for GBM progression. 
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Chapter 5 
 
EGFR heterodimerises with Axl 
to promote GBM cell invasion 
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5.0 Introduction 
Acquired resistance to conventional and targeted therapies is becoming 
a major hindrance in cancer management. It is increasingly clear that cancer 
cells are able to evolve and rewire canonical signalling pathways to their 
advantage, thus evading cell death and promoting cell invasion, amongst other 
cancer hallmarks (3). Overexpression of Axl RTK has been correlated with poor 
prognosis in patients, promotion of increased cancer cell invasiveness, 
epithelial-to-mesenchymal transition (EMT) and chemoresistance in both breast 
and lung cancers (215, 216), as well as with poor overall survival of GBM 
patients and increased cell invasiveness (137). In addition, in the previous 
chapter, inhibition of Axl with a small molecule inhibitor was shown to hinder 
glioma cell survival, migration and invasion (217), thus highlighting the viability 
of targeting Axl specifically in cancer therapy.  
In addition to its principal role in invasion, numerous studies suggest that 
Axl overexpression mediates secondary resistance to both conventional and 
targeted therapies. The most noteworthy observation to date is acquired 
resistance to erlotinib (a reversible tyrosine kinase inhibitor) in EGFR-mutated 
lung adenocarcinoma by induction of an EMT-like phenotype through Axl 
activation both in vitro and in vivo (218). Similarly, in another study Axl 
overexpression correlated with acquired resistance to gefitinib (EGFR SMI) 
(219). Recently, expression of Axl has been identified as a predictor of lack of 
response to the EGFR–targeted inhibitors lapatinib and erlotinib in triple-
negative breast cancer cells (220). Interestingly, it has been found that EGFR 
signalling trans-activates Axl and that this ligand-independent Axl activity, 
through possible hetero-interaction amongst different RTKs, could then 
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diversify downstream signalling pathways beyond those triggered by EGFR 
alone. Activation of EGFR by EGF stimulation of MDA-MB-231 breast cancer cells 
was shown to lead to both Axl and MET phosphorylation but not vice versa 
(220). The EGFR-mediated Axl activation led to widespread downstream 
signalling changes that were blocked by Axl siRNA, whilst Gas6 stimulation had 
lesser effects. This pivotal study therefore suggests that Axl can serve as an 
alternative conduit for EGFR signalling, at least when it comes to Akt activation 
(220).  
In the present study, results are presented that show the identification 
of a novel protein-protein interaction between EGFR and Axl. This hetero-
interaction involves Axl as a gateway for EGFR to activate invasive signalling 
pathways in GBM cells, which are known for their highly invasive and 
proliferative phenotype (200), and which overexpress both RTKs (137) (221). 
We show that EGF, via EGFR, indirectly activates invasive signalling via Axl in 
human cancer cells in a unidirectional manner, through a protein-protein 
interaction between EGFR and Axl. The EGFR-Axl hetero-interaction promotes 
cell invasion through the TIMP1-MMP9 invasion regulatory axis whilst also 
inhibiting cell proliferation. This phenomenon does not occur via EGFR signalling 
alone but exclusively via the EGFR-Axl hetero-interaction. These findings reveal 
a greater diversity to the various functions of RTKs than previously thought and, 
in cancer, have implications for guiding molecular targeted therapies as well as 
for managing secondary drug resistance.  
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5.1 Results 
5.1.1 EGF activates Axl via EGFR in SNB-19 cells 
In order to examine the relationship between EGFR and Axl in GBM cells, 
Axl activation was investigated; this was done through analysing residue-
specific phosphorylation in serum-starved SNB-19 cells in response to 
stimulation by EGF over a time course of 0-60 minutes, with PDGF and FGF as 
controls. EGF, in addition to causing a rapid increase in EGFR phosphorylation 
in under 2 minutes, also rapidly stimulated Axl phosphorylation within the same 
time period (Figure 5.1A). Interestingly, EGF stimulated phosphorylation of only 
the mature fully glycosylated 140 kDa Axl but not the partially glycosylated 120 
kDa form (both forms are activated by Gas6) (Figure 5.1A). The same EGF-
stimulated phosphorylation of Axl was also observed in the UP007 cell line; 
however, this effect was not unique to cells of this cancer type, but was also 
observed in human breast and head and neck cancer cell lines (Figure 5.1C-D). 
In contrast to the effects of EGF, no significant change in Axl phosphorylation 
occurred after treatment with the other distinct RTK ligands PDGF or FGF 
(Figure 5.1B). In addition, a similar response to EGF stimulation was observed 
for the Tyro3 receptor, with EGF causing a rapid phosphorylation of Tyro3 in 
under 2 minutes, the same time period as for EGFR and Axl (5.1A). Also, neither 
PDGF nor FGF had such an effect on Tyro3, and moreover, as with Axl, the 
effect was observed in cells from several different cancer types (Figure 5.1B).  
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Figure 5.1: EGFR activates Axl. A. Western blot of time-course of EGFR, Axl and Tyro3 
phosphorylation by EGF (50 ng/ml) (N=3) in SNB-19 cells. B. Axl (N=3 blots) and Tyro3 
(N=2 blots) phosphorylation by PDGF (10ng/ml) and FGF (10 ng/ml) in SNB-19 cells. 
C. Western blot of time-course of Axl and Tyro3 by EGF (50 ng/ml) in UP007 (N=1). 
D. Western blot of Axl and Tyro3 stimulated with Gas6 (400 ng/ml) and EGF (50 ng/ml) 
for 10 minutes in breast cancer cells (MDA-MB-231) and head and neck cancer cells 
(SCC-25 and Detroit) (N=1 blot).  
 
To probe the specificity of the kinase-substrate relationship, pre-
treatment with the highly selective Axl SMI BGB324, which blocks the kinase 
activity of Axl (15, 21), did not affect the phosphorylation stimulated by EGF 
(15), whereas pre-treatment with the EGFR-specific SMI gefitinib blocked Axl 
phosphorylation following EGF treatment. EGFR in cells was rapidly activated by 
EGF stimulation within 15 minutes, an effect that was abolished by gefitinib, 
but which was not affected by pre-incubation with the Axl-specific BGB324 
(Figure 5.2A, Western blot semi-quantification for both SNB-19 and UP007 cell 
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is shown in appendix 3). Therefore, Axl activation in response to EGF is specific 
and relies on EGFR activity and not Axl activity, suggesting a direct 
phosphorylation of Axl by EGFR. To investigate whether this cross 
phosphorylation observed in SNB-19 cells occurs in both directions, we tested 
EGFR phosphorylation following stimulation by Gas6, the natural ligand for Axl. 
Gas6 had no effect on EGFR phosphorylation, further indicating a unidirectional 
relationship between EGFR and Axl (Figure 5.2B). Additionally, Western blotting 
of pERK and pAkt, two well-known downstream targets of RTK signalling 
pathways, showed no change in phosphorylation upon EGF stimulation in the 
presence of the Axl inhibitor BGB324, indicating that the two intracellular 
kinases are regulated predominantly by EGFR signalling in this context (Figure 
5.2C).  
 
Figure 5.2: A. Western blot of Axl and EGFR phosphorylation by EGF and its inhibition 
by gefitinib and BGB324. B. Western blot of EGFR phosphorylation by EGF and Gas6 
and its inhibition by gefitinib. C. Western blot of pERK and pAkt levels after EGF 
stimulation and influence of gefitinib and BGB324. Each blot is representative of three 
separate blots carried out for that experiment.  
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5.1.2 EGFR kinase directly activates Axl kinase in vitro 
Having observed that EGF stimulation leads to native Axl phosphorylation 
in living cells, we investigated whether the observed unidirectional 
transactivation of Axl by EGFR occurs through a physical interaction between 
EGFR and Axl. Indeed, EGFR protein co-immunoprecipitated (co-IPed) with Axl 
protein even in the absence of EGFR stimulation by EGF (Figure 5.3).  
 
Figure 5.3: Hetero-interaction of EGFR and Axl RTKs. Co-IP of Axl and EGFR, followed 
by Western blot probing for presence in the complexes of Axl (left blot) and EGFR 
(right blot). Control co-IP antibodies were anti-GAPDH (Ctrl Ig1).  
 
The potential of EGFR to activate Axl in a cell-free in vitro system using 
Kinase-Glo Luminescent Kinase Assay (Promega) was then investigated (222). 
Both recombinant active Axl and EGFR kinases were able to phosphorylate the 
Axl substrate peptide containing Y779, a residue that is a well-known docking 
site in Axl for multiple signalling proteins and marker of Axl activation (22). 
Furthermore, the in vitro phosphorylation of Axl Y779 peptide by Axl and EGFR 
kinases was inhibited by BGB324 and gefinitib respectively (Figure 5.4A, 
p<0.0001 and p<0.0003 for EGFR and Axl respectively, ANOVA with Tukey 
multiple comparison post-hoc analysis). 
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In addition, the influence of EGF-EGFR on kinase activity of native Axl in 
cells was investigated. Axl that was IPed from SNB-19 cells following 5-minute 
incubation with EGF exhibited a greater in vitro activity, as reflected by 
phosphorylation of the Axl Y779 peptide. Therefore, Axl is a direct substrate of 
EGFR kinase in vitro, as well as in vivo in intact cells following activation of EGFR 
by EGF (Figure 5.4B, p<0.0268, ANOVA with Tukey multiple comparison post-
hoc analysis).  
 
Figure 5.4: A. In vitro kinase activity of recombinant Axl and EGFR kinases, with Axl 
Y779 peptide as substrate. Kinases were tested either alone or in the presence of the 
specific Axl or EGFR inhibitors, BGB324 (10µM) and gefitinib (10 µM), respectively. 
Values are normalised against background Y779 peptide luminescence. B. In vitro 
kinase activity of native Axl immunoprecipitated from SNB-19 cells after EGF 
stimulation, with or without 1 hour gefinitib (10 µM) pre-treatment. Sec15B and GAPDH 
IPs following EGF stimulation were used as negative control pulldowns (data not 
shown). Data are mean±SEM (N=3 separate experiments); ANOVA with Tukey multiple 
comparison post-hoc analysis, ****p<0.0001, **p<0.01, *p<0.05 versus untreated.  
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5.1.3 EGFR induces upregulation of pro-invasive genes via Axl  
The observed hetero-interaction between EGFR and Axl prompted us to 
explore the potential discrete downstream signalling pathways that emanated 
from EGFR either via Axl or not. Therefore, SNB-19 cells were treated with EGF 
to activate the receptors, with some treatments also including BGB324 to block 
Axl kinase, thus concentrating the effect of EGF towards the EGFR receptor 
only. Axl has been shown to promote invasion as well as chemoresistance to 
EGFR SMIs through the induction of EMT genes (216, 218, 220, 223). 
Therefore, a qRT-PCR analysis of the expression of 15 EMT-related genes 
(CD44, CD24, CD133, ALDH1, CCND1, CDK4, KRT19, NOTCH1, TWIST, MMP9, 
AKT2, TIMP1, AKT1, MMP2, PI3K) was carried out. Out of these, we observed 
a significant change in the mRNA levels of CCND1, TIMP1, CD44, MMP2 and 
MMP9 genes (Figure 5). TIMP1 and CD44 mRNA levels were significantly 
increased when Axl kinase was blocked during EGF stimulation (Figure 5.5A. 
p<0.0029 and D, p<0.0040, ANOVA with Tukey multiple comparison post-hoc 
analysis), whereas CCND1 mRNA was significantly increased by EGF stimulation 
irrespective of Axl kinase activity (Figure 5.5A, p<0.0028, ANOVA with Tukey 
multiple comparison post-hoc analysis). Interestingly, EGF stimulation increased 
MMP9 mRNA levels, whilst concomitant Axl inhibition by BGB324 blocked this, 
despite presence of EGF (Figure 5.5B, p<0.0165, ANOVA with Tukey multiple 
comparison post-hoc analysis). In contrast, MMP2 was significantly reduced by 
EGF stimulation only when Axl signalling was inhibited (Figure 5.5C, p<0.0352, 
ANOVA with Tukey multiple comparison post-hoc analysis).  
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Figure 5.5: qRT-PCR analysis of TIMP1 (A), MMP9 (B), MMP2 (C) and CD44 (D) genes 
in SNB-19 cells treated for 24 hours with 50 ng/ml EGF, with or without 2 µM BGB324. 
Data are mean±SEM (N=3 independent experiments); ANOVA with Tukey multiple 
comparison post-hoc analysis, **p<0.01, *p<0.05 compared to either 
untreated/controls or as indicated.  
 
Moreover, Axl stimulation activated STAT3 signalling which was inhibited 
by BGB324 as seen in Figure 5.6 which can potential indicate a regulatory 
mechanism for MMP9 and MMP2 expression. 
 
Figure 5.6: Western blot showing STAT3 phosphorylation following 15 minute Gas6 
stimulation followed by BGB324 inhibition in UP007 and SNB-19 cell lines. (N=1) 
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5.1.4 EGFR positively regulates cell invasion signalling via Axl  
In Chapter 2, Axl signalling was demonstrated to regulate the migration 
and invasion of the GBM cells used in this study (15), therefore identifying genes 
involved in invasion to be altered by EGFR-Axl signalling was of particular 
interest. In order to functionally evaluate the importance of this interaction, 
cells were treated with EGF with or without Axl kinase blockade by BGB324, or 
EGFR blockade by gefitinib, and subsequently observed its effect on GBM cell 
invasion, compared to untreated and the inhibitors on their own. EGFR 
activation significantly increased cell invasion, an effect that was counteracted 
by Axl blockade. Most importantly, the combination of EGFR stimulation with 
Axl inhibition led to a greater decrease in invasion compared to Axl inhibition 
alone (Figure 5.7C, p<0.0001, ANOVA with Tukey multiple comparison post-
hoc analysis). Moreover, gefitinib was able to reduce invasion back to basal 
levels (Figure 5.7C). Furthermore, TIMP1 knockdown by siRNA (Figure 6.5A, 
p<0.000218765, p<0.0200244, p<0.00491499, multiple t-test) was also able 
to increase invasion regardless of EGFR-Axl stimulation/inhibition, indicating 
that they may act via TIMP1 to regulate invasion (Figure 5.7B, p<0.001, two-
way ANOVA with Tukey multiple comparison post-hoc analysis).  
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Figure 5.7: EGFR-Axl hetero-interaction regulates the balance between gene 
expression for invasive and proliferative signalling in SNB-19 cells. A. qRT-PCR 
confirmation of TIMP1 gene knockdown in SNB-19 cells treated for 24 hours with 50 
ng/ml EGF with or without 2 µM BGB324. B. Effect of siRNA TIMP1 knockdown in 
combination with EGF stimulation on SNB-19 cell invasion through matrix, using PDGF-
AA as chemoattractant.  C. Invasion assay for SNB-19 cells following treatment with 
EGF, BGB324 and gefinitib using PDGF-AA as chemoattractant. Data are mean±SEM 
(N=3 independent experiments); ANOVA with Tukey multiple comparison post-hoc 
analysis, ****p<0.0001, ***p<0.001, **p<0.01, * p<0.05 compared to either 
untreated/controls or as indicated. # indicates significance when compared to EGF 
treatment.  
 
In order to further probe the mechanisms behind this behaviour, the 
mRNA levels of the other altered genes under these conditions and upon TIMP1 
knockdown were monitored. MMP9 mRNA levels were increased upon EGF 
stimulation (p<0.0001, two-way ANOVA with Tukey multiple comparison post-
hoc analysis), an effect that was enhanced by TIMP1 knockdown (p<0.268691, 
p<0.0540195, p<0.725338, multiple t-test). Interestingly, Axl kinase inhibition 
blocked the EGF-induced upregulation of MMP9, irrespective of TIMP1 
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knockdown (Figure 5.8A). In contrast to MMP9, TIMP1 knockdown had no effect 
on the EGF-induced changes in CD44 (p<0.860447, p<0.8284, p<0.831766, 
multiple t-test) and MMP2 expression (p<0.312455, p<0.854102, p<0.953393, 
multiple t-test) (Figure 5.8B-C). Therefore, these results indicate that Axl 
positively regulates cancer cell invasion via the TIMP1-MMP9 axis, that EGF also 
activates this pathway only via Axl, and moreover that discrete EGFR signalling 
alone in fact directly counteracts Axl invasive signalling.  
 
Figure 5.8: qRT-PCR analysis of MMP9, MMP2 and CD44 genes in SNB-19 cells with 
siRNA knockdown of TIMP1 over 3 days, in the presence of EGF (50 ng/ml) with or 
without Axl blockade by BGB324 (2 µM). Data are mean±SEM (N=3 independent 
experiments); two-way ANOVA with Tukey multiple comparison post-hoc analysis, 
followed by multiple t-test, ***p<0.001, **p<0.01, * p<0.05 compared to either 
untreated/controls or as indicated.  
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5.1.5 EGFR stimulates cell cycle progression independently of Axl 
The observed increase in the CCND1 gene, which codes for the cell cycle 
regulator cyclin D1, in response to EGF stimulation was then further 
investigated. Cell cycle analysis after treatment with EGF alone or in 
combination with BGB324 revealed a decrease of cells in the G1 phase of the 
cell cycle with a concomitant increase in the G2/M population (Figure 5.10B). 
Therefore, EGFR signalling alone stimulates cell cycle progression in SNB-19 
cells in addition to attenuating Axl invasive signalling.  
The effect of EGFR blockade on cell proliferation/survival was also 
investigated by MTS assays. A concentration killing curve was initially conducted 
to identify sub-optimal gefitinib concentrations to be used with BGB324. 
Treatment with gefitinib resulted in concentration-dependent decreases in 
viability of both UP007 and SNB-19 cells from 5 µM (Figure 5.9, p<0.0001 and 
p<0.0016 for SNB-19 and UP007 cells respectively, ANOVA with Tukey multiple 
comparison post-hoc analysis).  
 
 
Figure 5.9: Effect of gefitinib on viability of SNB-19 and UP007 cell lines as shown by 
MTS assay. Data are mean±SEM (N=3 separate experiments); ANOVA with Tukey 
multiple comparison post-hoc analysis, ****p<0.0001, ***p<0.001 versus untreated 
(UT).  
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Figure 5.10: Quantitative RT-PCR analysis of CCND1 gene expression in SNB-19 cells 
altered by EGFR activation, with and without the influence of Axl. (A) qRT-PCR analysis 
of CCND1 gene in SNB-19 cells treated for 24 hours with 50 ng/ml EGF, with or without 
2 µM BGB324. (B) Cell cycle analysis of cells treated for 24 hours with EGF alone or in 
EGF in combination with BGB324. Data are mean±SEM (N=3 independent 
experiments); ANOVA with Tukey multiple comparison post-hoc analysis 
****p<0.0001, ***p<0.001, **p<0.01, * p<0.05 compared to either 
untreated/controls or as indicated.  
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The concentrations of 2, 5 and 10 µM of gefitinib were then used in 
conjunction with 1.5 µM BGB324 for UP007 and 2 µM for SNB-19 cells. The 
inhibitory effect of gefitinib at 2 and 10 µM for SNB-19 was significantly 
enhanced by co-incubation with 2 µM of BGB324. For the UP007 cells, the 
inhibitory effect of gefitinib at 2 µM was significantly enhanced by co-incubation 
with 1.5 µM BGB324 (Figure 5.11, p<0.0001 for both cell lines, two-way ANOVA 
with Tukey multiple comparison post-hoc analysis).  
 
Figure 5.11: Effect of gefitinib on GBM cell growth in combination with BGB324. MTS 
assay showing cell growth/survival of SNB-19 and UP007 cells treated with varying 
concentrations of gefitinib alone or in combination with BGB324. Data are mean±SEM 
(N=3 separate experiments); ANOVA with Tukey multiple comparison post-hoc analysis 
**p<0.01, *p<0.05.  
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5.2 Discussion 
5.2.1 EGF activates Axl via EGFR in SNB-19 cells 
EGFR is a transmembrane glycoprotein that is a member of the RTK 
superfamily, and is activated by EGF. EGFR has been shown to regulate cell 
proliferation, differentiation, migration and survival in cancer (224). Moreover, 
EGFR activation in cancer has been shown to promote resistance to 
chemotherapy and radiation treatment (225).  
Amplification and overexpression of the EGFR gene presents a hallmark 
for GBM tumours. The most common EGFR mutant is named EGFRvIII which 
results from the deletion of exons 2-7 of the EGFR gene. EGFRvIII is unable to 
bind ligand and is rendered constitutively active (226). In GBM, it is usually co-
expressed with the wild type receptor. Fan and colleagues showed that EGFR 
and EGFRvIII liaise in cellular transformation assays, with the combination being 
more potent than either expressed alone. EGF stimulation was able to further 
enhance their effect (39). Presence of the EGFRvIII mutation has been reported 
in breast and lung cancers, but several of these reports remain controversial 
due to technical problems with EGFRvIII detection. These are discussed in a 
detailed review by Hui and colleagues, who point out that reports of EGFRvIII 
expression in other cancers such as ovarian, prostate, breast and lung are 
inconsistent with studies reporting no expression whilst others report low levels 
of expression compared to GBM, in which it is most highly expressed (227). The 
EGFRvIII mutant has been closely associated with MET RTK and cross-activation 
has been linked to increased chemoresistance (228). In the same study, they 
report that increased Axl phosphorylation was observed in EGFRvIII cells by 
tandem liquid chromatography MS (228), although no other reports of 
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interaction between the two receptors have been published. Additionally, 
EGFRvIII was found to be co-expressed with ELMO1 and Dock180, two proteins 
that interact to activate Rac GTPase to promote invasion in glioma (229, 230). 
Moreover, Axl was recently found to be a direct binding partner of ELMO and 
to promote cell proliferation and invasion through its phosphorylation (231). 
These findings imply an indirect interaction between EGFRvIII and Axl to regulate 
glioma cell invasion. The exact relationship between EGFRvIII and Axl remains 
to be established; however, it represents a new avenue of research that could 
potentially produce a more beneficial treatment for patients harbouring the 
mutation.  
Nonetheless, overexpression of wildtype EGFR has been widely 
associated with Axl overexpression, and several studies have demonstrated Axl 
transactivation by EGFR to promote an EMT phenotype which leads to 
resistance to therapy (192). However, even though the relationship is now 
increasingly indicated as a mediator of chemoresistance, a direct physical 
interaction between the two receptors has hitherto not been shown. The first 
part of this chapter focuses on demonstrating a physical interaction between 
the receptors and therefore direct activation of Axl by EGFR.  
Treatment of SNB-19 cells with EGF, and not other growth factors, 
stimulated activation of Axl directly through EGFR-Axl hetero-interaction in a 
unidirectional way, i.e. that EGFR activates Axl but not vice versa (Figure 5.1). 
The activation of Axl was shown to occur through direct phosphorylation by 
EGFR of Axl tyrosine 779, one of the key residues within Axl that serves as a 
multi-substrate docking site for further downstream signalling (22) (Figure 5.1). 
Moreover, EGFR stimulated activation of native Axl protein in SNB-19 cells, an 
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effect that was blocked by specific inhibition of EGFR. In agreement with our 
findings, Meyer and colleagues have shown that EGF stimulation trans-activated 
Axl in breast cancer cells (which we also observed here), which intensified 
downstream EGFR signalling (18). However, in GBM cells, EGF stimulation and 
Axl kinase inhibition had no effect on EGF-stimulated activation of the 
intracellular signalling kinases Akt and ERK. This indicates that Axl cannot be 
the sole mediator of the EGFR signals to these kinases in these cells. Tyrosine 
779 of Axl is a major kinase target and docking site for several intracellular 
signalling adaptors and kinases (2, 22). Therefore, Axl phosphorylation by EGFR 
could be required for protein docking and activation of alternative downstream 
signalling pathways that would not be canonically regulated by either receptor 
alone through homo-dimerisation. Recently, Elkabets et al showed that Axl 
activates the EGFR/PKC/mTOR axis in head and neck and oesophageal 
squamous cell carcinomas, in order to arbitrate resistance to PI3Kα inhibitors 
(23). However, here we did not observe any effect on EGFR phosphorylation by 
Gas6-induced Axl activation. Furthermore, specific Axl kinase small molecule 
inhibition did not hinder phosphorylation by EGFR (15), indicating that the event 
occurs independently of Axl kinase.  
Most importantly, a direct interaction between EGFR and Axl by co-IP 
was shown for the first time in this study (Figure 5.3). The co-IP assay is used 
to determine whether two proteins of interest are physically associated in a 
protein complex. Briefly, this is achieved through lysis of cells under conditions 
that preserve protein-protein interactions. The target protein is specifically IPed 
from the cell extracts by binding of a specific antibody that is then immobilised 
by Protein A/G beads. Any protein that is not precipitated is washed away. The 
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separate proteins present in the IP complexes are resolved by SDS-PAGE and 
each protein of interest is detected by Western blotting using a specific antibody 
(232). Even though co-IPs are straightforward in principle, each IP experiment 
relies on the strength and stability of the particular protein association complex 
under study for successful detection. In the case of EGFR-Axl pulldown, this 
presented a technical challenge. A large amount of protein was required to pull 
down enough protein as the interaction was apparently weak for IP signal 
purposes. Ideally, the physical interaction between the receptors would be 
better demonstrated as well as investigated by Förster resonance energy 
transfer (FRET). FRET is a technique based on a donor fluorophore, which in an 
excited electronic state transfers its energy to a nearby acceptor through non-
radiative dipole–dipole coupling. The proteins of interest are tagged and 
fluorescence is captured by confocal microscope imaging and only occurs if 
proteins physically interact (233). Using this method, the live interaction of 
EGFR and Axl could be studied in real time. Moreover, since only the 
phosphorylation of Y799 residue, which presents one of many phosphorylation 
sites on Axl, was investigated, creation of specific Axl tyrosine residue mutations 
would shed light on the exact mechanism of activation by EGFR. This could 
easily be achieved by transfection of cells with plasmids harbouring the 
mutations, followed by activation of EGFR and subsequent Western blotting of 
lysates and probing for phosphor-Axl. The mutation prohibiting Axl 
phosphorylation by EGFR would thus be indicated to be involved in their 
interaction.  
 Another interesting observation was that EGFR was only able to 
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 phosphorylate the fully glycosylated form of Axl. Axl is a transmembrane 
receptor of molecular weight between 100 and 140kDa (Figure 5.1). Axl is 
highly glycosylated and is present on the cell membrane as fully and partially 
glycosylated protein species (234). The differences in signalling between Axl 
glycosylated forms is still unknown. Moreover, the functional significance of 
different Axl forms remains to be elucidated. One report shows that Axl 
deglycosylation reduces cell proliferation and invasion in mouse hepatocellular 
carcinoma cell lines (235). It is possible that differential glycosylation burden 
alters protein-protein interactions to diversify signalling. Efforts during this PhD 
to study the interaction between EGFR and the different glycosylated forms of 
Axl were futile. Treatment with tunicamycin, which blocks N-linked glycosylation 
to obtain partially glycosylated Axl forms, was unsuccessful and therefore I was 
not able to perform EGFR co-IP or activation experiments. The preferential 
activation of the 140 KDa Axl by EGFR could be due to the spatial conformation 
of the receptors. However, a multifaceted study is required so as to probe 
further this biophysical selectivity. Determination of the X-ray crystal structures 
of EGFR and the alternatively glycosylated forms of Axl would enable 
mathematical modelling to address this question. Moreover, a detailed analysis 
of downstream signalling for each glycosylated Axl form should be performed 
with microarrays to determine if downstream signalling differs depending on 
glycosylation levels.  
 Interestingly, Tyro3 was also activated by EGFR within two minutes of 
stimulation by EGF (Figure 5.1). To date, there are no reports of any interaction 
between EGFR and Tyro3; hence the significance of this novel interaction 
remains to be investigated. Tyro3 is highly expressed in the brain, with regions 
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of high expression including the olfactory bulbs, cerebral cortex, piriform cortex 
(ventrolateral edge of the cerebral hemispheres), all cortical layers of the 
cerebellum, the amygdala, hippocampus and the cerebellum (128). Even 
though the function of Tyro3 in the brain is still not fully understood, reports 
show that Tyro3 activation by Gas6 activates downstream ERK and PI3K 
signalling pathways in cortical neurons, likely modulating strength of synaptic 
connection (128). Moreover, Tyro3 was demonstrated to promote neuronal 
survival through Akt phosphorylation (128) and to maintain the integrity of the 
blood-brain barrier (128). Given the pro-survival abilities of Tyro3, it is 
conceivable that EGFR partners up with the receptor to increase survival of 
cancer cells. Furthermore, the interaction observed may not be through direct 
phosphorylation of Tyro3 by EGFR but via Axl. We and others have shown that 
EGFR physically interacted with and activated Axl, which may in turn activate 
Tyro3 through interaction. Indeed, in a recent study, Brown and colleagues 
showed Tyro3 to co-IP with Axl and enhance Axl activation by their common 
ligand Gas6, while Axl was shown to phosphorylate a kinase-dead form of Tyro3 
(180). These results indicate that heterodimers of Axl and Tyro3 may exist on 
the cell surface, and which interact with EGFR. These findings are still 
preliminary, but portray an exciting avenue for investigation.  
5.2.2 EGFR induces pro-invasive genes upregulation via Axl  
The EGFR-Axl interaction came into the spotlight after the discovery of 
Axl overexpression as a mediator of increased chemoresistance to EGFR SMIs. 
Axl has been shown to promote chemoresistance in gastrointestinal stromal 
tumours (236), head and neck cancer (237), lung cancer (218, 219) and breast 
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cancer (220, 238). Several studies have proposed Axl signalling pathways to be 
controlled by EGFR in order to promote EMT-mediated chemoresistance in 
breast and lung cancers (220, 223, 239).  
Canonically, EMT is the process by which epithelial cells lose their cell 
polarity and cell-cell adhesion, and gain migratory and invasive properties to 
become mesenchymal stem cells; these are multipotent stromal cells that can 
differentiate into a variety of cell types. EMT is essential for numerous 
developmental processes including mesoderm formation and neural tube 
formation. EMT has also been shown to occur in wound healing, in organ fibrosis 
and in the initiation of metastasis for cancer progression (240). However, recent 
findings challenge the role of EMT in metastasis and highlight an unexpected 
role in chemoresistance. Indeed, Fischer and colleagues showed that in lung 
cancer, EMT induction does not promote metastasis but contributes to increase 
resistance to therapy (241); this observation was also supported by similar 
findings in pancreatic (242) and colorectal cancer (243).  
In light of these findings, the rest of the study in this chapter focused on 
investigating the significance of EGFR-Axl EMT related signalling in glioma. Five 
EMT related genes were identified to be specifically regulated by Axl-EGFR 
signalling but not by Axl alone. More specifically, the anti-invasive genes TIMP1, 
CD44 and CCND1 genes were found to be upregulated when EGFR was 
activated together with Axl kinase activity shut off (Figure 5.5). This indicates 
that Axl actively suppresses their expression when activated by EGFR.  
A novel observation is the regulation of expression of the matrix 
metalloproteinase inhibitor TIMP1 by the EGFR-Axl hetero-complex. In order to 
investigate the effect of EGFR-Axl-TIMP1 signalling on cell behaviour, invasion 
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assays where TIMP1 expression was transiently knocked down and stimulated 
with EGF, or EGF in combination with BGB324 to block Axl kinase, were 
performed. As expected, TIMP1 knockdown on its own resulted in a significant 
increase in cell invasion. EGF stimulation in combination with BGB324 led to a 
significant increase in cell invasion compared to TIMP1 siRNA alone. Moreover, 
EGF stimulation led to a significant increase in invasion, an effect which was 
counteracted by Axl kinase inhibition. Axl kinase inhibition in concert with EGFR 
activation completely diminished any baseline invasion to a greater extent than 
Axl inhibition alone. Indeed, we observed an increase in TIMP1 mRNA upon EGF 
stimulation concomitantly with Axl inhibition, which can account for this 
phenomenon. EGFR inhibition alone was able to restore the number of invaded 
cells back to baseline, indicating that EGFR alone cannot account for the 
invasive potential of these cells. With the purpose of identifying why EGFR 
activation further increased cell invasion under these conditions, we also 
investigated and confirmed increases in MMP2 and MMP9 genes, with no further 
change in CD44. Interestingly, previous studies have established MMP9 to be 
directly regulated by Axl in breast cancer (11) and MMP2 in ovarian cancer (24) 
independently of TIMP1 activity. Given our results, we found that in GBM cells, 
the EGFR-Axl-TIMP1 axis promotes invasion through upregulation of MMP9, 
whilst Axl regulates MMP2 expression independently of EGFR or TIMP1. Our 
results are supported by previous studies that reported that MMP9 binds to 
TIMP1 whilst failing to bind MMP2 (25). Furthermore, Axl has been reported to 
regulate MMP2 at the transcriptional level in ovarian cancer through the PI3K 
pathway (24). In Chapter 1, Axl was shown to activate the PI3K pathway in 
glioma and in Chapter 2 Axl inhibition was shown to suppress it (15), indicating 
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that the same regulation exists in glioma. Additionally, recent reports place 
MMP2 and MMP9 under the regulation of STAT3 signalling in breast cancer 
(244), a known downstream Axl effector (245). Indeed, not only Gas6 
stimulates STAT3 phosphorylation in both SNB-19 and UP007 cell lines but 
BGB324 effectively inhibits Gas6-mediated stimulation (Figure 5.6) indicating 
another possible regulatory mechanism. 
In addition, the gene for cyclin D1, CCND1, was upregulated upon EGF 
stimulation, irrespective of Axl kinase activity. Coupled with this, cell cycle 
analysis revealed that EGF stimulation, with or without Axl blockade, drove cells 
to enter mitosis. Taken together, these data show that EGF-EGFR signalling 
promotes cell proliferation through upregulation of TIMP1 and cyclin D1 (26), 
whilst EGFR can also exploit Axl signalling to promote cell invasion through 
downregulation of TIMP1 and cyclin D1 with concomitant upregulation of MMP9. 
Moreover, combination of gefitinib and BGB324 reduces cell viability more 
potently than either agent alone (Figure 5.11). Conclusively, inhibition of Axl 
and EGFR potentiates a more effective GBM treatment as it presents a dual 
targeting approach in which the proliferation and invasion of cancer cells is 
inhibited.  
5.2.3 Summary 
In this chapter, a specific relationship between EGFR and Axl RTKs was 
demonstrated, enabled through a direct protein-protein interaction, which 
diversifies the signalling pathways available to EGFR. Having previously shown 
that Axl signalling is required for GBM cell invasion (15), in this chapter it is 
shown for the first time that EGFR can also signal via Axl to promote cell 
invasion (Figure 5.12), a role for which EGFR, being a major mitogenic growth 
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factor, is not well known as a single entity. Furthermore, it is likely that EGFR-
Axl signalling balances invasion and proliferation through the regulation of key 
genes such as CCND1, TIMP1 and CD44; indeed, EGFR alone promotes 
expression of these genes whilst EGFR-Axl supresses their expression. Given 
these observations, it is conceivable that a combination of EGFR and Axl 
inhibition can be more effective than monotherapy for treating some cancer 
patients, in particular as a means to prevent or delay secondary resistance to 
targeted therapy. 
 
Figure 5.12: Schematic summary of this study, showing hetero-interaction between 
EGFR and Axl, with unidirectional activation of Axl by EGFR, leading to activation of 
pro-invasive signalling pathways, involving TIMP1 as a central regulator.  
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6.0 Introduction 
Receptor tyrosine kinases are cell surface receptors known to regulate 
major biological processes such as growth and survival of cells. RTKs have been 
studied extensively throughout the years both in normal and pathological cell 
behaviour. Indeed, they were established early on as oncogenes, promoting 
cancer progression and metastasis (246), and therefore presented as promising 
new selective targets for therapy using small molecule inhibitors (247). The 
TAM subfamily of RTKs has generated much interest in recent years, especially 
due to the observation that overexpression of Axl, through its ability to interact 
with EGFR, is linked to cancer cell chemoresistance (248) as well as induction 
of EMT in breast (216, 220) and lung (218) cancers.  
Axl and MerTK have been shown to be overexpressed in glioblastoma 
multiforme (GBM) (137, 138). GBMs are highly invasive in nature and do not 
respond to current therapies (200). Preliminary studies in GBM show that 
inhibition of Axl or MerTK signalling decreases cell growth, invasion and 
chemoresistance (138, 144, 177, 178), making the TAMs an attractive target 
for GBM therapy. However, while Axl and MerTK have become very popular 
cancer research topics, Tyro3 has been left in the shadows. Only recently, Tyro3 
overexpression was linked to increased proliferation in hepatocellular carcinoma 
(249) as well as acquired resistance to taxol (chemotherapeutic drug) in ovarian 
cancer (250). Even less is known of the function of Tyro3 in GBM. Tyro3 
overexpression (217) in GBM cell lines was shown in Chapter 3 although its 
exact role still remains to be unveiled.  
As Tyro3 has been shown to have neuro-protective functions in the CNS 
(130), I speculate that it is probably not a sole promoter/driver of glioma but 
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rather may exert pro-tumorigenic properties through association with other 
RTKS. Indeed downregulation of both Axl and Tyro3 was able to reverse taxol 
resistance in ovarian cancer (209, 251). Also, studies in rat fibroblasts 
demonstrated that Tyro3 overexpression leads to increased cell proliferation in 
the presence of Axl. Additionally, Tyro3 co-IPed with Axl and enhanced Axl 
activation by their common ligand Gas6, while Axl was shown to phosphorylate 
a mutated, kinase-dead form of Tyro3 (180). In previous chapters, the 
possibility of interaction between the two receptors in glioblastoma was 
proposed, although their relationship was not investigated further. The purpose 
of this chapter is dual: firstly, the Axl-Tyro3 interaction is explored, as well as 
downstream signalling in GBM. A second aim was to investigate Axl signalling 
in GBM independently of any other interactions. 
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6.1 Results 
6.1.1 Tyro3 physically interacts with Axl 
In Chapter 3, Tyro3 and Axl receptor as well as their common natural 
ligand Gas6 were shown to be overexpressed in glioblastoma (217). To 
investigate the relationship between Tyro3 and Axl, co-IP experiments were 
performed in SNB-19 cells, which confirmed a physical interaction between the 
two endogenous RTKs (Figure 6.1A). Addition of human recombinant Gas6 for 
20 minutes only slightly increased the co-IP association. Having previously 
observed high levels of Gas6 in this cell line (217) (which can stimulate Axl and 
Tyro3 both in an autocrine and paracrine matter (108) (Figure 6.1B), the 
importance of Gas6 in this interaction was further investigated. Cells were either 
left untreated, treated with Gas6 for 20 minutes or treated with the vitamin K 
antagonist warfarin for 24 hours to deactivate any endogenous Gas6. Co-IP 
experiments revealed that Gas6 enhances the complex formation resulting in a 
greater pulldown of the Axl-Tyro3 complex. In confirmation, warfarin treatment 
resulted in a lower amount of the complex, thus indicating that Gas6 is required 
for heterodimerisation (Figure 6.1C).  
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Figure 6.1: Hetero-interaction of Axl and Tyro RTKs. A. Co-IP of Axl and Tyro3, followed 
by Western blot probing for presence in the complexes of Axl (left blot) and Tyro3 
(right blot). B. Co-IP of Axl and Tyro3, followed by Western blotting for presence in 
the complexes of Axl (left blot) and Tyro3 (right blot) following 15-minute stimulation 
with Gas6 (400 ng/ml). C. Co-IP of Axl and Tyro3, followed by Western blotting for 
presence in the complexes of Axl (left blot) and Tyro3 (right blot) following 24-hour 
pre-treatment with warfarin and 15-minute stimulation with Gas6 (400 ng/ml). Control 
co-IP antibody (Ctrl Ig1) was anti-GAPDH. N=3 separate experiments.  
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6.1.2 Axl and Tyro3 protein expression are interdependent 
Initially, in order to investigate signalling downstream of the Axl-Tyro3 
hetero-interaction, expression of each receptor was transiently silenced in turn. 
Surprisingly, Axl knockdown resulted in a significant decrease in Tyro3 protein 
levels, whilst Tyro3 knockdown had no effect on Axl expression (Figure 6.2A, 
p<0.0043 and p<0.0053 for Axl and Tyro3 respectively, ANOVA with Tukey 
multiple comparison post-hoc analysis). Analysis of the mRNA levels by qRT-
PCR showed no significant difference in gene expression of Tyro3 after Axl 
knockdown (Figure 6.2B, p<0.4260 unpaired two tailed student t-test); this 
indicated that the results observed were not due to off-target effects on Tyro3 
mRNA by the Axl siRNA, but rather that there is some kind of reciprocal 
regulation by both receptors on each other’s protein expression levels at the 
post-transcriptional level. Alternatively, Tyro3 was less stable without Axl 
present, resulting in faster degradation. Consequently, due to the observation 
of this co-dependent expression amongst Axl and Tyro3, which was a novel 
finding, as well as the fact that they share a common ligand (Gas6), further 
investigation of this phenomenon and its downstream signalling became very 
challenging. Moreover, in Chapter 4, Axl inhibition by the highly specific SMI 
BGB324 was able to reduce phosphorylation of Tyro3 in UP007 GBM cells (217), 
also indicating that Tyro3 activation and signalling is dependent on Axl.  
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Figure 6.2: Effect of gene silencing by RNAi on TAM phosphorylation and signalling in 
GBM cells. Western blot showing protein knockdown by increasing concentrations of 
Axl siRNAs (A, N=3) and Tyro3 siRNAs (B, N=3) in SNB-19 cells, followed by semi-
quantification of the results in bar graphs. C. qRT-PCR data showing effect of Axl siRNA 
knockdown (15 nM) on Axl and Tyro3 gene expression. Data are mean±SEM protein 
expression normalised against loading control protein; ANOVA with Tukey multiple 
comparison post-hoc analysis (A) and unpaired two tailed student t-test (B), **p<0.01, 
*p<0.05 and ns, not significant.  
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6.1.3 Tyro3 knockdown induces a cell cycle G2/M arrest 
The primary aim of this section was to identify genes targeted by Tyro3 
in GBM. Since Axl and Tyro3 share the same ligand, Gas6, (92) and Tyro3 
expression is Axl co-dependent, Tyro3 knockdown was utilised to identify 
changes in gene expression. Briefly, cells were treated with 20 nM of Tyro3 and 
control siRNAs, and after 48 hours they were treated with Gas6 for an extra 24 
hours in order to activate gene expression. Total RNA was extracted and 
reversed transcribed, and cDNA derived from an original RNA concentration of 
50 ng/µl was loaded into each well of the Qiagen RT2 profiler PCR array and 
gene expression analysed according to manufacturer’s protocol (SABiosciences) 
(252). The manufacturer’s RT2 profiler PCR array data analysis package was 
employed to derive fold-regulation, presented in Table 7. Positive fold-change 
values indicate an up-regulation whilst negative values indicate a down-
regulation. Out of the 84 genes in the array, the 3 most upregulated and 3 most 
downregulated genes (with a cut-off of ≥1.30 fold-change) were selected. 
Notably, the cell cycle regulatory gene CCND1 was downregulated, whilst MOS, 
S1004A and CDH1 genes were upregulated. Additionally, cell survival and DNA 
damage repair related genes JUN and BCL2L1 were downregulated. 
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Table 7: Effects of Tyro3 knockdown on tumour suppressor and oncogenes expressed 
by qRT-PCR using the Qiagen ‘Tumour suppressor and oncogene’ RT2 profiler PCR 
array. Data are fold-change (FC) determined in SNB-19 cells incubated for 24 hours 
with Gas6 (400 ng/ml), compared to SNB-19 cells in the absence or presence of Tyro3 
knockdown (N=1 experiment). 
Symbol Fold Change Type 
MOS     ↑ 1.815 Serine/threonine kinase 
S100A4     ↑ 1.4845 Signalling molecule 
CDH1     ↑ 1.366 Adhesion molecule 
JUN ↓ -1.4845 Transcription factor 
BCL2L1 ↓ -1.4743 Signalling molecule 
CCND1 ↓ -1.3379 Kinase activator 
 
Having measured changes in genes relevant to the cell cycle and cell 
survival, the functional role of Tyro3 knockdown was then investigated through 
cell cycle analysis and annexin V/PI staining. Prior to cell cycle analysis, SNB-
19 cells were treated with Tyro3 and control siRNAs and Gas6 for 24 hours. Cell 
cycle analysis revealed that following Tyro3 knockdown 52.4% of the cells 
(Figure 6.3B) analysed were in the S-phase of the cell cycle compared to 37.3% 
in control cells (Figure 6.3A). Moreover, in the case of Tyro3 knockdown only 
12.1% of cells (Figure 6.3B) were able to progress to the M phase compared to 
27.3% for control cells (Figure 6.3A), indicating a defect in the G2/M transition 
upon Tyro3 knockdown.  
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Figure 6.3: Cell cycle analysis of SNB-19 cells treated for 24 hours with Gas6 following 
siTyro3 knockdown (B) and control (A). Markers in the displayed plots were used to 
demarcate G1, S ad M phases of the cell cycle (N=1 experiment).  
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Annexin V/PI staining also revealed that cells with Tyro3 knocked down 
were less healthy compared to control. Indeed, 54% of Tyro3 knockdown cells 
were in the early apoptotic phase compared to 29% for control cells. In 
addition, treatment with staurosporine, a well-established inducer of apoptosis, 
increased early apoptosis in 55% of control cells, but had no further effect on 
Tyro3 knockdown cells, indicating an already existing commitment to apoptosis 
in these cells (Figure 6.4).  
 
Figure 6.4: Effect of Tyro3 knockdown on cell survival. Propidium iodide (PI) vs Annexin 
V fluorescence intensity in SNB-19 cells for incubated with Tyro3 (siTyro3) and control 
(siControl) siRNAs and treated with either Gas6 or combination of Gas6 + 
staurosporine. Quadrants and markers in the displayed plots were used to demarcate 
the various cell populations (N=1).  
 
6.1.4 Axl downstream signalling in GBM 
The activation/deactivation of TAM network-related intracellular 
signalling kinases in SNB-19 cells was evaluated using the human phospho-RTK 
array, a semi-quantitative tool which allows for the simultaneous identification 
of the phosphorylation status of 42 kinases in a rapid and sensitive manner. 
SNB-19 cells were serum-starved overnight and then stimulated with either 400 
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ng/ml Gas6 for 15 minutes or pre-incubated with 5 µM BGB324 for 1 hour. 
Quantification by optical densitometry of pixel density (OD/mm2) confirmed 
activation (through phosphorylation state) of 33 kinases following Gas6 
stimulation. Pre-incubation with BGB324 either completely inhibited the 
activation state of some kinases, or reduced the effect of Gas6, or had no effect. 
Specifically, a complete inhibition of Gas6-induced phosphorylation of β-catenin, 
AMPK1α, Akt 1/2/3 (S473), c-jun, PLC-γ1, STAT5 α/β and PYK2 kinases was 
observed, indicating exclusive Axl regulation (Figure 6.6). Moreover, whilst Gas6 
was able to induce phosphorylation of ERK1/2, GSK3 α/β, Akt 1/2/3 (T308), 
STAT6 and HcK kinases, BGB324 was unable to block this activation, indicating 
that another TAM such as Tyro3 or MerTK likely mediated those Gas6 effects 
(Figure 6.5). In addition, interestingly, PRAS40 and Fgr phosphorylation were 
completely abolished upon Gas6 stimulation, whilst treatment with BGB324 
significantly increased their phosphorylation above basal levels (Figure 6.6).  
  
Figure 6.5: Relative pixel densitometry bar graph indicating changes in phosphorylation 
levels of kinases for untreated, treated with Gas6 (400 ng/ml) or Gas6 in combination 
with 5 µM BGB324 for SNB-19 cells (N=1 experiment (membrane)).  
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Figure 6.6: Relative pixel densitometry bar graph indicating changes in phosphorylation levels of kinases for untreated, treated with 
Gas6 (400 ng/ml) or Gas6 in combination with 5 µM BGB324 in SNB-19 cells (N=1 experiment (i.e. one membrane probed)).
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As an additional investigation, the activation of the NF-κB signalling 
pathway was investigated by measuring its downstream gene transcriptional 
activity through a luciferase assay system. The Dual-Luciferase® Reporter 
(DLR™) Assay System utilizes two reporter assays. Plasmids are transfected 
into the cell and after lysis the activities of firefly and Renilla luciferases are 
measured sequentially from a single sample. The Renilla luciferase vector acts 
as an internal control for plasmid transfection, whilst the firefly luciferase vector 
is used to measure transcriptional activity for the gene of interest. The 
luminescence values are then normalised to the activity of the Renilla control 
to minimise experimental variability. (253). Using this system, Gas6 treatment 
for 24 hours was not observed to activate NF-κB signalling (Figure 6.7A, 
p<0.8447, p<0.5322 for SNB-19 and UP007 cells respectively, unpaired two 
tailed student t-test), nor did Axl blockade with BGB324 affect the pathway in 
both SNB-19 and UP007 cells (Figure 6.7C, p<0.2497 and p<0.7088 
respectively, ANOVA with Tukey multiple comparison post-hoc analysis). 
However, treatment with BMS777607 significantly reduced NF-κB pathway 
activity at both at 15 and 24 hours after treatment in both cell lines (Figure 
6.7D, p<0.0083 and p<0.0017 for SNB-19 and UP007 respectively, ANOVA with 
Tukey multiple comparison post-hoc analysis). In addition, SNB-19 cells with 
Axl expression stably knocked down through shRNA did not show any significant 
difference in NF-κB activity as compared to control knockdown cells, whilst a 
significant decrease in NF-κB activity was observed upon Axl knockdown in the 
UP007 cell line (Figure 6.7B, p<0.1515 ANOVA with Tukey multiple comparison 
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post-hoc analysis for SNB-19 cells and p<0.0064 unpaired two tailed student t-
test for the UP007 cells).  
 
Figure 6.7: NF-κB expression levels in SNB-19 and UP007 cells as indicated by 
percentage LARII/Renilla after A. Gas6 (400 ng/ml) treatment for 24 hours, B. Stable 
Axl knockdown clones, C. treatment with 1 µM BGB324 for 15 and 24 hours and D. 
treatment with 100 µM and 35 µM BMS777607 for SNB-19 and UP007 cells respectively 
for 15 and 24 hours. Data are mean±SEM; N=3, ANOVA with Tukey multiple 
comparison post-hoc analysis or student t-test **p<0.01, * p<0.05, ns; not significant 
vs control. 
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6.1.5 EGFR-Axl downstream signalling in GBM 
In Chapter 5, the EGFR-Axl heterodimerisation was investigated. Axl was 
shown to act a gateway for EGFR to invasive signalling through regulation of 
the TIMP1-MMP9 axis. In order to further investigate EGFR-Axl downstream 
signalling, the human phospho-RTK array was employed, which allows for the 
simultaneous detection of relative phosphorylation of 49 different RTKs by 
chemiluminescence detection. SNB-19 cells were serum-starved overnight and 
then stimulated with either 50 ng/ml EGF for 10 minutes or pre-incubated with 
5 µM BGB324 for 1 hour before EGF stimulation. Quantification by optical 
densitometry of pixel density (OD/mm2) confirmed activation of 34 signalling 
kinases following EGF stimulation. Pre-incubation with BGB324 was used to 
block Axl kinase activity and pinpoint which kinases are phosphorylated by EGFR 
only or in cooperation with Axl. Interestingly, Akt 1/2/3 (S743), eNOS, β-catenin 
and HSP60 were strongly phosphorylated after EGF stimulation, whilst this was 
completely inhibited in the presence of BGB324, indicating a unique EGFR-Axl 
signalling pathway. Moreover, WINK1 was deactivated by EGF stimulation and 
completely reactivated above basal levels when Axl kinase was blocked. An 
increase in phosphorylation was also observed after EGF stimulation of PI3K 
pathway-related kinases such as Akt 1/2/3 (T308), TOR and CREB, which was 
kept at basal levels by Axl kinase blockade. Interestingly, phosphorylation of 
FAK and PRAS40 as well as Fgr were completely inhibited following EGF 
addition, with Axl inhibition having no effect on this, thus indicating a direct 
regulation by EGFR independently of Axl (Figure 6.9). Furthermore, GSK3 α/β, 
STAT3 (S727) and STAT5 α/β were all increased in their phosphorylation states 
by EGF stimulation with a lack of influence of BGB324 on this (Figure 6.8).  
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Figure 6.8: Relative pixel densitometry bar graph indicating phosphorylation levels of 
kinases for untreated, treated with 50 ng/ml EGF or EGF in combination with 5µM 
BGB324 in SNB-19 cells (N=1 experiment).  
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Figure 6.9: Relative pixel densitometry bar graph indicating phosphorylation levels of kinases for untreated, treated with 50 ng/ml EGF 
or EGF in combination with 5µM BGB324 in SNB-19 cells (N=1 experiment (one membrane probed))
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6.2 Discussion 
6.2.1 Tyro3 physically interacts with Axl 
The TAM receptor genes share similar genomic structures, with Axl and 
Tyro3 sharing more similarity than MerTK as well as having a higher affinity for 
their common ligand Gas6 (97, 119, 254, 255). A heterodimerisation between 
the receptors has been speculated for years although supporting evidence was 
not shown until recently. In one study, Axl co-immunoprecipitated with Tyro3 
in gonadotropin-releasing hormone (GnRH) neuronal cells and was shown to 
promote survival (117). In Rat2 fibroblasts, Gas6 treatment induced Tyro3-
dependent Axl phosphorylation, which further lead to the trans-phosphorylation 
of Tyro3 (180). Furthermore, downregulation of both Axl and Tyro3 were able 
to reverse taxol resistance in ovarian cancer (209, 251). In Chapter 3, Tyro3 
overexpression in GBM was reported for the first time, whilst in Chapter 4 a hint 
of such hetero-interaction was presented when BGB324, a highly specific Axl 
inhibitor, was observed to also affect Tyro3 phosphorylation. The aim of the 
first part of this chapter was to investigate the Axl-Tyro3 protein-protein 
interaction and downstream signalling in GBM cells. Indeed, co-IP experiments 
confirmed a physical interaction between the two RTKs in GBM cells on 
endogenous levels (Figure 6.1). Importantly, this interaction was shown to be 
dependent on the presence of Gas6 in the system (Figure 6.2), indicating that 
ligand presence may be essential for receptor interaction, countering the notion 
of the TAMs being able to homodimerise even in the absence of their ligand 
(179, 256). 
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A study by Tsou and colleagues on ligand specificity and TAM receptor 
activation that Gas6 alone was sufficient to induce Axl homodimerisation, which 
occurred with 2:2 stoichiometry (103). However, this was not observed with 
MerTK and Tyro3. The same investigators also reported that only one minor 
Gas6 binding site is highly conserved in all TAMs, whereas the second major 
Gas6 binding site in MerTK and Tyro3 is not (103, 109). Furthermore, 
computational modelling performed by Sasaki and colleagues shows that 
monomeric Tyro3 is readily accommodated at the major Axl binding site of Gas6 
(109). Moreover, co-precipitation studies and competition studies with soluble 
TAMs revealed that Axl interaction with Gas6 was more conspicuous compared 
with MerTK and Tyro3 interactions with Gas6, pointing out that if all three 
receptors were present on a single cell, Axl would be the preferred receptor for 
ligand binding (103). These results together indicate that Axl heterodimerisation 
with MerTK or Tyro3 may also occur in addition to the canonical 
homodimerisation of each RTK, in order to promote Gas6-induced signalling 
and/or ligand-independent signalling. To further investigate this phenomenon, 
we performed co-IP experiments after 15-minutes stimulation with exogenous 
Gas6 and observed a slight increase in the amount of Tyro3 that co-IPed with 
Axl. Furthermore, pre-treatment of cells with warfarin, which blocks 
endogenous vitamin K epoxide reductase and therefore prevents -
carboxylation of synthesised Gas6, rendering it unable to activate the receptor 
(103), reduced the Axl-Tyro3 co-IP, indicating that Gas6 also has an influence 
on the heterodimerisation and that it is not entirely ligand-independent. In order 
to further understand this interaction, structural analysis of the three-
dimensional structures of Axl and Tyro3 receptors with Gas6 binding by X-ray 
 167 
 
crystallography is needed to understand the functional architecture of this 
interaction. Furthermore, mutational analysis can delve further into the ligand-
receptors interaction as well as how heterodimerisation is induced through 
ligand binding.  
6.2.2 Axl and Tyro3 protein expression are interdependent 
In an effort to dissect Axl-Tyro3 signalling, a gene knockdown approach 
was employed. Surprisingly, knockdown of either receptor resulted in a 
reduction of protein expression of the other. At the mRNA level, Tyro3 
knockdown did not have any effect on Axl (Figure 6.3), whereas Axl knockdown 
significantly reduced Tyro3 levels, indicating a possible regulation of expression 
by Axl. Little is known about the regulation of these receptors. One mechanism 
suggests endocytosis as a mechanism of Axl receptor downregulation after 
Gas6 stimulated interaction of Axl with the ubiquitin ligase c-Cbl which leads to 
ubiquitination and eventual degradation (101). At the post-transcriptional level, 
Axl was shown to be regulated by two miRNAs, miR-34a and miR199a/b, 
identified by a bioinformatics screen using non-small cell lung, breast and 
colorectal cancer cell lines (119). The Axl gene promoter harbours binding sites 
for transcription factors Sp1/Sp3, MZF1, CREB and AP2 (257). MerTK was found 
to also harbour the same Sp1/Sp3 binding sites as Axl in Sertoli cells (258). 
Therefore, given the homology of the TAM genes, it is possible that Tyro3 also 
contains the Sp1/Sp3 regulatory binding sites. Sp1 activity has been shown to 
be induced by the MAPK and PI3K pathways in response to growth factors 
(259). Therefore, Axl can possibly regulate Sp1 activity through a feedback loop 
in either a MAPK- or PI3K-dependent manner. Upon Axl knockdown, the loop is 
disrupted and Tyro3 expression is also downregulated.  
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At the post-translational level, proper folding of the Axl protein, and its 
final expression, was shown to be dependent on the molecular chaperone 
HSP90, which functions to maintain conformational maturation and structural 
integrity of a variety of cellular proteins (260). Indeed, inhibition of HSP90 was 
shown to result in CHIP E3 ligase-dependent Axl degradation (260). 
Furthermore, the TAMs are post-translationally modified through N-
glycosylation. Sasaki and colleagues pointed out that, although all three TAMs 
possess homologous domains with conserved glycosylation sites, Tyro3 and Axl 
nevertheless possess major differences in their conformations, in particular with 
respect to the position of the Ig domains, where Axl-Ig1 is fully extended 
whereas Tyro3-Ig1 appears to bend, thus making a glycosylation side 
inaccessible (109). This indicates that proper protein folding and modification 
is essential for receptor expression. Furthermore, Axl could possibly regulate 
Tyro3 expression through a variety of ways: for instance, Src, which is a non-
receptor tyrosine kinase protein linked to cancer progression by promoting 
other RTK signals (147) possesses SH2, SH3, and tyrosine kinase domains, has 
been shown to bind Axl in B-cell chronic lymphocytic leukaemia cells (147). 
Moreover, Src is able to phosphorylate HSP90 and thereby affect the folding 
and activation of certain proteins. The same regulation of Axl expression by 
Tyro3 can be expected as Tyro3 can also bind and activate the Src kinase (261). 
Interestingly, Axl may also regulate HSP90 through eNOS, whose product nitric 
oxide (NO) can mediate S-nitrosylation of HSP90, which is a reversible covalent 
modification that inhibits HSP90 ATPase activity (262). Furthermore, eNOS is 
negatively regulated through sequestration by caveolin-1 scaffolding domain 
(263), which is an Axl binding partner (264), therefore removal of Axl would 
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promote activation of eNOS and NO production that leads to HSP90 inhibition 
and therefore incorrect Tyro3 folding and subsequent degradation (Figure 
6.10).  
 
Figure 6.10: Proposed model of the mechanism of post-translational Tyro3 regulation 
by Axl. On the left, the sequestration of eNOS by caveolin-1 allows correct Tyro3 folding 
and expression by HSP90. On the right, upon Axl knockdown eNOS is released and 
inhibits HSP90 function through S-nitrosylation.  
 
Currently, there are no reports on regulation of Tyro3 by Axl or vice 
versa. Given the limited amount of information there is on TAM gene regulation 
as well as post-translational modification, no direct links can be drawn to explain 
the phenomenon observed in this study. However, an exciting new field of 
investigation is presented and more research should be done on the how the 
TAMs are regulated.  
6.2.3 Axl-Tyro3 related signalling 
Due to their common ligand, a technical challenge was presented in 
terms of probing further the nature of the Axl-Tyro3 interaction in order to e.g. 
map both their discrete and concerted signalling effects. As an attempt, I 
decided to knockdown Tyro3, as Axl expression was not affected by its 
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knockdown, and stimulate the cells with exogenous Gas6 followed by a qRT-
PCR expression screen of well-known tumour suppressors and oncogenes 
(Table 7). 
6.2.3.1 Upregulated genes 
6.2.3.1.1 The MOS gene 
 From the screen, we identified MOS, the product of which is a kinase 
first discovered to control the meiotic cell cycle in vertebrate oocytes (265). Mos 
kinase functions via activating maturation promoting factor (MPF), a universal 
G2/M regulator in eukaryotic cell division (265). Mos has been reported to act 
as an oncogene and to be a potent activator of the MAPK cascade(266). 
Interestingly, constitutive activation of the MOS/MAPK pathway, results in S-
phase-induced apoptosis or G1 cell cycle arrest (265). Moreover, cells in G2 enter 
the M phase but are unable to undergo cytokinesis and instead arrest as 
binucleated cells in a G1-like state (267, 268). Additionally, MOS has been shown 
to disrupt the M phase through its localisation and phosphorylation of a 
kinetochore component, thus increasing chromosome instability and preventing 
normal congregation (269). There are no reports of direct suppression of MOS 
kinase by Tyro3 in the literature, making this a novel finding. The MOS gene is 
a CREB responsive gene, which can act as an activator or a suppressor of a 
gene depending on its phosphorylation state (270-272). CREB is usually 
activated by the MAPK pathway, which is downstream of Tyro3 (92) and could 
present a novel negative regulatory pathway for MOS by Tyro3. This 
suppression enables cancer cells to progress through the cell cycle even though 
they are characterised by genomic instability and would otherwise enter 
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apoptosis. Moreover, MOS kinase is negatively regulated by Casein Kinase 2 
(CK2) (273) which is activated by the Src family of kinases (274), which are in 
turn activated by Tyro3 (261) pointing to a second negative regulatory 
mechanism mediated by Tyro3. Moreover, CK2 acts as a positive modulator of 
Wnt/β-catenin/Lef-Tcf pathway, suppressing β-catenin degradation and β-
catenin binding to APC (275), a known proliferation inducer in glioma (276). 
Therefore, the data outlined above collectively indicate that Tyro3 may suppress 
Mos kinase whilst upregulating pro-proliferative signalling, thus establishing its 
role as a propagator of GBM cell growth (Figure 6.11).  
 
Figure 6.11: Proposed mechanism of Tyro3-mediated MOS kinase suppression in GBM 
cell survival and proliferation.  
6.2.3.1.2 The S100A4 gene 
The second most upregulated gene was S100A4, which encodes for a 
Ca+2-binding protein. Even though no known enzymatic activity has been 
assigned to this protein, it is considered to promote its effect through interaction 
with other proteins (277). The S100A4 protein has been shown to regulate cell 
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cycle G2-M transition by sequestering p53 (277). The S100A4 gene promoter 
has been shown to contain sequences recognised by Sp1, AP-1 and CBF 
transcription factors (278) Even though no known direct interaction has been 
identified between S100A4 and Tyro3, Tyro3 is known to activate ERK1/2 
downstream (92), which regulates AP1-mediated transcription (279). Once 
again, the effect of Tyro3 presence in cancer cells seems to promote the 
successful entry and progression through the cell cycle, enabling evasion of 
checkpoint mediated arrest and apoptosis. 
6.2.3.1.3 The CDH1 gene 
The third most upregulated gene was CDH1, which encodes for E-
cadherin. E-cadherin is known to interact with APC to regulate mitotic 
progression (280). Activation of APC/Cdh1 by genotoxic stress has been linked 
to abrogated G2/M progression, spindle body assembly and chromatid 
segregation (281). Furthermore, E-cadherin regulates the cell cycle on many 
levels: it controls the turnover of the CDK inhibitors p27 and p21; it inhibits 
cyclin D transcription by degradation of Ets2 and degradation of the CDK1 
activator Cdc25A; it modulates Chk1 activity by regulating claspin stability; 
lastly, it regulates microtubules dynamics and mitotic spindle formation by 
targeting JNK for degradation during G2/M transition (280-283). Moreover, E-
cadherin is a well-established tumour suppressor, as its loss usually leads to 
EMT induction and increased cell migration and invasion (284). E-cadherin has 
been shown to be negatively regulated in cancer through the recruitment of 
HDACs to remodel the chromatin structure by Twist (285). Twist expression is 
activated by Akt, STAT3, MAPK, Ras, and Wnt signalling (286), and Tyro3 has 
been shown to activate Akt and MAPK (92). Therefore, these observations 
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together suggest that Tyro3 signalling leads to downregulation of E-cadherin 
whilst its upregulation would occur upon Tyro3 signalling inhibition or 
knockdown (as we observed here). The importance of E-cadherin regulation by 
Tyro3 is dual: firstly, E-cadherin suppression is required for EMT induction, 
which has been shown to be mediated by Axl to increase chemoresistance. 
Additionally, Axl signalling promotes invasion, which requires the loss of cell 
adhesion. Secondly, one of the hallmarks of tumour cells is uncontrolled 
proliferation which is usually achieved through the loss of cell cycle regulatory 
checkpoints. Suppression of E-cadherin by Tyro3 relieves cancer cells from the 
G2/M transition checkpoint, thus allowing proliferation and survival.  
6.2.3.2 Downregulated genes 
6.2.3.2.1 The JUN gene 
 The JUN gene codes for the c-Jun, a transcription factor which together 
with fos transcription factor forms the AP-1 transcription factor complex (287). 
AP-1 controls expression of genes involved in proliferation, differentiation, cell 
death and the response to genotoxic agents or stress (288). c-Jun acts a cell 
proliferation promoter by activating cyclin D1 transcription and by inhibiting p21 
accumulation through repression of p53 expression (288). AP-1 was also shown 
to regulate apoptosis, although its role is very complex as it can trigger both 
pro- or anti-apoptotic signals depending on cell type or the death-inducing 
treatments (288). Moreover, c-Jun activation by JNK2 has been implicated with 
chemoresistance in cancer through transcription of Multi-Drug Resistance 
(MDR1) gene (289). c-Jun can be regulated by degradation and gene 
expression, and the main regulators of its expression include MAPK family 
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proteins (279, 290). Jun N-terminal kinase (JNK) binds and phosphorylates the 
c-Jun transactivation domain, increasing its ability to activate the transcription 
of target genes. c-Jun can also be phosphorylated and form a heterodimer with 
ATF-2 which activated the c-jun promoter. Moreover, ERK is found to increase 
c-jun transcription and stability through CREB, ATF-2 and GSK3 respectively 
(279, 290). Tyro3 has been known to activate ERK1/2 downstream (92), 
therefore promoting c-jun gene expression. Given the significance of c-Jun in 
chemoresistance, survival and proliferation, activation by Tyro3 in cancer cells 
provides them with an additional advantage. Axl has already been shown to 
mediate EMT-related chemoresistance to EGFR SMIs in several other cancers. 
This effect though could be mediated via Tyro3 through heterodimerisation, or 
it could provide an additive effect where Tyro3 induces pro-survival gene 
expression. Additionally, it can present another potential mechanism by which 
promotes neuronal survival.  
6.2.3.2.2 The BCL2L1 gene 
The second most downregulated gene was BCL2L1, which codes for BCL-
XL protein, a potent pro-survival factor. BCL-XL exerts its pro-survival effects in 
two main ways: firstly, it inhibits pro-apoptotic BAX and BAK action by 
competing with them for binding to membranes, thus preventing the formation 
of lethal pores in the mitochondrial outer membrane (291). Secondly, BCL-XL 
binds to the voltage-dependent anion channel 1 (VDAC1), a porin ion channel 
located on the outer mitochondrial membrane, and inhibits mitochondrial 
permeability transition and thus cell death (292, 293). Overexpression of BCL-
XL in cancer is very common and has been linked to increased multidrug 
chemoresistance (294). Moreover, it has been shown to aid cancer cells 
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overcome mitotic spindle damage checkpoint and genomic instability (295, 
296). Upregulation of BCL-XL by Tyro3 was also observed by Protein S 
stimulation in an excitotoxic injury neuronal model. Moreover, BCL-XL 
upregulation was shown to be mediated by the PI3K-Akt pathway and to protect 
neurons from cell death (130). In GBM, Tyro3 could utilise BCL-XL expression 
to protect the cancer cell from chemotherapy-induced cell death, as well as 
increased genomic instability-induced cell death.  
6.2.3.2.3 The CCND1 gene 
The third most downregulated gene upon Tyro3 knockdown in GBM cells 
was CCND1, which encodes for cyclin D1. Cyclin D1 promotes cell proliferation 
by binding to and activating CDK4 and CDK6; the complex formed then 
phosphorylates the tumour suppressor protein pRB, which regulates the E2F 
transcription factors, promoting gene expression required for entry of cells into 
the S phase of cell cycle (297, 298) (Figure 6.12). 
 
Figure 6.12: Cyclin D1 function. Entrance into S phase is characterised by 
phosphorylation of pRb by cyclin D1–cyclin-dependent kinase (CDK)-4, cyclin D1–CDK6 
and cyclin E–CDK2 complexes. The phosphorylation of pRb is associated with release 
of the E2F1–3 transcription factors, which then activate genes that are required for 
cell-cycle progression (299). 
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Besides its major role in the cell cycle, cyclin D1 can bind the promoter 
and initiate transcription of genes involved in migration and invasion, such as 
thrombospondin and the Rho effector ROCK2 (297, 298). Moreover, cyclin D1 
regulates the expression of genes that are involved in DNA replication and the 
DNA damage checkpoint, and can directly bind proteins involved in the DNA 
damage response (297, 298). Cyclin D1 has been shown to promote 
homologous recombination-mediated DNA repair by forming a complex with 
recombinase RAD51 and BRCA2 and recruiting them to the damage site (297, 
298). Cyclin D1 is often overexpressed in cancer and aids cells to mount an 
enhanced DNA damage response and increased genomic instability (298). Cyclin 
D1 gene expression has been previously associated with Tyro3 in cancer. Tyro3 
knockdown in breast cancer and hepatocellular carcinoma resulted in decreased 
proliferation which correlated with a decrease in cyclin D1 (154, 249, 300). The 
cyclin D1 gene is regulated by a variety of transcription factors. Studies have 
shown sp1, AP-1 as well as the ATF2-CREB complex of transcription factors to 
promote its transcription (301). Even though no direct link has yet been 
reported between Tyro3 and these transcription factors, in melanoma Tyro3 
has been shown to regulate MITF gene expression through the transcription 
factor SOX10 (153). SOX10 has been shown to interact with sp1, synergistically 
activate the MBP promoter in oligodendrocytes (302). Therefore, Tyro3 may be 
able to promote cyclin D1 expression through SOX10. Additionally, cyclin D1 
expression in glioma has been shown to be highly dependent on CREB, which 
was shown to be activated by the PI3K and MAPK pathways (303), both of 
which are downstream targets of Tyro3 activity (92). During gene screening, I 
also showed that c-Jun, which belongs to the Ap-1 complex, is positively 
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regulated by Tyro3 and can promote cyclin D1 expression directly. This finding 
has major implications for cancer cells as Tyro3 promotes entry through the cell 
cycle and increases cell division.  
6.2.3.3 NF-κB signalling 
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is 
a protein complex that controls transcription of DNA to promote cell survival. 
Normally, NF-κB dimers are sequestered in the cytoplasm by IκBs (Inhibitor of 
κB). When a stimulus activates the pathway, IκB kinase (IKK) phosphorylates 
and marks the IκB molecules for ubiquitination, thus freeing NF-κB and allowing 
nuclear translocation to occur (Figure 6.13). NF-κB has been shown to be 
activated by Akt (304, 305).  
 
Figure 6.13: Schematic representation of NF-κB activation. NF-κB dimers are 
sequestered in the cytoplasm by IκBs. Upon stimulation, IκB kinase (IKK) 
phosphorylates and marks the IκB molecules for ubiquitination, thus freeing NF-κB and 
allowing nuclear translocation to occur (306). 
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Recently, it has been shown in schwannoma that activation of the 
Gas6/Axl signalling pathway recruits Src, focal adhesion kinase (FAK) and NF-
κB, and that NF-κB mediates Gas6/Axl-mediated overexpression of survivin, 
cyclin D1 and FAK, leading to enhanced survival, cell-matrix adhesion and 
proliferation (307). In order to investigate the role of TAMs on the regulation of 
NF-κB in GBM cells, we utilised a luciferase assay to detect changes in specific 
NF-κB pathway-regulated gene expression under different conditions. 
Stimulation of TAM signalling by exogenous Gas6 had no effect on NF-κB 
pathway transcriptional regulatory activity. Also, stable Axl knockdown did not 
affect NF-κB activity in SNB-19 cells, whilst it was reduced in UP007 cells. This 
difference could be due to the expression of MerTK in SNB-19 cells (absent in 
UP007 cells) which may compensate for the loss of Axl. Additionally, inhibition 
of Axl showed a time-dependent decrease in NF-κB expression which was not 
significant. However, the SMI BMS777607 completely inhibited NF-κB activity, 
which can be explained by the fact that BMS777607 not only inhibits Axl but 
also Tyro3 and MET receptors, all of which have been shown to regulate NF-κB 
in other contexts.  
6.2.4 Tyro3 promotes GBM cell proliferation and survival 
 Following the genetic alterations observed after Tyro3 knockdown cell 
cycle analysis confirmed an increase of cells in the S and G2-M phases (Figure 
6.3), which could be due to the aforementioned upregulation of MOS, S1004A 
and CHD1 genes with concomitant downregulation of BCL2L1, CCND1 and JUN 
genes. Moreover, Annexin V/PI staining indicated increased apoptosis in cells 
lacking Tyro3 (Figure 6.4). Collectively these results indicate that Tyro3 
 179 
 
signalling positively promotes the cell cycle, thus increasing cancer cell 
proliferation, whilst protecting cells from cell death (Figure 6.14). These results 
identify a new exciting role for Tyro3 in cancer. Due to Tyro3 being the least 
studied TAM receptor, the mechanisms behind these phenomena certainly 
warrants further investigation.  
 
 
Figure 6.14: Proposed mechanism of Tyro3 mediated GBM cell survival and 
proliferation. Tyro3 activates Akt and ERK signalling which leads to MOS, S100A4 and 
CDH1 suppression, whilst upregulating BCL1L2, JUN and CCND1 transcription, thus 
providing GBM cells increased survival and cell cycle checkpoint evasion.  
 
Additionally, it is still unclear whether Tyro3 achieves these functions 
through regulation of certain gene sets alone or in co-operation with Axl. It 
would be interesting to determine whether Axl takes advantage of Tyro3 to 
exert pro-proliferative and survival signalling or else whether Tyro3 can fulfil 
this role alone. What is becoming more clear from these studies is that Axl and 
Tyro3 have distinctive roles, at least in GBM cells but most likely in other cells 
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in which they are co-expressed. Whilst Axl mediates GBM cell invasion, Tyro3 
predominantly promotes cell proliferation and cell survival, thus making GBM 
therapy very difficult and currently unsuccessful. These findings indicate that a 
combinatory inhibition of both receptors may be more effective than targeting 
either alone.  
6.2.5 Axl downstream signalling in GBM 
In order to dissect the Axl related intracellular signalling kinase network 
in SNB-19 cells, a phosphokinase screen was performed after Gas6 stimulation 
alone or in the presence of BGB324 (Figure 6.5 and 6.6). Pre-incubation of cells 
with BGB324 either completely inhibited activation or reduced the effect of 
Gas6, or had no effect. Specifically, we observed a complete inhibition of Gas6-
induced phosphorylation of the kinases β-catenin, AMPK1α, Akt 1/2/3 (S473), 
c-Jun, PLC-γ1, STAT5 α/β and PYK2 in the presence of BGB324, indicating their 
exclusive regulation by Axl out of the TAMs. In addition, Gas6 induced 
phosphorylation of a further set of kinases, ERK1/2, GSK3 α/β, Akt 1/2/3 
(T308), STAT6 and HcK, which BGB324 pre-incubation was unable to affect; 
this therefore indicates that another TAM such as Tyro3 or MerTK is the main 
RTK for their activation by Gas6, further supported by their having previously 
been shown to be activated downstream (120). Conversely, Gas6 stimulation 
actually completely abolished phosphorylation of PRAS40, a downstream target 
of Akt and a negative regulator of the mTOR pathway, which is involved in the 
control of cell growth, survival, proliferation (308). Phosphorylation was also 
abolished of Fgr, a member of the Src family of protein tyrosine kinases, which 
acts a negative regulator of cell migration and adhesion (309). Treatment with 
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BGB324 significantly increased phosphorylation of both kinases above basal 
levels indicating that Axl is responsible for their negative regulation. As Axl is 
now well-established as a pro-invasion signalling molecule, its inhibition of Fgr 
and PRAS40 is therefore reasonable in the context of cancer as they are both 
negative regulators of the hallmarks of cancer cells: invasion and proliferation.  
The Wnt signalling pathway is centred around the regulation of β-catenin 
phosphorylation/degradation. Canonically, in the absence of Wnt, β-catenin 
protein is sequestered and degraded through the actions of a complex of 
proteins formed by the scaffolding protein Axin, the tumour suppressor APC, 
casein kinase 1 (CK1), and GSK3. CK1 and GSK3 sequentially phosphorylate the 
amino terminal region of β-catenin, resulting in β-catenin recognition by β-Trcp, 
an E3 ubiquitin ligase subunit, and subsequent β-catenin ubiquitination and 
proteasomal degradation. When Wnt ligand is present, the Frizzled (fz) receptor 
and its co-receptor, low-density lipoprotein receptor related protein 6 (LRP6) 
are activated and form a complex that recruits Dishevelled (Dvl). The completed 
complex then promotes LRP6 phosphorylation and inhibition of the inhibitory 
Axin complex, thus stabilising β-catenin, which then translocates to the nucleus 
to form complexes with TCF/LEF to activate gene expression (310) (Figure 
6.15).  
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Figure 6.15: Schematic representation of the canonical Wnt/beta-catenin signalling 
pathway. (a) In the absence of Wnt signal, beta-catenin is recruited into the 
APC/Axin/GSK3β complex, and phosphorylated by GSK3β. The phosphorylated beta-
catenin binds to the proteosome machinery and is targeted for degradation, 
suppressing transcription (b) Wnt binds to its Fz receptor and LRP5/6 co-receptor and 
activates Dvl, leading to the inhibition of APC/Axin/GSK3β-mediated β-catenin 
degradation leading to gene transcription (311).  
 
β-catenin signalling has been shown to be crucial for GBM cell 
proliferation and invasion (276). Moreover, it has been shown to be under the 
regulation of the RTK MET in GBM (312). In the present study, we observed 
increased phosphorylation of β-catenin after stimulation with Gas6 and its 
complete inhibition upon Axl blockade with BGB324, indicating a complete 
regulation by Axl signalling. Indeed, Gas6 been shown to activate Akt and 
concomitantly inhibit GSK3 activity, promoting β-catenin stabilisation in breast 
cancer cells (313). Moreover, as Axl is a strong activator of Akt, it therefore 
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makes sense that Axl thereby controls GSK3 activity (92). MET could also 
regulate the Wnt signalling pathway via Axl. Indeed, MET was found to co-IP 
with Axl in GnRH neuronal cells; MET signalling acted via Axl to trigger p38 
MAPK/Akt and induce neuronal migration. The activation of MET by its ligand 
HGF was only possible when Axl was present, indicating that cross-talk between 
MET and Axl can exist and may be essential for signal diversification (314). 
Additionally, Gas6 was shown to induce β-catenin stabilisation and subsequent 
TCF/Lef transcriptional activation in a mammary system through Axl activation 
but not Tyro3 (313).  
 AMPK was also phosphorylated upon Gas6 stimulation. AMPK is a 
regulator of cellular energy homeostasis and increases cellular energy levels by 
inhibiting anabolic energy-consuming pathways and stimulating energy-
producing, catabolic pathways (Figure 6.16). AMPK is a complex of three 
proteins, STE-related adaptor (STRAD), mouse protein 25 (MO25), and LKB1, 
a serine/threonine kinase that activates AMPK (315). Recently, LKB1 was shown 
to be under the regulation of Protein kinase C (PKC) (316), which is also 
regulated by Axl (317). Even though no direct relationship was found between 
Axl and AMPK regulation, in our system Axl exclusively regulates AMPK 
activation, probably to manage increasing energy demands of invading cancer 
cells.  
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Figure 6.16: Schematic representation of AMPK’s subunits and its activation process. 
AMPK detects changes in the cellular energy state that occur in response to nutrient 
variations or metabolic stress caused by changes in the AMP/ATP ratio. The activation 
of AMPK triggers key enzymes of glucose metabolism and fatty acids (318). 
  
The Akt serine/threonine kinase is part of the PI3K pathway, which 
promotes survival and growth in response to extracellular signals. Growth factor 
stimulation caused activation of the cell surface receptor PI3K. PI3K in turns 
phosphorylates lipids on the cell membrane forming the second messenger 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3). Akt is then recruited to the 
membrane containing PIP3 through its lipid docking sites, where it becomes 
activated. Axl has been shown to interact with the p85β subunit of PI3K and 
the adaptor protein Grb2 through tyrosine 821, leading to their activation (319). 
Full activation of Akt requires phosphorylation by both kinases PDK1 and 
mTORC2 on T308 and S473, respectively (320). In our cells, phosphorylation 
of S473 seems to be exclusively regulated by Axl as both Gas6 and EGF induced 
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phosphorylation was completely abolished upon Axl blockade by BGB324. Axl 
signalling through PI3K/Akt has been firmly established to regulate cell 
migration (321), growth, angiogenesis (322), and apoptosis (323, 324) in many 
circumstances, processes which are all taken advantage of by cancer cells to 
spread, grow and survive.  
 The primary function of phospholipase C (PLC) is to catalyse the 
hydrolysis of phosphatidylinositol 4,5-bisphophate (PIP2) to generate inositol 
(1,4,5) trisphosphate (IP3) and 1,2-diacylglycerol (DAG). IP3 initiates an 
increase in intracellular calcium, whereas DAG activates protein kinase C (PKC). 
Axl has already been shown to mediate PLCγ signalling through the latter’s 
interaction with tyrosines 821 and 866 in Axl (120). PLC-γ signalling initiates a 
signalling cascade (Figure 6.17) that results in cytokine production, activation 
of effector function, cell proliferation and cell migration (325, 326). 
 
Figure 6.17: PI3K activation. Activated PI3K phosphorylates PIP2, thereby creating 
PIP3 at the plasma membrane. Both Akt and PDK1 are then recruited to the membrane 
by binding PIP3. This positions PDK1 and Akt such that PDK1 can phosphorylate Akt 
on threonine 308 (T308) and activate downstream signalling (327).  
 
  
 186 
 
Axl has been shown to activate PLC-γ in CLL B cells and increase their 
survival (147). PLC-γ has been shown to mediate HIF1α-induced 
chemoresistance in glioma (328). It would thus be reasonable to propose that 
Axl activates PLC-γ in GBM cells in order to counteract the effects of 
chemotherapy and promote cell survival. 
 Signal transducer and activator of transcription 5 (STAT5) protein exists 
in two forms, STAT5A and STAT5B which are 90% identical. STAT5 proteins 
are involved in cytosolic signalling and in mediating the expression of specific 
genes. The STAT5B complex has been shown to be instrumental in glioma cell 
survival by direct activation of the BCL-XL promoter (329). Activation of STAT5 
by Axl has been described in natural killer cell development (330) but there 
their association has not been documented in any other context. It is possible 
that Axl promotes glioma cell survival through BCL-XL transcription by STAT5 
but more studies are required to elucidate the repercussions of such regulation. 
STAT5 has also been to promote transcription of invasion-related genes in 
glioma through a pathway dependent on STAT5 DNA binding (331). It is 
therefore also conceivable that Axl may directly activate STAT5 to promote 
glioma invasion.  
 PYK2 is a non-receptor protein-tyrosine kinase that regulates 
reorganisation of the actin cytoskeleton, cell polarisation, cell migration, 
adhesion, spreading and bone remodelling primarily by activating the MAPK 
pathway (332). Moreover, activated Pyk2 acts as a scaffold for Src-dependent 
phosphorylation of PDK1, which in turn phosphorylates paxillin and thus 
regulates integrity of focal adhesions (333). PYK2 has been shown to partner 
up with FAK to promote the Wnt/β-catenin pathway through phosphorylating 
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GSK3β (334). Signalling via Gas6/Axl in schwannoma resulted in FAK/Src/NFκB 
activation and increased cell-matrix adhesion and survival (307). PYK2 
activation has also been demonstrated to occur through PKC (335) which can 
be activated through the interaction of Axl with PLC-γ (120). Given the invasive 
role of Axl in many cancers, PYK2 regulation may add to its pro-invasion role 
through the regulation of focal adhesions.  
In conclusion, we have shown Axl to act as a promoter of cell invasion 
through the exclusive regulation of β-catenin, AMPK1α, Akt 1/2/3 (S473), c-jun, 
PLC-γ1, STAT5 α/β and PYK2 (Figure 6.18).  
 
Figure 6.18: Summary of Axl-mediated activation of downstream intracellular signalling 
effectors resulting in increased migration, invasion, survival and proliferation of GBM 
cells.  
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6.2.6 EGFR-Axl downstream signalling in GBM 
 As shown in the previous section, Axl was found to exclusively 
phosphorylate Akt 1/2/3 (S473) and regulate β-catenin even when activated by 
EGFR, making these proteins direct Axl targets. Moreover, eNOS and HSP60 
were strongly phosphorylated after EGF stimulation, which was blocked 
completely by BGB324, indicating a unique EGFR-Axl hetero-interactive 
signalling. Moreover, we show for the first time eNOS phosphorylation by Axl, 
which confirms indirect HSP90 regulation by Axl and its probable involvement 
in protein folding. WINK1 was deactivated by EGF stimulation and completely 
reactivated above basal levels when Axl kinase was blocked. WINK1 kinase has 
been shown to be phosphorylated and activated by EGFR to promote ERK5 
MAPK cascades to promote neuronal growth (336); therefore this novel Axl 
regulation may diversify EGFR signalling in GBM. Furthermore, an increase in 
phosphorylation of PI3K-pathway related kinases such as Akt 1/2/3 (T308), TOR 
and CREB was observed after EGF stimulation, which was reduced to basal 
levels by Axl kinase blockade. When considering these together with the kinase 
assay results described in the previous section, it is apparent that Axl is not the 
main regulator of these proteins but amplifies the EGFR response. Interestingly, 
FAK and PRAS40 as well as Fgr were completely inhibited following EGF 
addition, while Axl inhibition had no effect on their phosphorylation. These 
results therefore indicate that both EGFR and Axl negatively regulate these 
proteins, as Axl activation by Gas6 had the same effect. As with Gas6 
stimulation, GSK3 α/β, STAT3 (S727) were also phosphorylated by EGF 
stimulation. BGB324 mediated Axl blockade was unable to counteract the EGF 
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effect indicating that Axl is not the primary regulator of these proteins but 
another TAM receptor (Figure 6.19). 
 
Figure 6.19: A. Summary of EGFR-Axl mediated activation of intracellular downstream 
signalling effectors resulting in increased migration, invasion, survival and proliferation 
of GBM cells. B. EGFR specific downstream targets.  
 
6.2.7 Summary 
In summary, this chapter demonstrates that Axl interacts with its “sister” 
RTK, Tyro3, to promote proliferation and survival of GBM cells. Moreover, 
whereas Axl mainly regulates, either on its own or via interaction with EGFR, 
genes and kinases involved in cell invasion and chemoresistance, the Axl-Tyro3 
hetero-interaction could diversify Axl signalling to additionally regulate cell 
survival and proliferation. This is in keeping with the notion that EGFR utilises 
Axl to access signalling pathways for cell migration and invasion (Chapter 4). 
Furthermore, as we have shown EGFR to also phosphorylate Tyro3, a 
supramolecular complex of these proteins may exist which gives a significant 
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advantage to cancer cells. Therefore, it is possible that targeted molecular 
therapies aimed at inhibiting all 3 RTKs in this complex might be in order for 
the successful treatment of a subset of GBM patients in whose tumours this 
complex and associated signalling has been detected.  
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Chapter 7 
 
General Discussion 
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7.1 Summary of key findings 
In this study, I began with examining the expression levels of TAM 
receptors in GBM. Axl overexpression in reactive astrocytes was confirmed in a 
GBM tissue array as well as in GBM cell lines, in which Tyro3 overexpression 
was also identified. Moreover, activation by traditional (Gas6 and Protein S) as 
well as novel TAM ligands (Galectin-3 and Tulp-1) was shown through phospho-
RTK Western blotting.  
A key novel finding was the identification of RTK hetero-complexes 
involving Axl and/or Tyro3 with EGFR. The three receptors seem to co-operate 
in order to promote invasion, survival and growth of GBM cells respectively. 
Gliomas are characterised by excessive growth, invasion, anti-apoptotic 
signalling, angiogenesis and areas of necrosis. During this study, Axl was first 
shown to promote invasion of GBM cells, following which EGFR was revealed to 
also signal via Axl, a process that diversifies its role beyond cell proliferation to 
cell migration and invasion. Axl inhibition by both small molecule inhibition and 
RNAi reduced cell invasion, whilst EGFR inhibition by gefitinib did not affect 
basal invasion levels. Importantly, EGF-activated EGFR significantly increased 
invasion only in the presence of an active Axl kinase, indicating that EGFR 
invasive potential is mediated by Axl. In addition, RNAi and qRT-PCR gene 
screening also revealed Tyro3 to provide GBM cells with alternative signalling 
pathways, in this case the ability to evade cell cycle checkpoint-induced death. 
Most importantly, EGFR was able to induce activation of both Axl and Tyro3 
receptors, indicating that perhaps some co-operation between all three 
receptors is required for GBM cells to become resilient to therapy. Interestingly, 
more than 57% of GBM tumours either overexpress EGFR or possess an 
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overactive mutant version, which achieves constitutive signalling. However, 
blockade of EGFR sooner than later leads to resistance to small molecule 
inhibitors, thus making therapy ineffective for patients. In cancers such as 
breast, lung and head and neck cancers, resistance to EGFR inhibition arises 
from the overexpression of Axl, which activates downstream EMT signalling, 
thus promoting chemoresistance. Tyro3 has not been implicated in this thus 
far, probably because it has been the least studied of the three TAM receptors; 
it would therefore be interesting to further investigate TAM signalling, both via 
canonical homo-dimer formation as well as the novel potential heterodimer with 
EGFR, or even possible hetero-trimer/multimers with other RTKs. Additionally, 
in this study only the effect of EGF ligand was investigated. Taking into 
consideration the existence of 6 additional ligands that are able to activate EGFR 
their significance for this novel interaction needs further investigation. It is still 
not clear if Axl can also be activated by EGFR activation via its alternative ligands 
and how this affects downstream signalling.  
7.2 The TAMs as therapeutic targets 
 The TAMs present promising targets for the treatment of cancers and 
specifically GBM as they have been established as regulators of anti-apoptotic 
pathway activation, cell growth and survival in a variety of malignancies. In this 
thesis, as well as in a series of other studies, Axl inhibition results in decreased 
invasion and proliferation. More importantly, Axl inhibition sensitises cells to 
chemotherapy, indicating that its effects are multifaceted and the aim of 
“shutting down” multiple key biological processes in cancer cells can be 
achieved through a single target.  
 194 
 
Even though the angiogenic switch observed in brain cancers as well as 
necrosis was not investigated in this study, it would be reasonable to speculate 
that TAM signalling positively regulates those processes in GBM as well. Tyro3 
signalling has been shown to be critical in the regulation of the BBB integrity 
(124) although the mechanisms are not known. Of significance, Axl signalling 
has been shown to downregulate angiopoietin-2, an antagonist of angiopoietin-
1, a master promoter of vascular development and angiogenesis, in HUVEC cells 
(337). Moreover, Axl-dependent activation of Akt is thought to promote tumour 
angiogenesis in conjunction with VEGF-A and VEGFR2 (322). Importantly, 
phosphorylated Axl was localised in vascular proliferates within GBM xenograft 
tumours; in the same study Axl inhibition significantly decreased angiogenesis 
both in vitro and in vivo (146). Gas6 was also demonstrated to induce 
angiogenesis in the human retinal endothelial cells by ERK signalling (338). 
Indeed, in this study Gas6 stimulation of Axl resulted in eNOS phosphorylation, 
which positively regulates angiogenesis (339). Collectively these findings 
indicate that TAM signalling is important for tumour angiogenesis and they 
would make an attractive therapeutic target. By targeting the TAMs, the tumour 
blood supply, survival and invasive potential would be interrupted thus making 
them susceptible to chemotherapeutic induced death.  
Previous efforts to target angiogenesis in glioma with bevacizumab failed 
despite an initial response, leading to decreased abnormal morphology and 
organisation of tumour-related vasculature because tumours become more 
invasive (Figure 7.1) (340). Therefore, Axl inhibition may represent a more 
promising therapy as it would target both tumour angiogenesis and GBM cell 
invasion (138, 146, 217).  
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Figure 7.1: Schematic drawing: pre-treatment and during treatment with angiogenic 
agents in GBM. A. Contrast leakage (white) occurs around leaky tumour vessels 
enhancing the tumour area on MRI. Capillaries in surrounding tissue are not leaky 
before treatment. B. Contrast-enhanced area is strongly reduced under anti-VEGF 
treatment. Tumour cells migrate furtively into the surrounding tissue and co-opt 
existing vasculature after treatment (341). 
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7.3 Concerns about TAM inhibition 
Targeting of the TAMs in cancer is now widely believed to results in high 
therapeutic potential. Nonetheless there are some concerns that need to be 
weighed with regards to their normal function. For example, MerTK mutations 
lead to defective phagocytosis of photoreceptor outer segments by the retinal 
pigment epithelium (RPE) resulting in retinal degeneration. However, studies in 
rodents suggest that retinal degeneration only occurs after prolonged MerTK 
inhibition, which is further supported by clinical data in humans (342). Whilst 
this example concerns specifically the consequences of inhibition of MerTK, the 
same potential concerns may also apply for Axl and Tyro3.  
Tyro3 signalling is essential for normal development and function (132) 
of the brain as well as that of the BBB (124). Therefore, Tyro3 blockade over 
an extended period of time could result in BBB collapse as well as the 
progression of neurological disorders resulting from synaptic rigidity and 
demyelination.  
Another important aspect that needs to be considered is the role of the 
TAMs in immunity. Not only are the TAMs expressed in microglia to regulate 
inflammation but they also seem to be essential for systemic immunity (Figure 
7.2). Deficiencies in TAM signalling have been shown to result in sustained 
immune activation and chronic inflammation (343). Additionally, cytokine 
receptor signalling systems, such as signalling via the type 1 interferon receptor, 
are co-dependent on TAM family receptors (344). Both Axl and MerTK are 
expressed on multiple immune cells, such as dendritic cells and macrophages 
and have an essential immune-suppressive role via the abrogation of Toll-like 
receptor and cytokine receptor signalling. In a model of colorectal cancer, 
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deficiency of Axl and MerTK in mice led to increased production of inflammatory 
cytokines favouring a tumour-promoting environment, leading to enhanced 
formation of colonic adenomatous polyps (345). TAM targeting could therefore  
have adverse effects for tumour promotion, in which case the development of 
targeting strategies that avoid inciting adverse pro-inflammatory effects might 
be optimal for future therapy development.  
On the other hand, the TAMs drive natural killer (NK) cell functional 
maturation and normal expression of inhibitory and activating NK cell receptors 
(346). NK cells are anti-tumorigenic and conduct immune surveillance through 
their ability to monitor cell surfaces of autologous cells for aberrant expression 
of MHC class I molecules and cell stress markers, thus differentiating between 
normal and malignant cells (347). A recent study, demonstrated a role for TAM 
receptors in the regulation of cancer metastases by the modulation of NK cell 
activity. In this study, mice with targeted inactivation of the E3 ubiquitin ligase, 
Cbl-B, demonstrated enhanced NK cell activity against metastatic tumour 
models and this unique activity was found to be related to the regulation of 
TAM family receptors that were found to be ubiquitination substrates for Cbl-B. 
Additional studies showed that TAM small molecule inhibition confers treatment 
potential through enhancing in vivo NK cell activity. Moreover, Gas6 inactivation 
by warfarin yielded similar results, indicating that TAM inhibition can have 
additional anti-cancer activity through NK cell-mediated action against 
metastatic disease (348).  
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Figure 7.2: TAM-Regulated Cycle of Inflammation. A. Schematic representation of APC signalling showing the engagement of TLR (green), 
cytokine receptor (blue), and TAM receptor (red) signalling pathways. B. Schematic representation of the inflammatory cycle initiated by 
TLR activation (green pathway) which results in the activation of cytokine receptors and Axl. The final stage of the cycle (red pathways) 
results in TAM signalling activation, the transcription of SOCS genes, and the inhibition of both cytokine receptor and TLR signalling 
pathways (343).
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7.4 Future directions 
Although, as discussed above, chronic and sustained inhibition of TAM 
family RTKs may have deleterious side effects such as autoimmunity and 
retinitis, they can still be effective targets in the treatment of cancer in the 
short-term. The TAM kinases present a multifaceted grouping of anti-cancer 
targets through their involvement in tumour invasion, proliferation, survival and 
angiogenesis. Therapeutic TAM inhibition may sensitise tumour cells to killing 
by chemotherapy, radiation or other targeted agents and, in doing so, may 
create an even more robust innate immune response, which may enhance 
immunotherapeutic efficacy in combination with immune checkpoint inhibitors. 
A key challenge is the development of highly specific and effective TAM 
inhibitors in order to limit toxicity and adverse effects resulting from pan-kinase 
inhibition. Currently the most specific Axl inhibitor present is BGB324 (R428 ), 
which potently blocks autophosphorylation of Axl at the multiple docking site 
Tyr821 within the tyrosine kinase domain, with consequent inhibition of 
activation of Akt, Src family of proteins phosphorylation with low nanomolar 
affinity (160). BGB324 entered phase I clinical trials in 2013 for breast and lung 
cancers but its effectiveness in clinical glioma is still unknown. In addition to 
BGB324, new drugs are currently being developed which on the bench-side 
seem to be very potent and hopefully they will enter into clinical trials sometime 
in future (Table 8), amongst which at least one will be proven to be suiTable 
for GBM and cross the BBB.  
.  
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Table 8: Axl inhibitors currently in development 
DP3975 Small 
molecule 
inhibitor 
AXL Preclinical Inhibited cell migration and 
proliferation in mesotheliomas (349). 
LDC1267 Small 
molecule 
inhibitor 
AXL, 
Tyro3, 
Mer 
Preclinical Induces NK cells to kill tumour cells in 
mouse metastatic breast cancer and 
melanoma model (348) 
NA80x1 Small 
molecule 
inhibitor 
AXL Preclinical Inhibits AXL phosphorylation, cell 
motility, and invasion in MDA-MB-435 
cells (350). 
YW327.6S2 Antibody AXL Preclinical Anti-AXL monoclonal antibody (351). 
GL21.T Aptamer  Axl Preclinical Binds the extracellular domain of Axl at 
high affinity (352) 
NPS-1034 Small 
molecule 
inhibitor 
Axl 
MET 
Preclinical Inhibits cell proliferation and induces 
cell death in EGFR resistant lung cancer 
cell lines (353)  
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Appendix 1 
Western blot showing timecourse of Axl phosphorylation by Gas6 (400 ng/ml) 
(A), of Tyro3 phosphorylation (B) and of Akt levels (C) in SNB-19 and UP007 
cells 
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Appendix 2 
 
Western blots showing inhibition by BGB324 (0.1-100 µM) of phosphorylation 
of Axl (A), Tyro3 (B) and Akt kinase downstream (C) stimulated by Gas6 (400 
ng/ml) in SNB-19 an UP007 cells.  
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Appendix 3 
 
Western blot of EGFR phosphorylation by EGF and inhibition by gefitinib and 
BGB324 in SNB-19 and UP007 cells. Data are mean±SEM (n=3 separate 
experiments); ANOVA with Tukey’s multiple comparisons post hoc analysis, 
**p<0.01, *p<0.05, ns, not significant, for comparisons indicated 
 
